The Development of Boron Containing Hydrogels for Sensing and Drug Delivery by Williams, George
        
University of Bath
PHD








If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.








The Development of Boron Containing 
Hydrogels for Sensing and Drug 
Delivery 
 
George Thomas Williams 
 
A thesis submitted for the degree of Doctor of Philosophy 
University of Bath 










 Attention is drawn to the fact that copyright of this thesis rests with the author. A copy of this 
thesis has been supplied on condition that anyone who consults it is understood to recognise that 
its copyright rests with the author and that they must not copy it or use material from it except 
as permitted by law or with the consent of the author. 
Restrictions of use 
This thesis may not be consulted, photocopied or lent to other libraries without the permission 




















Declaration of External Input 
Biological testing reported within this thesis was performed in part by L. Gwynne and 




First and foremost I must thank my Supervisor Prof Toby Jenkins for his support throughout 
my Ph.D, and for offering me the opportunity to undertake this project in the first place. Many 
of my best experiences in the last 3 years have been due to being able to present my work and 
go to a number of conferences, which without you would have been impossible. I would also 
like to thank Prof Tony James for his advice and scientific knowledge, particularly in the field 
of boron chemistry. My meetings with Dr Mark Sutton were also something I will be eternally 
grateful for, it was often not until down the road did I realise the relevance of what I was being 
told. 
The Jenkins group members both past and current have also been an invaluable source of 
encouragement, knowledge, support, necessary abuse and great memories. I probably in part 
owe Dr Adam Sedgwick my Ph.D, as my lab time essentially doubled with his coming into my 
life. Lauren Gwynne I need to thank for putting up with my constant moaning and generally 
being one of the best technicians (kidding) and best friends I could have ever hoped for. I also 
must thank Beth Patenall for her help in teaching me what genes actually are, and to both her 
and Lauren for helping me with all of the microbiology and proof reading my thesis. From 
within our group and without it I have had a wealth of other Ph.D students offer me knowledge, 
support and guidance, so I must thank Dr Liam Stephens, Dr Jordan Gardiner, Dr Holly 
Hathaway, Dr Scarlet Milo, Dr Thet Nuang Tun, Dr Maria Odyniac, Dr Stephen Flower, Dr 
Simon Lewis, Rachel Heylen and Lloyd Murfin, not to mention the entire Pantos, Lewis and 
Carberry groups for adopting me into their labs. I also have to thank my previous Students Anna 
Mroz, Hugh Wetherly, Ash Parker and Astrid Hafner, you guys taught me more about chemistry 
than you realise, and how much I enjoyed supervising your projects is one of my major draws 
to academia. 
Outside of my university life I was blessed to have an inspirational family, and without their 
support I don’t know where I would be. My Mum, Nan and Gramps have always been my 
biggest fans, and are a constant source of love and encouragement.  
My friends have been the keepers of my sanity. Jake Matt and Colby have been the most reliable 
constants in my life, and I can confidently say Jakes pep talks have had me doing more work 
iv 
 
than any other factor. Nothing will ever surpass the Zits! It is a known fact that Polzeath with 
the Pennocks is the greatest relaxation known to man, so I would like to thank Andy, Jake and 
Robbie for those adventures. After 8 years or so at Bath I have met some truly fantastic people 
who have all made living here and doing, what felt like a never-ending task, a pleasure. So I 
would also like to thank Emily, Liam, Lloyd (again), Matt, Sam, Spoon, and all of the staff at 
the Stable. We sank just the right number of pints. I am going to miss Bath greatly 
I also need to say a huge thankyou to my wonderful girlfriend Kaya. You have put up with me 
during the writing of my thesis and never once complained about the fact I was unrelentingly 
grumpy for a good few months. You deserve a medal!  
I also would like to thank the University of Bath and Public Health England for the financial 



























I dedicate my thesis to Jake Oliver, the greatest human being I  
have ever had the good fortune of meeting.  
















A Colorimetric  chemosensor based on a Nozoe azulene that detects fluoride in 
aqueous/alcoholic media 
Murfin L, C., Chiang K. X., Williams, G. T., Jenkins, A. T. A., James. T. D., & Lewis S., E. In 
Frontiers in Chemisty 
Boronate ester cross-linked PVA hydrogel for the H2O2 triggered delivery of small 
molecules Chapter 4 
Williams, G. T., Sedgwick, A. C., Gwynne L., Murfin L, C., Gardiner J. E., Brewster II, J. T., 
Lewis S., E., Sutton M., James. T. D., Jenkins, A. T. A. & Sessler, J. L., In Chemical 
communications 
Reaction-based indicator (RIA) displacement hydrogel for the development of a triggered 
release system capable of biofilm inhibition Chapter 2 
Patenall. B. L.1, Williams G. T.1, Gwynne L., Stephens, L. S., Lampard. E, V. L., Hathaway, H. 
J., Thet N. T., Young, A. E., Sutton, M., Short R. D., Bull S. D., Sedgwick A. C., James T. D. 
& Jenkins, A. T. A., 02 Dec 2019, In Chemical Communications 
Delivery and quantification of hydrogen peroxide generated via cold atmospheric pressure 
plasma through biological material 
Hathaway H. J., Patenall, B. L., Thet N. T., Sedgwick A. C., Williams G. T., Jenkins A. T. A., 
Allinson S. L. & Short R. D., 17 Sep 2019, In : Journal of Physics D : Applied Physics. 
A boronic acid-based fluorescent hydrogel for monosaccharide detection 
Xu, S., Sedgwick, A. C., Elfeky, S. A., Chen, W., Jones, A. S., Williams, G. T., Jenkins, A. T. 
A., Bull, S. D., Fossey, J. S. & James, T. D., 21 May 2019, In : Frontiers of Chemical Science 
and Engineering. 
Long wavelength TCF-based fluorescence probe for the detection of Alkaline Phosphatase 
in live cells 
Gwynne, L., Sedgwick, A. C., Gardiner, J. E., Williams, G. T., Kim, G., Maillard, J. Y., Jenkins, 
T., Bull, S. D., Sessler, J. L., Yoon, J. & James, T. D., 30 Apr 2019, In : Frontiers in Chemistry.  
An ESIPT Probe for the Ratiometric Imaging of Peroxynitrite Facilitated by Binding to 
Aβ-Aggregates 
Sedgwick, A. C., Dou, W. T., Jiao, J. B., Wu, L., Williams, G. T., Jenkins, A. T. A., Bull, S. D., 





Limiting Pseudomonas aeruginosa Biofilm Formation Using Cold Atmospheric Pressure 
Plasma 
Patenall, B, L., Hathaway, H. J., Sedgwick, A. C., Thet, N. T., Williams G. T., Young A. E., 
Allinson S. L. Short R. D. & Jenkins A. T. A., 26 Sep 2018, in Plasma Medicine 
Dye Displacement Assay for Saccharides using Benzoxaborole Hydrogels Chapter 2 
Lampard, E. V., Sedgwick, A. C., Sombuttan, T., Williams, G. T., Wannalerse, B., Jenkins, A. 
T. A., Bull, S. D. & James, T. D., 1 Mar 2018, In : ChemistryOpen.  
 
Manuscripts in Appendix 
Oral Presentations 
BioNano Summer School, Hirschegg Austria 08/2017 
VBST, Attendorn, Germany 10/2017 
BioNano Summer school, Hirschegg Austria 08/2018 
VBST, Hirschegg Austria 02/2019 
Advanced Polymers via Molecular Engineering, Stellenbosch, 04/2019 

















°C  Degrees centigrade 
µg Microgram 
µL Microliter 
µM Micromolar  
1H NMR  Hydrogen nuclear magnetic resonance  
5-FBPBA 5-fluorouracil bis-phenyl boronic acid 
AcOH Acetic Acid 
AF-647  Alexafluor-647  
AHL Acetyl-homoserine lactone 
AI Autoinducer 
ARS  Ailizarin Red S 
BOB  Benzoxaborole 
BODIPY Boron-dipyrromethene 
Bpin Boronic pinacol ester 
Br2 Bromine 
CAMHB Calcium adjusted mueller hinton broth 
CAP Cold atmospheric plasma 
CBPBA Ciprofloxacin bis-phenyl boronic acid 
CCC  Critical colonisation concentration  
CDI Carbonyldiimidazole 
Cipro Ciprofloxacin 
CMC  Carboxymethyl cellulose 
CMO  Chief medical officer  
d Doublet 
Da  Dalton  
DCM  Dichloromethane  
dd Doublet of doublets 
DI  De-ionised  
DLS  Dynamic light scattering  
DMF Dimethyl formamide 
ix 
 
DMSO  Dimethyl sulfoxide  
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic acid  
E. coli  Enterococcus coli  
EDTA  Ethylenediaminetetraacetic acid  
EPS  Extracellular polymeric substance 
ESI  Electrospray ionisation  
EtOAc Ethyl Acetate 
FTIR  Fourier transform infra-red  
FRET Fӧrster Resonance Energy Transfer 
g Gram 
Gment Greenment 
H2S Hydrogen Sulfide 
HA  Hyaluronic acid  
HAase  Hyaluronidase  
HAaz  Hyaluronic acid with azide moieties  
HGT  Horizontal Gene transfer  
HPLC  High pressure liquid chromatography  
HOMO Highest occupied molecular orbital 
HRMS  High Resolution Mass Spectrometry 
HWE  Horner-Wadsworth-Emmons  
ICT Internal charge transfer 
IR  Infra-red  
ISC Internal system crossing 
J Coupling constant 
K2CO2 Potassium Carbonate 
KDa  KiloDalton  
LB  Luria-Bertani broth  
LUMO Lowest unoccupied molecular orbital 
M Molar 
M  molar  
x 
 
m  Metre  
m/z  Mass to charge ratio  
MAA Methacrylic acid 
MBA Methylene Bisacrylamide 
MeCN Acetonitrile 
mg milligram 
MgSO4 Magnesium Sulphate 
MH  Mueller-Hinton  
MHz  Megahertz  
MIC  Minimum inhibition concentration  
mL Millilitre 
mM Millimolar 
mm  Millimetre  
Mol  moles 
Mp Melting Point 
MRSA  Methicillin resistant S. aureus  
mw  Weight average molecular weight  
NaCl  Sodium Chloride 
NAG  N-acetyl glucosamine  
NaHCO3 Sodium Hydrogen Carbonate 
NAM  N-acetyl muramic acid  
NEt3 Triethylamine 
NHS N-hydroxysuccinimde  
NICE 
National institute for health and care 
excellence 
P. aeruginosa  Pseudomonas aeruginosa  
PAA  Polyacrylic acid  
PBA Phenyl boronic acid 
PBP  Penicillin Binding Protein  
PCR Polymerase Chain Reaction 
PEG  Polyethylene glycol  
xi 
 
PET Photoinduced electron transfer 
Pment Purplement 
PNIPAM Poly(N-isopropylacrylamide) 
PVA Poly(vinyl alcohol) 
q Quartet 
quin Quintet 
RFI Relative fluorescence intensity  
RNS Reactive nitrogen species 
RONS Reactive Oxygen and Nitrogen Species 
ROS Reactive oxygen species 
s Singlet 




TPE Tetraphenyl ethylene 
TPE Tetre phenylene ethene 
Tric Triclosan 
UV Ultra-violet 
UV-vis  Ultraviolet-visible light  
VRSA  Vancomycin resistant Staphylococcus aureus 












The threat of antibiotic resistant bacteria is a global one, with no single cause or cure. One of 
the many faces of this problem is in wound infection. Certain pathogenic bacteria can prevent 
wound healing, cause pain, and in extreme cases lead to patient mortality. To administer topical 
antibiotics, or to assess if a wound is infected, a clinician must remove the wound dressing, 
exposing the wound to contamination from potentially pathogenic species of bacteria. In this 
research, novel hydrogel materials have been developed that aim to deliver antibacterial 
compounds into an infected wound environment, without the need for dressing removal. 
The novel smart materials developed in this study utilise the reversible, covalent binding of 
boronic acids to diols. Boronic acid containing monomers have been developed for the 
development of boronic acid functionalised polyacrylamide gels, which have been shown to 
bind and release the dye alizarin Red S (ARS) in a controlled fashion. ARS has inherent anti-
biofilm activity, and this system has been shown to prevent the growth of S. aureus biofilms. 
Novel prodrugs and fluorophores have been synthesised featuring boronic acids and esters, to 
mask the reactivity of the active compounds. These compounds have been used as crosslinkers 
to form hydrogels using poly(vinyl alcohol) (PVA), and their use as H2O2 sensitive drug delivery 
vehicles has been proved using microbiological assays with clinically relevant bacteria. PVA 
has been successfully crosslinked using both literature reported and novel boronic ester masked 
fluorophores to yield collapsible hydrogels that find utility both as potential smart materials for 













1.1 The Clinical Need for Smart Wound Dressings .......................................................................... 19 
1.2 Bacteria ....................................................................................................................................... 19 
1.3 Wounds and Wound Infection .................................................................................................... 19 
1.4 Biofilms....................................................................................................................................... 20 
1.4.1 Biofilm Formation............................................................................................................... 21 
1.4.2 Quorum Sensing .................................................................................................................. 22 
1.5 Bacterial Infection ....................................................................................................................... 23 
1.6 Antibiotics ................................................................................................................................... 23 
1.6.1 Cell Wall Inhibitors ............................................................................................................. 24 
1.6.2 Antibiotics that Target the Bacterial Ribosome .................................................................. 30 
1.6.3 Antibiotics that Target DNA Synthesis............................................................................... 31 
1.7 Antimicrobial Resistance ............................................................................................................ 32 
1.7.1 Intrinsic Resistance ............................................................................................................. 33 
1.7.2 Acquired Resistance ............................................................................................................ 33 
1.7.3 Specific Resistance Genes .................................................................................................. 35 
1.8 What is Being Done to Combat Antibiotic Resistance? ............................................................. 36 
1.8.1 Biofilm Inhibitors and Biofilm Disruptors .......................................................................... 37 
1.9 Fluorescence ............................................................................................................................... 38 
1.9.1 Designing a Fluorescent Probe ........................................................................................... 39 
1.9.2 Molecular Mechanisms of Fluorescence ............................................................................. 40 
1.10 Boron Chemistry ......................................................................................................................... 44 
1.10.1 Boronic Acids and Esters .................................................................................................... 45 
1.10.2 Applications of Boronic Acids ............................................................................................ 48 
1.11 Hydrogels .................................................................................................................................... 49 
1.11.1 Hydrogels Based on Naturally Occurring Polymers ........................................................... 49 
1.11.2 Synthetic Polymer Hydrogels ............................................................................................. 51 
1.12 Cold Atmospheric Plasma (CAP) ............................................................................................... 53 
1.12.1 CAP; an Overview .............................................................................................................. 53 
1.12.2 The Biological Effect of CAP ............................................................................................. 53 
1.13  Bibliography .............................................................................................................................. 55 
2.1 Introduction ................................................................................................................................. 64 
14 
 
2.1.1 Boronic Acid and Boronic Ester Soft Materials ................................................................. 64 
2.1.2 Dye Displacement Assay Saccharide Detector ................................................................... 66 
2.1.3 Biofilm Inhibitors ................................................................................................................ 68 
2.2 Chapter Aims .............................................................................................................................. 69 
2.3 Materials and Methods ................................................................................................................ 72 
2.3.1 General Information ............................................................................................................ 72 
2.3.2 Blank Gel Synthesis ............................................................................................................ 72 
2.3.3 PBA/BOB Containing Gel Synthesis .................................................................................. 72 
2.3.4 Dye Uptake Experiments .................................................................................................... 73 
2.3.5 Dye Washing Experiments .................................................................................................. 73 
2.3.6 Dye Release Experiments with H2O2 .................................................................................. 73 
2.3.7 Dye Release Experiments with Plasma Activated Buffer ................................................... 73 
2.3.8 Media, Buffers and Stock Solutions.................................................................................... 74 
2.3.9 Bacterial Strains and Overnight Cultures ............................................................................ 74 
2.3.10 Bacterial MICs .................................................................................................................... 74 
2.3.11 Bacterial Biofilm Formation ............................................................................................... 74 
2.3.12 Crystal Violet Biofilm Staining .......................................................................................... 75 
2.4 Results and Discussion ............................................................................................................... 76 
2.4.1 Synthesis of the Boronic Acid Containing Hydrogels ........................................................ 76 
2.4.2 Dye Loading and Washing Studies ..................................................................................... 76 
2.4.3 Triggering the Release of ARS With H2O2 ......................................................................... 80 
2.4.4 Using Cold Plasma to Trigger ARS release ........................................................................ 84 
2.4.5 The Biological Activity of ARS .......................................................................................... 87 
2.4.6 Addition of H2O2 to Biofilms at Lag Phase ........................................................................ 90 
2.4.7 Addition of H2O2 to Biofilms at Exponential Phase ........................................................... 91 
2.4.8 Addition of H2O2 to Biofilms at Stationary Phase .............................................................. 93 
2.4.9 Addition of H2O2 and ARS to a Biofilm at the Lag Phase .................................................. 94 
2.4.10 Testing the Gel System with Biofilm Inhibition ................................................................. 95 
2.5 Conclusions ................................................................................................................................. 97 
2.6 Future Work ................................................................................................................................ 98 
2.7 Bibliography ............................................................................................................................. 101 
3.1 Introduction ............................................................................................................................... 103 
3.1.1 Prodrugs ............................................................................................................................ 103 
3.1.2 ROS Responsive Prodrugs ................................................................................................ 104 
15 
 
3.1.3 Antibiotic Prodrugs ........................................................................................................... 105 
3.2 Aims .......................................................................................................................................... 107 
3.3 Materials and Methods .............................................................................................................. 108 
3.3.1 General Information .......................................................................................................... 108 
3.3.2 Blank Gel Synthesis .......................................................................................................... 108 
3.3.3 Drug/Dye Loaded Gel Synthesis ....................................................................................... 108 
3.3.4 Dye Release Studies .......................................................................................................... 109 
3.3.5 Gel Disc Diffusion Assay ................................................................................................. 109 
3.3.6 Modified Gel Disc Diffusion Assay .................................................................................. 109 
3.4 Results and Discussion ............................................................................................................. 110 
3.4.1 Dye Release Studies with AzuFluor 483-Bpin™ ............................................................. 110 
3.4.2 Anchoring Drugs to Hydrogels ......................................................................................... 112 
3.4.3 Synthesis of Triclosan-PBA .............................................................................................. 114 
3.4.4 Crosslinking PVA Doped with Triclosan-PBA ................................................................ 115 
3.4.5 Disc Diffusion Assays with Triclosan-PBA ..................................................................... 117 
3.4.6 Synthesis of Ciprofloxacin-PBA ....................................................................................... 119 
3.4.7 Modified Disc Diffusion Assay ........................................................................................ 123 
3.5 Conclusions ............................................................................................................................... 126 
3.6 Future work ............................................................................................................................... 127 
3.7 Bibliography ............................................................................................................................. 129 
4.1 Introduction ............................................................................................................................... 132 
4.1.1 Hydrogen Peroxide Sensing .............................................................................................. 132 
4.1.2 Detecting ROS/RNS ......................................................................................................... 133 
4.1.3 ROS/RNS and Their Uses ................................................................................................. 134 
4.1.4 Hydrogels for Bio-imaging ............................................................................................... 135 
4.2 Aims .......................................................................................................................................... 136 
4.3 Materials and Methods .............................................................................................................. 137 
4.3.1 General Information .......................................................................................................... 137 
4.3.2 Synthetic Experimental ..................................................................................................... 137 
4.3.3 Solution Based UV-vis Studies ......................................................................................... 137 
4.3.4 Solution Based Fluorescence Studies................................................................................ 137 
4.3.5 Hydrogel Synthesis ........................................................................................................... 138 
4.3.6 Gel Based UV-vis Studies ................................................................................................. 138 
4.3.7 Gel Based Fluorescence Studies ....................................................................................... 138 
16 
 
4.3.8 Gel Dissolution Study ....................................................................................................... 138 
4.3.9 Gel Stability Study in Air .................................................................................................. 138 
4.3.10 Gel Stability in Aqueous Solution .................................................................................... 139 
4.4 Results and discussion .............................................................................................................. 140 
4.4.1 Existing Boronate Ester Fluorophores .............................................................................. 140 
4.4.2 Synthesis of PF-1 .............................................................................................................. 140 
4.4.3 PF-1 Testing in Solution ................................................................................................... 141 
4.4.4 PF-1 Crosslinked Hydrogel Development ........................................................................ 143 
4.4.5 Gment Gels in H2O2 Solutions .......................................................................................... 144 
4.4.6 Purplement ........................................................................................................................ 147 
4.4.7 Purplement Testing in Solution ......................................................................................... 147 
4.4.8 Purplement Crosslinked PVA Hydrogel Development ..................................................... 149 
4.4.9 Pment Gels in H2O2 Solutions ........................................................................................... 150 
4.4.10 Gel Stability ...................................................................................................................... 152 
4.4.11 Gel Dissolution ................................................................................................................. 153 
4.5 Conclusions ............................................................................................................................... 155 
4.6 Future Work .............................................................................................................................. 156 
4.7 Bibliography ............................................................................................................................. 157 
5.1 Introduction ............................................................................................................................... 159 
5.1.1 Polymeric Drug Delivery Systems .................................................................................... 159 
5.1.2 Ciprofloxacin .................................................................................................................... 159 
5.1.3 Ciprofloxacin Mechanism of Action ................................................................................. 160 
5.1.4 Structure Activity Relationship of Ciprofloxacin ............................................................. 160 
5.1.5 Resistance to Ciprofloxacin .............................................................................................. 161 
5.1.6 Infection and Cancer ......................................................................................................... 162 
5.1.7 5-Flourouracil ................................................................................................................... 162 
5.2 Aims and Objectives ................................................................................................................. 163 
5.3 Materials and methods .............................................................................................................. 164 
5.3.1 General Information .......................................................................................................... 164 
5.3.2 Gel Synthesis .................................................................................................................... 164 
5.3.3 UV-vis Measurements in Solution .................................................................................... 164 
5.3.4 UV-vis Measurements Using CBPBA Hydrogels ............................................................ 165 
5.3.5 Fluorescence Measurements in Solution ........................................................................... 165 
5.3.6 Initial Fluorescence Measurements Using CBPBA Hydrogels ......................................... 165 
17 
 
5.3.7 Ciprofloxacin Standard Curve .......................................................................................... 165 
5.3.8 MIC Determination ........................................................................................................... 165 
5.3.9 Pseudo-MIC CBPBA Release Studies .............................................................................. 166 
5.4 Results and Discussion ............................................................................................................. 167 
5.4.1 Modification of Ciprofloxacin .......................................................................................... 167 
5.4.2 Solution Testing CBPBA .................................................................................................. 168 
5.4.3 Initial Ciprofloxacin Release From CBPBA Hydrogel ..................................................... 170 
5.4.4 UV-vis CBPBA Gel Release Studies ................................................................................ 172 
5.4.5 Converting Absorbance to Concentration ......................................................................... 173 
5.4.6 Biological Testing – MICs of Ciprofloxacin and H2O2 .................................................... 175 
5.4.7 Pseudo MICs to Measure Ciprofloxacin Release from CBPBA Gels .............................. 178 
5.4.8 CBPBA Biological Activity .............................................................................................. 180 
5.4.9 Expansion of the Methodology ......................................................................................... 181 
5.4.10 Gel Stability ...................................................................................................................... 183 
5.5 Conclusions ............................................................................................................................... 185 
5.6 Future Work .............................................................................................................................. 186 
5.6.1 Increasing Scope ............................................................................................................... 186 
5.6.2 Theranostic Development ................................................................................................. 187 
5.7 Bibliography ............................................................................................................................. 191 
6.1 Chapter 2 ................................................................................................................................... 194 
6.2 Chapter 3 ................................................................................................................................... 196 
6.3 Chapter 4 ................................................................................................................................... 198 
6.4 Chapter 5 ................................................................................................................................... 202 
7.1 Chapter 1 ................................................................................................................................... 204 
Appendix 1 ........................................................................................................................................ 204 
7.2 Chapter 2 ................................................................................................................................... 205 
Appendix 1 – Acrylamide gel synthesis............................................................................................ 205 
Appendix 2 ........................................................................................................................................ 205 
Appendix 3 ........................................................................................................................................ 205 
Appendix 3 ........................................................................................................................................ 206 
Appendix 4 ........................................................................................................................................ 207 
Appendix 5 ........................................................................................................................................ 207 
7.3 Chapter 4 ................................................................................................................................... 208 
18 
 
Appendix 1 ........................................................................................................................................ 208 
Appendix 2 ........................................................................................................................................ 208 
7.4 Chapter 5 ................................................................................................................................... 209 
Appendix 1 ........................................................................................................................................ 209 
Appendix 2 ........................................................................................................................................ 210 
7.5 Published Manuscripts .............................................................................................................. 212 


























1.1 The Clinical Need for Smart Wound Dressings 
Wounds, subsequent wound infection and thus wound care are a near unavoidable aspect of life. 
Whilst the majority of wounds will heal normally and without the interference of infection, there 
is a large clinical burden associated with those that do not. An estimation of the economic cost of 
wound management to the NHS was studied in 2012-13 and was found to be comparable to obesity 
at £5 billion.1 Current diagnostics for wound infection rely on clinical inspection of a wound for 
symptoms such as redness and swelling.2 To allow for this inspection, wound dressings must be 
removed, exposing the wound to the environment, at which time infection or re-infection is likely.3 
The same potential for contamination occurs when there becomes a need for the application of 
topical antibiotics. There is thus a need for dressings that are able to detect infection and administer 
topical treatments, without the requirement for clinical infection. 
1.2 Bacteria 
Bacteria are unicellular, microscopic, prokaryotic organisms, which exist in almost every possible 
ecological niche. They often exist symbiotically with other organisms, including humans, and aid 
with such processes as digestion and immunity.4, 5 These organisms can be broadly categorised 
into two types, gram positive and gram negative. These are named after  the Danish scientist Hans 
Christian Gram who developed the Gram staining procedure in 1884.6 Gram-positive bacteria 
retain the stain appearing a violet colour, owing to their thick peptidoglycan cell walls (discussed 
in 1.5.1.1). As they have a much less porous lipid bilayer, gram-negative bacteria do not retain the 
stain as it is washed out with solvent. They can instead be counter stained with safranin.7 Bacterial 
cells have a global biomass greater than that of both the animal and plant kingdoms, with over 5 x 
1030 bacterial cells worldwide.8 
1.3 Wounds and Wound Infection  
The skin is the body’s first line of defence against a number of potentially harmful external stimuli, 
both physical (such as sunlight), and biological, namely microbial pathogens. 
A wound is a breaking of this barrier, exposing the body to these risks. Wounds are generally 
categorised as either acute or chronic. An acute wound is one that will progress normally through 
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the four stages of healing (haemostasis, inflammation, proliferation and remodelling), and will 
show evidence of healing in a predictable timeframe.9 Chronic wounds do not progress through 
these stages at the normal rate, or can be non-healing entirely. Often influenced by other factors, 
for example diabetes, these wounds will not heal via the usual path, often stalling at one of the 
aforementioned stages of healing. This extended healing time causes chronic wounds to be far 
more susceptible to infection, and greatly increases associated morbidity and mortality. In the UK 
the national health service (NHS) is estimate to spent £2.3 - £3.1 billion a year on the treatment of 
such wounds.10 
The skin is host to vast quantity and variety of micro-organisms including bacteria, fungi and 
mites.11 The presence of such species is often beneficial, and many of them work symbiotically to 
maintain healthy skin.12 However, amongst the skins microbiome there are a number of 
opportunistic pathogens that can develop infections within wounds. Opportunistic pathogens are 
those that are not ordinarily harmful, but when allowed to grow in a certain environments can 
cause harm.13 Common bacteria that are found within infected wounds include Staphylococcus 
aureus, Pseudonomas aeruginosa and Enterococcus. faecalis. Whilst a wound will always contain 
bacteria, only at high bacterial concentration is there risk of infection. The critical colonisation 
concentration (CCC) is the point at which the bacterial density becomes high enough to out-
compete the host’s immune system. This exact point of this threshold is not fully understood, 
owing to the myriad of factors that influence it. Not only do the species of bacteria present alter 
this point, known as the ccc, but also the general health and the immune response of the patient.14 
Despite this lack of clinical consensus of what defines an infection, it is universally acknowledged 
that bacterial infections prevent normal wound healing, often leading to chronic wounds. In 60% 
of such wounds the bacteria are in the form of a biofilm.15 
1.4 Biofilms 
Biofilms are surface associated, complex communities of bacteria, surrounded by a three 
dimensional extra-cellular polymeric substance (EPS).16 Within these architectures bacteria are 
intrinsically more resistant to conventional antibiotics, owing in part to their low metabolic rate, 
as well as the EPS providing another barrier of protection.17 The EPS consists of approximately 
90% a combination of  DNA, extracellular proteins, sugars, and allows regulation of nutrients and 
waste for the bacteria as a community, as opposed to as single cells.18 Bacteria within this 
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protective layer have minimum inhibition concentrations (MICs) much higher than their 
planktonic counterparts. Planktonic bacteria are those that are free floating, unbound to surfaces 
or larger bacterial aggregations Anderl et al. found that Klebsiella pneumoniae biofilms treated 
with ten times their planktonic MIC, of both ciprofloxacin and ampicillin, remained unaffected in 
terms of the number of remaining viable cells.19 Other papers have reported the MIC increasing to 
100-1000 times that the planktonic MIC when the bacteria is protected within a biofilm.20, 21 This 
decrease in susceptibility to antimicrobial agents introduced the development of a new measure of 
drug efficacy, the minimum biofilm eradication concentration (MBEC).22 This is a much more 
useful value when dealing with the harder to treat communities.  
1.4.1 Biofilm Formation  
Biofilm formation is a multi-step process, beginning with the adhesion of planktonic bacteria to a 
surface.23 A number of chemical signals and physiological processes then cause the bacteria to 
bind to the surface, utilising membrane proteins such as SadB in the case of P. aeruginosa.24 
Following this binding, extracellular secondary messengers begin to stimulate the production of 
EPS. These messengers are dependent on environmental conditions, and their regulation and thus 
that of the EPS production reflects this.25 As the biofilm matures it forms micro-colonies, the 
bacterial cells begin to divide and produce more EPS. Within this enclosed matrix the bacteria are 
protected and are able to communicate via quorum sensing.26 The structures of these architectures 
vary between bacterial species as well as environmental conditions, allowing them to more 
efficiently make use of nutrients and remove waste products.27 The biofilm can also act as a 
reservoir of bacteria, which themselves are then able to leave the relative protection of the biofilm 
to start new biofilms of their own. This dispersal can be either passive, owing to the shearing force 
of a flow, or active, with intentional release of bacterial cells from the matrix.28 The intentional 
release of bacteria is triggered by environmental changes, including a change in temperature, 
oxygen levels and the increased concentration of metabolites.28 This overall process can be seen 




Figure 1 The formation and lifecycle of biofilm formation on a surface, used with permission from29. 
1.4.2 Quorum Sensing 
Quorum sensing is the name given to the chemical signalling pathways that allow intercellular 
communication between bacteria, allowing them to increase their survivability and synchronise 
their activities when existing in high concentrations, for example in a biofilm.30 Auto-inducers 
(AIs) are a class of compounds produced by bacteria, which are released and are able to produce 
a response based on population density.31 The number of AIs detected by a bacterium is 
proportional to the concentration of bacteria that are present around it. The structures of these 
signalling molecules are varied; different bacterial species produce different AIs, although there is 
often overlap in the recognition of compounds.30 Examples of their structures can be seen below 















Figure 2 a) Acetyl-homoserine lactones (AHL), an AI with an R chain length that varies between bacterial species. 
b) AI-2, a family of autoinducers, c) Streptomyces γ-butryolactones 
The detection of these species can induce changes in gene expression in individual bacteria to 
increase the survivability of the biofilm as a whole. The development of a biofilm is not the full 
extent of quorum sensing’s use however; it can also trigger the production of virulence factors.32 




1.5 Bacterial Infection 
Bacterial species that are able to cause harm to the host are known as pathogenic. This 
pathogenicity will confer an increased level of survivability to the bacteria; this can be through the 
production of excreted virulence factors.33 These disease-causing molecules can be either chemical 
or enzymatic in nature. Within a wound environment one of the most damaging forms of virulence 
factor are extracellular proteases.34 Proteases are enzymes that can degrade host tissues, in turn 
generating both space and nutrients for the invader.35 These excreted compounds are not restricted 
to local effects. Non-enzymatic proteins, for example toxic shock syndrome toxin (TSST) 
produced by S. aureus, is a superantigen responsible for a number of disease states. A traditional 
protein antigen promotes a response only following its ingestion by an antigen presenting cell; 
super antigens however bind to cells and are not taken up by said cell but rather produce the effect 
simply by binding. It effects the entire body producing symptoms such as fever, shock and in 
serious cases death.36 The bacteria do not however enter the blood stream and produce the toxin, 
rather they produce the toxin in the local infection site (i,e, wounds), and the toxin enters the blood 
and spreads to receptor sites.36  
Infections are most commonly treated with antimicrobial chemotherapies, however as previously 
mentioned, the bacteria become much less susceptible to traditional antimicrobials when they 
adopt the biofilm phenotype. As a result, novel targets must be found. The term antimicrobial 
encompasses agents that feature activity against any microbe, including but not limited to fungi, 
viruses and bacterial. Antibiotics however are specific to bacteria; within this work these terms 
will be used interchangeably. 
1.6 Antibiotics  
The discovery and development of antimicrobials was arguably the most important breakthrough 
in the history of modern medicine.  The first antibiotic was discovered by Flemming in 1928 with 
the introduction of penicillin. This kick started a golden age of antibiotics. Penicillin, being a β-
lactam, is ineffective in the treatment of gram negative infections (discussed further in 1.17). This 
prompted the discovery of a number of other different classes of antibiotics. The WHO’s list of 
100 essential medicines includes 38 antibiotics for general treatment of bacterial infection.37 
Without the use of antibiotics even minor infections can grow unchecked, causing potential 
complications with drastic implications for health. This is an even greater danger for 
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immunocompromised patients, for example those undergoing cancer chemotherapy. Without the 
prophylactic use of antibiotics, many anti-cancer agents could not be used.38 The objective of 
antibacterial drug design is to find a molecule that is toxic to bacterial cells, but does not show 
activity towards mammalian cells. Common targets include bacterial ribosomes (e.g. 
aminoglycosides and tetracyclines), the cell wall (β-lactams) and the enzymes, including DNA 
gyrase (fluoroquinolones).39-41  
1.6.1 Cell Wall Inhibitors   
1.6.1.1 β-lactams – Penicillins 
The first generation of β-lactams produced were the penicillins. Since the first variation (benzyl-
penicillin) was isolated from the Penicillium fungi a number of analogues have been produced 

































Benzyl Penicillin Amoxicillin Oxacillin 
Figure 3 Three commonly prescribed penicillins, Benzyl Penicillin (also known as penicillin G), Amoxicillin and 
Oxacillin 
Bacterial cell walls are peptidoglycan layers of repeated dimers of N-acetylglucosamine and N-



















. These layers are crosslinked by chains of amino acids, typically with a tetrapeptide.42 In cell wall 
synthesis, the step in which the peptidoglycan chains are crosslinked is catalysed by the penicillin 
binding protein (PBP). The mechanism of action for penicillin is the inhibition of this protein, with 
the characteristic 4-membered lactam ring inactivating the transpeptidase by binding to its active 
site.40 The bacterial cell wall is constantly being formed and destroyed within bacteria, and the 
PBP is only essential for the formation. This means that with the PBP inhibited, the forward 
reaction cannot occur whilst cell wall destruction is not affected. This leaves the bacteria with a 
much weaker cell wall, which is not able to withstand the osmotic pressure changes that the cells 
regularly experience, ‘bursting’ the bacteria through osmotic lysis.43  
This bacterial cell wall is much thicker in gram-positive bacteria (20 – 80 nm) when compared to 
gram-negative bacteria (<10 nm) which also consists of a far less porous lipopolysaccharides, 
which is how the previously discussed Gram staining test is able to distinguish the two. Whilst 
thinner, the lipid bilayer features mechanical strength great enough to withstand the osmotic 
changes experienced by the bacteria. As a result, the susceptibility of gram-negative bacteria to 
beta lactams is much lower.44 
1.6.1.2 β-lactams – Cephalasporins 
This lack of ability to treat gram-negative bacteria led to research attempting to create analogues 
of the drugs with a broader spectrum of activity. Structurally, cephalasporins are very similar 
compounds to the penicillins, featuring a six membered ring bound to the four membered ring. 
This class of compounds is slightly less susceptible to the inactivating β-lactamase enzymes (which 























































Figure 5 An example of a member of the first four generations of the cephalosporin class of β-lactams. Top left first 
generation Cefazolin, top right second generation cefoxitin, bottom left third generation cefotaxime and bottom right 
fourth generation cefepime. 
One of the earliest cephalosporins was Cefolazin, figure 5. First reported in 1970, it offers a far 
greater activity against gram-negative bacteria, including E. coli and Klebsiella pneumoniae.45, 46 
The second generation cephalasporin Cefoxitin offers a similarly broad spectrum of activity, but 
has the advantage that it is more resistant to the action of β-lactamase, a drug inactivating enzyme 
that will be discussed further in 1.6.3.1.47  The next step in the continuing improvement of this 
class of antibiotics, was the discovery of the third generation drug Cefotaxime. Cefotaxime was 
found to have a similar efficacy in the inhibition of gram-positive bacterial growth, however, 
showed a 50-100 times increase in activity to previously tested cephalosporin sensitive strains, and 
a 100-1000 times increase in activity against cephalosporin resistant strains.48 This increased the 
spectrum of activity of the second generation drugs, which unlike cefotaxime, were not effective 
against bacterial species such as Streptococcus faecalis and Proteus spp. Further improvements 
came with the fourth generation, exemplified by cefepime. Cefepime has a greater activity against 
both gram positive and gram negative isolates, whilst being more stable to β-lactamase catalysed 
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hydrolysis. Its increased penetration into gram negative bacteria owes itself to the presence of the 
N-methylpyrrolidine. 
1.6.1.3 β-lactams – Carbapenems 
 The carbapenems are another class of β-lactam, and tend to offer both a broader spectrum of 
activity and greater efficacy, combined with a lower likelihood of resistance when compared to 
the penicillins. This is due to their ability to inhibit the β-lactamase enzymes.49 As a result of their 
efficacy, they are currently used as “last resort” antibiotics.50  
Thienamycin was isolated from Streptomyces cattleya in the 1970’s, and remains one of the most 
potent antibiotics discovered. It was faced with the damning disadvantage however that it was 
unstable not only in the solid state, but also in any aqueous solution, removing any possible medical 
utility it may have had, figure 6.51 It was therefore of great interest to develop a compound with a 
similar activity, but greater stability and pharmokinetic profile. This led to the development of 
Imipenem. It is degraded by dehydropeptidase enzymes, but can be co-administered with cilastatin, 
which is an inhibitor of these enzymes. It offers a broad spectrum of activity, being one of the few 
drugs able to treat P. aeruginosa infections, yet is inactive against methicillin resistant 
Staphylococcus aureus (MRSA).51 A recently released carbapenem is Doripenem, which offers a 
greater hydrolytic stability versus previously mentioned members of this class. This gives it a 


















































Figure 6 Examples of carbapenems showing the development of treatment. Top left initially discovered natural product 
thienamycin, top right first available carbapenem Imipenem, bottom left dehydropeptidase inhibitor Cilastatin, bottom 
right recent development in carbapenem treatments Doripenem  
1.6.1.4 Glycopeptides  
Glycopeptides are another class of antibiotic that affect bacterial cell wall synthesis. As with the 
penicillins, glycopeptides have a narrow spectrum of activity, chiefly targeting gram-positive 
bacteria. Unlike β-lactams which bind to PBPs, glycopeptides bind to lipid II, a precursor to 
peptidoglycan.52 The first to be isolated and approved for clinical use was vancomycin, figure 7. 
It has been used as a drug of last resort (not being in regular use owing to its high nephrotoxicity) 







































Figure 7 The first glycopeptide to be isolated, vancomyin 
Vancomycin remained the drug of choice for a number of multi-drug resistant (MDR) bacteria, 
however in the 1990s isolates of vancomycin resistant S. aureus (VRSA) were discovered.53 
Vancomycin is not the only commercially available glycopeptide however, figure 8 shows the 
timeline of the discovery and clinical use of a number of important glycopeptides (important 
structures found in appendix 7.1.1). 
 
Figure 8 Development and release timeline for the glycopeptide antibiotics, adapted with permission from 54 
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1.6.2 Antibiotics that Target the Bacterial Ribosome  
A key feature of antibacterials is that they must be as non-toxic towards mammalian cells as 
possible. As such, the bacterial ribosome is a common target.55 The ribosome is the organelle 
within a cell in which protein synthesis occurs – this is true of both prokaryotic and eukaryotic 
cells. However, whilst exhibiting the same basic functions, the structure of these two organelles 
differ. Ribosomes are split into sub-units, the larger eukaryotic ribosome is split into 60s and 40s 
subunit to form an 80s ribosome, whilst the prokaryotic equivalent is split into 50s and 30s subunits 
forming a 70s whole unit.56 Preventing these organelles to function can occur through a number 
of chemical pathways including preventing the subunits splitting, and preventing the binding of 
DNA. Either of these mechanisms prevents the bacteria from being able to synthesise enzymes 
and other proteins crucial to their survival, leading to cell death. 
1.6.2.1 Aminoglycosides 
Aminoglycosides have a wide spectrum of activity against gramnegative bacteria, yet most fall 
short when attempting to treat gram positive infections.57 As the name implies they all contain 
amine functionalised sugars. All of the aminoglycosides are produced from grampositive 
actinomycetes of two families. Those produced by Streptomyces are given the suffix -mycins, (i.e. 
streptomycins) and those produced by Micromonospora are given the suffix –micins (i.e. 






























                 Streptomycin                                                           Gentamicin 
Figure 9 Two commonly prescribed aminoglycoside antibiotics, left Streptomycin, right Gentamicin 
Despite showing great efficacy in the treatment of P. aeruginosa infections, they are only active 
against Enterococci when co-administered with a bacterial cell wall synthesis inhibitor, such as 
those previously discussed.58 This, owing to inefficient active transport across the cytoplasmic 




The tetracyclines are natural products, or semi-synthetic broad-spectrum antibiotics, which were 
initially isolated from Streptomyces spp. in the 1940’s.60 Despite the nomenclature, the original 
compound tetracycline was not the first to gain FDA approval (in 1953), and actually both 
chlortetracycline and oxytetracyline were isolated first, gaining FDA approval in 1948 and 1951, 
respectively, figure 10.61 This anomaly in naming comes due to their antibiotic activity being 

















































Tetracycline Chlortetracycline Oxytetracycline 
Figure 10 Left Tetracycline and the generic numbering system used for all tetracyclines, Middle Chlortetracycline, 
Right Oxytetracycline 
The tetracylines used to be favoured as treatments for those patients with allergies to β-lactams, 
however, increasing levels of resistance have reduced their usefulness.62 
This list of ribosome targeting antibiotics is not exhaustive, and there are a number of other 
therapies available, i.e. the macrolides, but for the purpose of this work they will not be explored. 
1.6.3 Antibiotics that Target DNA Synthesis 
1.6.3.1 Quinolones 
The quinolones are broad-spectrum antibiotics. Fluoroquinolones are a subset of quinolones that 
feature a fluorine atom. Owing to how commonly the structures feature fluorine these two terms 
are often used interchangeably. Unlike all previously discussed antibiotic classes, the quinolones 
are one of the few classes that were synthetically isolated. The original ‘quinolone’ was not 
actually a quinolone, but a napthyridone, nalidixic acid, figure 11. Nalidixic acid, first isolated in 
the 1960s, showed good activity towards a number of bacterial species, but with a relatively high 
toxicity to mammalian cells.63 It was over a decade before cinoxacin was approved for use, offering 
an increase in activity against all bacteria, with no increase in toxicity to mammalian cells.64 Until 
the late 1980s there was a developmental boom in the production of quinolones, with over 10,000 
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quinolones being patented for antimicrobial use by 2003.63 Many of the antibiotics produced in 



















Nalidixic acid Cinoxacin Levofloxacin 
Figure 11 Left The first ‘quinolone’ Nalidixic acid, Middle Cinoxacin, Right Levofloxacin 
As with all of the mentioned classes of antibiotic, resistance has been identified in a number of 
bacterial strains, but it is not only resistance threatening their use. It has been found that a number 
of quinolones are causing damage to tendons, joints and the central nervous system with prolonged 
exposure.65 
The recurring theme in all of the antibiotic classes mentioned is that they are losing efficacy over 
time owing to the bacteria that they are designed to treat gaining resistance. The mechanisms by 
which this resistance occurs are varied, and will be discussed in greater detail.  
1.7 Antimicrobial Resistance 
The rising resistance of bacteria to current antibiotics is considered to be one of the greatest threats 
to modern medicine. The speed at which bacteria are able to acquire resistance to new therapeutic 
compounds has made the development of such drugs less financially viable, leaving 
pharmaceutical companies unwilling to spend money on the development of a product that may 
only be on the market for under five years.66 There are many reasons why antibiotic resistance is 
becoming such a grave problem, major factors are: the over use of antibiotics in agriculture, over 
prescription of antibiotics within healthcare and also exposure to ineffective antibiotics (through 
either misdiagnosis or mis-prescription).67, 68 Exposing a bacterial population to sub-therapeutic 
concentrations of an antibiotic will always select for survival, and as such, in the UK the given 
advice is to finish an antibiotic course, to prevent incomplete eradication of an infection. A recent 
paper by Llewelyn et al. has contradicted this however, indicating that this is not founded in 
evidence and that it has been shown that prolonged exposure to the antibiotics may in fact be 
increasing the prevalence of resistance.69 
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1.7.1 Intrinsic Resistance  
Certain bacteria have an intrinsic resistance to some drugs; as previously discussed, a number of 
drugs that are active against the bacterial cell wall are inactive against gram-negative species. 
These resistances are a result of a spontaneous mutation and Darwinian selection pressures, as 
opposed to horizontally transferred genes.70 These resistance genes have often been part of 
bacterial genomes for millions of years, as exemplified by the resistome of Paenibacillus spp. 
found in the Lecugulia cave in New Mexico, which has resistance to most clinically available 
antibiotics despite never having been in contact the compounds.71 
Efflux pumps are ubiquitously present in all bacteria, suggesting that their initial purpose was not 
for the development of resistance to antibiotics.72 These are essentially protein channels which 
actively transport chemical entities across membranes, utilising energy produced from adenosine 
tri-phosphate (ATP). Efflux pumps can be either specific for certain molecules or can transport a 
range of compounds.73 As a result, these efflux pumps can convey resistance to a number of 
antimicrobial entities (including metal ions like silver, with a known toxicity to bacterial thought 
to be attributed to their interactions with thiols), and are common to a range of bacterial species.74, 
75 These are known as multi-drug resistant (MDR) efflux pumps. 
1.7.2 Acquired Resistance  
Bacteria mutate rapidly. This can lead to the spontaneous development of genes coding for proteins 
that can infer resistance to a particular species.76 Whilst initially this would yield a negligible 
percentage of the population that featured this gene, that the bacteria have the ability to transfer 
genetic material horizontally.  
Bacterial genetic material is not histone bound like that of eukaryotic cells, but is free floating. 
There is a large, single loop of DNA known as the bacterial chromosome, and a number of smaller 
loops known as plasmids. These plasmids code for a far smaller number of genes than the bacterial 
chromosome.77 
1.7.2.1 Horizontal Gene Transfer (HGT) 
Bacteria are able to transmit DNA horizontally as well as vertically to offspring. There are three 
separate mechanisms by which this genetic material can be transferred: transformation, 




Transformation is the process by which bacteria are able to take up DNA from their surrounding 
environment, figure 12. The presence of such extracellular DNA is normal within typical bacterial 
growing conditions, but the cells must reach a state of ‘competence’ before they are able to take 
on said genetic material; this state is induced by a number of factors such as nutrient access.79 This 
genetic material often comes from lysed cells, but is also a component of biofilm EPS.80 
 
Figure 12 The two types of transformation; Left The uptake of fragmented bacterial DNA from a bacterial chromosome 
Right The uptake of a plasmid into a bacteria  
1.7.2.3 Transduction 
Transduction is another method by which bacteria can acquire new genetic material, however, this 
mechanism requires a vector to carry the DNA; this vector comes in the form of a bacteriophage.81 
Bacteriophage, or phage, are viruses that are highly specific towards bacteria. Depending on the 
phage this can be specific for a species of bacteria or even a single strain. Once bound to a bacteria, 
the phage ‘hijack’ the DNA replicative abilities of the bacteria and are able to reproduce. This can 
be either predatory, leading to bacterial cell death, or symbiotic.82, 83 Within transduction a 
bacteriophage will infect a bacteria, breaking down the hosts DNA. It will then proceed to 
replicate. During this replication, some of the newly produced phage will have acquired bacterial 
DNA. Once the new phage are released, they can infect other bacteria with the genetic material 
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from the previous bacteria.84 This requires the phage to be temperate as opposed to virulent. In 
essence this makes them non-toxic bacteria; these differences are beyond the scope of this work.85 
1.7.2.4 Conjugation 
The most studied and understood mechanism of the three is conjugation. Conjugation requires cell 
to cell contact of the bacteria. In this method the bacteria dock at recognition sites and form a 
conjugal pilus, through which they are able to transfer even large strands of DNA.86  
Regardless of the three methods in which HGT occurs, the end-result is that bacteria are able to 
transmit genes to other bacteria inferring an increased level of fitness to other bacterial cells. 
1.7.3 Specific Resistance Genes 
Bacteria can have resistance to antibiotics in a far more specific manner than blocking their entry 
or ejecting toxic chemicals from their cells. Either the bacteria will inactivate the attacking species 
(the antibiotic) or it can modify the drugs target site.87 
1.7.3.1 Antibiotic Destruction and Alteration  
Resistance to penicillin was one of the earliest reported, with the mechanism of resistance owing 
to the bacterial enzyme β-lactamase.88 These enzymes open the strained four membered ring within 
the β-lactam antibiotics that is essential to their activity. They do this through either a zinc centre, 
or more commonly through serine ester formation (via an acyl enzyme intermediate).89  
Aminoglycoside inactivation through bacterial enzymes has also been widely reported.90 Acyl-
transfer enzymes are able to inactivate the drugs through acylation of the hydroxyl and amine 
groups, preventing it binding to the bacterial ribosome (hydrogen bonding is essential to a number 
of drug binding interactions).  
Chloramphenicol is an antibiotic that also inhibits protein synthesis, figure 13. Chloramphenicol 
acetyl transferase (cat) acetylates the hydroxyl groups within the molecule, preventing it binding 










Figure 13 The antibiotic chloramphenicol  
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This is only a small number of the many compounds that bacteria have evolved enzymatic 
mechanisms for destroying or altering; Munita et al. have a more exhaustive list more in this 
review.92 
1.7.3.2   Target Alteration  
As well as preventing the action of antibiotics by altering the chemical structure, bacteria are able 
to alter the target site. This is exemplified in bacteria that are resistant to β-lactams. As the drugs 
have a very specific binding to the PBP, bacteria such as Streptococcus pneumoniae have evolved 
by altering the structure of the PBP, giving PBP2A.93 This altered protein no longer features the 
binding site for penicillin, yet retains the ability to construct the cell wall. 
It is not only single proteins like the PBPs that can be altered. Small structural changes to large 
organelles, such as that of the ribosome, have also been observed.94 One example is the di-
methylation of two amino groups, preventing the antibiotic erythromycin from binding.95 
It is possible for these genes that code for wide ranges of resistance, i.e. efflux pumps, to be 
transferred horizontally. In areas of higher bacterial density, such as in clinical settings, these genes 
can spread rapidly, causing widespread resistance. As more is being learned of the global threat 
that is antibiotic resistance, more action is being taken to slow it and to find new therapies.  
1.8 What is Being Done to Combat Antibiotic Resistance? 
Antimicrobial or antibiotic stewardship is a term that outlines the practise of avoiding incorrect 
prescription of antimicrobials. The National Institute for Health and Care Excellence (NICE) have 
developed a set of guidelines for the decision making processes when considering the correct 
choice of prescription.96 Point of care diagnostics for early wound detection can help prevent the 
prophylactic use of antibiotics following invasive surgeries.97  Within the agricultural settings the 
problem and the solution is predominately based in governmental policy; the use of preventative 
antibiotics in agriculture was banned in the European Union (EU) in October 2018, with an aim to 
reduce the prevalence of resistance. Therapies that are able to neutralise the pathogenicity in 
bacteria are also being explored. These are compounds that interfere with the bacteria’s quorum 
sensing, which can prevent it from switching its phenotype to one that produces virulence. 
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1.8.1 Biofilm Inhibitors and Biofilm Disruptors  
The exposure of an organism to an outside selection pressure, in this case an antibiotic, will always 
select for evolution that overcomes this pressure. This is the fundamental basis of the rise of 
antibiotic resistance. The inhibition of the quorum sensing that move between bacteria does not 
directly affect individual bacterial cells. This inhibition will simply prevent the chemical or 
biological effect of these signalling molecules. These treatments are essentially ‘shooting the 
messenger’. This can mean the prevention of the formation of a biofilm or even preventing 
virulence factors being produced.32, 98  
For P aeruginosa there are 3 chief quorum sensing pathways, las, rhl and PQS. The PQS pathway 
is regulated by 2-Heptyl-3-hydroxy-4(1H)-quinolone (PQS), figure 13.99 Li et al. noted that this 
regulatory chemical was essential to the formation of the P. aeruginosa biofilms, as well as a 
chelator of iron; bio-available iron can promote the biofilm formation.100 The group were able to 
produce a library of pyranone containing compounds, able to inhibit the action of PQS, preventing 
the formation of P. aeruginosa biofilms. Their lead compound can be seen in figure 14, and 









Figure 14 Left The PQS signalling molecule 2-Heptyl-3-hydroxy-4(1H)-quinolone Right PQS inhibitor 
Unlike biofilm inhibitors, biofilm disruptors are able to cause the breakdown of an already 
established biofilm. Böttcher et al. used the natural biofilm disruptor norspermidine as a starting 
point to develop a library of active compounds, figure 14. Norspermidine is a natural part of the 
bacterial physiological process to collapse existing biofilms in the developmental cycle of Bacillus 
subtilis. The most effective compound they produced, 1-(3-guanidinylpropane-1-yl)-1,1’-
(propane-1,3-diyl)-diguanidine, figure 15, was able to disrupt biofilms with an MBIC of  
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Figure 15 Left Natural  biofilm disruptor Norspermidine. Right Synthesised broader spectrum biofilm disruptor 
based on spermidine 
 
1.9  Fluorescence  
Luminescence is the production of light from an electronically excited substance; this can be 
broadly split into either fluorescence of phosphorescence. These processes involve the relaxation 
of an excited electron from either a singlet or triplet excited state respectively.103 The main 
difference between these two processes is the rate at which the emission occurs – this is much 
faster in fluorescence (108 s-1) than in phosphorescence (103 s-1). The process of fluorescence is 
most commonly described with the Jablonski diagram, figure 16. 
 
Figure 16 Jablonski diagram showing the potential excitation of an electron to a higher energy level and its 
subsequent relaxation with the release of a photon 
In figure 16 the absorption (arrows in green) indicates the excitation of the electron from its ground 
state, S0, to one of its excited states, S1 or S2 depending on the energy of the incoming photons. 
The levels within the electronic states are vibrational, and energy can be dissipated to the 
surroundings via these non-radiative steps, this is known as internal conversion (IC). The electron 
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in these states will have a spin opposite to that of the electron in the ground state. This means that 
the transition to S0 is allowed, making the emission of the fluorescence photon fast. Should the 
electron undergo internal system crossing (ISC) this spin flips. This makes the transition between 
the excited state, T1, and the ground state S0 forbidden (purple arrows). This results in in the 
wavelength of light being emitted increasing and the rate at which it is released decreases. Owing 
to the speed often being an important factor for diagnostic systems, fluorescence will be focussed 
on in this thesis.  
1.9.1 Designing a Fluorescent Probe 
A fluorescent probe is compound, which will give a fluorescent response in the presence of an 
analyte. Upon interaction they form a host-guest complex. There are two key types of fluorescent 
probe; chemodosimeters are reaction based sensors, in which the guest irreversibly changes the 
host to give a response. These tend to give greater selectivity as well as lessened influence by the 
environment.104 The other types of probes are chemosensors – these feature non-covalent 
reversible interactions between the host and the guest.105 For the purpose of medical diagnostics 
and fluorescent imaging, these two types of probe offer indistinguishable results, and as such the 
term fluorescent probe will henceforth be used to describe either of these. 
There are two key components to a fluorescent sensor, the reporting fluorophore and the receptor. 
The receptor, either bound directly to the fluorophore or via a linker, will in some-way change the 
fluorescence of the compound. The choice of reporter depends on the application. If it is for the 
imaging of cells then the fluorophore must have an adequate hydrophilicity to be transported to 
cells, yet still be hydrophobic enough to enter the cells it needs to image. A number of common 
fluorophores can be seen below, figure 17a. The fluorescence of some these compounds is pH 



































Figure 17 a) Three common fluorophores used for the creation of fluorescent probes b) The pH dependent equilibria 
illustrated by fluorescein, in which only the anionic forms are fluorescent. It is highly fluorescent with a large 
quantum yield at pH 5 – 9 (hence its use in physiological systems); with neutral forms exhibiting a much lower 
quantum yield 
These are of great utility as they have all been used in prior cell based studies, and as a result, they 
are known to be of low toxicity and high optical brightness.106, 107 High optical brightness is 
important for good image to background differentiation and low toxicity is essential to not damage 
mammalian cells. On exposure to light, fluorophores will lose efficacy, a process known as photo-
bleaching. Resistance to this process is of great importance in order to maintain activity. 
1.9.2  Molecular Mechanisms of Fluorescence  
There are three mechanisms of fluorescence at a particle level, photoinduced electron transfer, 
(PET), Förster resonance energy transfer (FRET) and internal charge transfer (ICT). 
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1.9.2.1  Photo-induced Electron Transfer 
The simplest of the three mechanisms is the PET. This mechanism can be utilised to generate both 
turn off or, more desirably, turn on fluorescent sensors. Turn on sensors for bio-imaging offer a 
bright object to analyse against a dark background, which is easier than a dark object against a 
light background. In PET a fluorophore has a receptor which quenches its fluorescence. Upon the 
binding of an analyte the HOMO of the receptor is lowered, which stops this quenching effect, 

















Figure 18 Left the quenching of fluorescence by occupation of the fluorophores LUMO with an electron from the 
receptor. Right Electron relaxation from the HOMO to the LUMO of the fluorophore via photon emission. Figure 
adapted with permission from108 
On the left of figure 18, there is an electron transfer from the HOMO of the receptor into the 
LUMO of the fluorophore, as it achieves a lower energy state. This prevents the relaxation of the 
HOMO into the LUMO or the fluorophore via the emission of a photon. Upon binding to an 
analyte, the HOMO of the receptor becomes lower in energy than the LUMO of the fluorophore. 
As a result, it is not energetically favourable for the electron in the HOMO of the receptor to 
occupy the vacancy in the fluorophore LUMO, allowing the relaxation of the electron from the 
HOMO to the LUMO of the fluorophore through emission of a photon.108 
This has been utilised by Burdette et al. in the development of a Zn2+ sensor. The receptor in this 
sensor is the pyridine groups, which are able to co-ordinate to the zinc ion, allowing the turn on 









Figure 19 A fluorescent Zn2+ sensor synthesised by Burdette et al. which uses PET as its fluorescence mechanism  
1.9.2.2  Förster Resonance Energy Transfer 
FRET requires two molecules of similar excited state energies to be spatially near to each other. 
One molecule is classed as the donor, the other the acceptor, and the donor transfers energy through 
a non-radiative process to the acceptor. The donor must have an emission band, and the acceptor 
an excitation band, that overlap as in figure 20. The energy is transferred from donor to acceptor 





Figure 20 The required overlap of the donor emission and acceptor excitation wavelengths in order to give rise to 
FRET. Adapted from111 
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The dependence of FRET on the distance between the donor and the acceptor can allow its use in 
the probing of protein structures, immunoassays and in enzymatic studies. 112-114 If using two 
distinct dyes (as the process can be done with the same molecules, for example fluorescein), then 
the process is ratiometric. As one signal decreases, the other increases. The donor signal can be 
used as an internal calibration when compared to the acceptors emission. This allows more 
quantitative analysis to be performed. 
Zhang et al. produced a ratiometric Hg2+ sensor utilising a rhodamine derivative (rhodamine B) 
and BODIPY, figure 21. This offered a large red shifted fluorescence response (100 nm) helped 
prevent signal interference, and was selective for Hg2+ ions vs other common metal ions.115 The 
Hg2+ ions induced the ring opening shown in figure 21, causing the formation of rhodamine which 
can act as an energy acceptor. Mercury’s toxicity to humans is well known, diagnostic tools such 




















Figure 21 A ratiometric probe for Hg2+ utilising a FRET response between a Rhodamine B donor and a BODIPY 
acceptor 
1.9.2.3  Internal Charge Transfer 
ICT probes also offer another attractive avenue for the production of ratiometric probes. Within 
ICT probes there must be an orbital overlap between the receptor and the reporter fluorophore. 
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There is an electron withdrawing group at one end of the molecule, with an electron donating 
group at the other; this is often referred to as ‘push-pull’ system. Upon excitation, there is a dipole 
formation within the molecule due to the redistribution of electron density. The binding of an 
analyte to the receptor site shifts the distribution of this electron density, which in turn shifts the 
excitation and emission wavelengths of the fluorophore. It is this change in fluorescence, rather 
than a turn on or off response, that often makes these probes ratiometric. 
An example of such a system is that developed by Han et al. for the visualisation of H2S within 
cells dubbed Cy – N3. H2S is utilised in a number of processes within cells, but above physiological 
concentrations can become problematic, contributing diseases such as Alzheimer’s.117 They used 
a heptamethine cyanine derivatised with an azide, which would react with H2S forming an amine. 
This adjusts the electron density within the push pull system in the heptamethine cyanine, figure 











Figure 22 The ICT based H2S sensor, Cy – N3 developed by Han et al. using heptamethine cyanine. 
1.10 Boron Chemistry 
All of the novel release systems and hydrogels discussed within this thesis are made possible by 
the unique chemistry of boron. Boron, the only non-metal group 13 element has a ground state 
electronic configuration of 1s2 2s2 2p1, and as a non-metal forms covalent bonds. The 
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electronegativity of Boron (χ = 2.0) is comparable to, but crucially lower than, that of both 
hydrogen and carbon (χ = 2.2 and χ = 2.5 respectively). This means that in organoboron compounds 
the boron centre will be electron deficient. This boron centre is trivalent and sp2 hybridised, 







Figure 23 Common trivalent trigonal planar organo boron compounds include R = H, Me, Et, Cl and Br 
This empty p orbital makes the boron centre susceptible to attack from electron rich species. Hard 
nucleophiles (such as fluoride) add, forming anionic tetrahedral complexes. Lone pairs on Lewis 
bases (such as pyridine) can also fill the empty p orbital forming dative covalent bonds, yielding 



















Figure 24 (a) Nucleophillic attack on the empty p orbital yielding an sp3  hybridised anionic tetrahedral boron centre. 
(b) the formation of a dative covalent bond from the lone pairs on a Lewis base to the boron centre yielding a 
tetrahedral sp3 complex 
1.10.1 Boronic Acids and Esters 
Possibly the most widely used organoboron compounds are the boronic acids and esters. These are 
compounds featuring sp2 hybridised boron bound to a carbon atom and two oxygen atoms, in the 
previously shown trigonal planar geometry.118 They are widely used within synthetic and other 
chemistries, owing to a combination of their general stability and their properties as a Lewis acid. 
The Suzuki coupling is a palladium catalysed carbon-carbon bond forming cross coupling reaction, 
widely utilised in organic synthesis. These reactions require two coupling partners, an aryl halide, 
as well as an aryl boronic acid. As a result of the huge utility of these reactions, a large number of 
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boronic acids are now commercially available. The boronic ester equivalents of these compounds 
are also widely used, as they often offer greater solubility in organic solvents. 
1.10.1.1  Boronic Ester Formation 
Boronic acids also have a strong and pH dependent affinity for diol containing compounds, 
forming 5 and 6 membered cyclic ester rings. Studies of these dihydroxyl interactions with boronic 
acids can be dated to the mid twentieth century with Lorand and Edwards, and have been studied 
extensively since.118 The pH dependence of this binding is thought to be due to the steric strain 
inherent in the trigonal planar complex, binding itself within a 5 membered ring. In more alkaline 
solutions the hydroxyl anion can bind to the boron centre, changing its hybridisation from sp2 to 











Figure 25 Boronate ester equilibrium with a 1,2 diol bound 
The pH at which this occurs is associated to the pKa of the boronic acid. It is at, or above this pKa 
that the boronate anions are preferentially formed. This pKa can be shifted by using analogous 

































































Figure 26 (a) Benzoxaborole and its corresponding boronate anion, (b) Wulff-type boronic acid and its ionisation 
equilibrium (c) carbonyl co-ordinating boronic acid (adapted from Brooks et al.119)  
The pKa of the benzoxaborole compounds is often much lower than that of analogous boronic 
acids, owing to the ring strain in the heterocycle being released upon the sp2 to sp3 transition of the 
boron centre.120 Wulff type boronic acids offer a dative bond formation between the lone pair on 
the nitrogen and the boron, lowering the pKa by increasing the sp3 nature of the boron centre.121 
Boronic acids with adjacent carbonyls show similar effects, and can facilitate diol binding over an 
even greater pH range.122 Alternatively, more simple aryl boronic acids can have their pKa adjusted 
with electronic effects; compounds featuring electron inductive groups will have an increased pKa, 
whilst those with electron withdrawing groups will have a decreased pKa.123 This can be useful 
for responsive materials dependent on pH.124 
It is not only the boron substituent that determines the stability of formed esters, but also the 
interacting diol. When considering the stability of a potential diol complex, geometry is the key 
characteristic, with cis-diols binding offering the greatest binding affinity as a result of it already 
being orientated in the conformation required for ester formation. Catechols, (1,2 diols on an 
aromatic ring), produce the most stable complexes. This is due, not only to their rigid cis diol 
structures, but also to electronic effects. The inductive nature of the aromatic ring increases the 
acidity of the diol compared to that of its alkyl alternative.125  
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1.10.2 Applications of Boronic Acids 
The reversible covalent bonds seen in these interactions give rise to a number of applications, 
including sensing, medicine and a number of different smart materials.126 As carbohydrates are 
such a biologically relevant class of compounds, the detection and differentiation of 
monosaccharides is an area that has obtained great interest. This can be achieved using a number 
of methods with a range of outputs including electrochemical, surface plasmon resonance (spr) 
and visual (either fluorescent or colour changing).127-129 For the sake of this thesis only those with 
optical outputs will be explored in detail.  
1.10.2.1 Sugar Sensors 
Diabetes mellitus is an incurable disease in which patients are unable to regulate their body’s blood 
glucose levels owing to their inability to produce insulin.130 Type one diabetes is a genetic disorder 
whilst type two is an acquired ‘life-style disease’ associated with lack of exercise and poor diet. 
There is a rising increase in type two diabetes within the population, with 4.7 million sufferers in 
2019. This figure is expected to rise to above 5 million by 2025.131 Early and rapid diagnosis is 
important, and as such point-of-care detection devices are of great interest. When haemoglobin in 
red blood cells comes into contact with glucose in the blood they can covalently bind, forming 
glycated haemoglobin, haemoglobin A1C (HbA1C). This is representative of ambient blood sugar 
levels over a number of months, and electrochemical sensors featuring boronic acids have been 
developed to monitor these.132 The level of glucose in the blood also must be monitored, and it is 
in the detection of monosaccharides that boronic acids excel. Selective glucose binding has been 
achieved with a number of boronic acid containing compounds and a wide array of fluorophores. 
These include an anthracene based sensor synthesised by James et al., as well as a tetraphenylene 


















Figure 27 D-glucose specific fluorescent turn on sensors based around anthracene (left) and TPE (right) 
Self-assembling micelles, based around dimethyl acrylamide and PBA have been developed by 
Sumerlin et al. that are able to collapse at physiologically relevant a pH in response to elevated 
concentrations of glucose; this offers a promising potential for the release of insulin in response to 
a diabetes sufferer becoming hyperglycaemic.135 
1.11 Hydrogels  
Hydrogels are three-dimensional, hydrophilic crosslinked polymeric networks. Hydrogels have 
application spanning a great number of fields including drug delivery, cell culture and sensing.136-
138 These gels can be categorised based on the polymer used within the matrix, as well as their 
crosslinking methods. The term hydrogel itself is used to describe a range of morphologies, from 
colloidal suspensions of nano-particles to larger, more rigid structures.139 The swellability of these 
materials and their resulting high water contents lends them to being more tissue like, and the 
ability of molecules to diffuse through this matrix offers an avenue for responsiveness. 
Whilst the range of uses of these gels is varied, for the purpose of this work those gels utilised for 
biological applications will be explored in detail. 
1.11.1 Hydrogels Based on Naturally Occurring Polymers  
Nature is a source of wide array complex polymers, including but not limited to polypeptides, 
polysaccharides and polyesters. These polymers are essential to life and have functions varying 
from the protective shells (chitin, a precursor of chitosan) to the storage of genetic material 
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(DNA).140, 141 With the rise in appreciation for the earths limited petro-chemical resources many 
polymer chemists have turned to such structures to find renewable material sources.   
1.11.1.1 Alginate 
One such polymer is alginate. Alginate is a biopolymer obtained from seaweed and has found 
regular use in biomedical applications, particularly in wound healing.142 Its structure consisists of 












Figure 28 Alginate repeating dimer 
Alginate can be crosslinked with divalent cations such as calcium to produce gels over a range of 
molar mass (32 kDa to 400 kDa), with the molecular weight being a major contributing factor 
towards its mechanical properties.143 Shorter gelation times lead to an increase in the order of the 
crosslinking network, in turn offering greater mechanical stability. The gelation time can be 
controlled by temperature, hence at lower temperatures the ioninc binding of the divalent cations 
is much slower, leading to increased order.144 Alternatively, competitive binding of the cation 
binding sites with a cationionic buffer solution can also slow the rate of binding.142 These 
hydrogels can also be covalently crosslinked with a number of linkers including polyethylene 
glycol (PEG), owing to the easily accessed functionality present. The different crosslinkers used 
in this situation can offer different properties depending on the application.145, 146 
Ionically crosslinked alginate gels are porous, with an average pore size of ~ 5 nm.147 This allows 
small molecules to diffuse through them. This is advantageous as most drugs are small molecules. 
Cerf et al. produced Ca2+ crosslinked nano-beads with the ability to release theophylline, an 
adenosine antagonist, in neutral pH.144 
1.11.1.2 Chitosan  
Chitosan is a cationic polysaccharide with repeating units of D-glucosamine and N-acetyl-D-
glucosamine figure 29. Chitin is a structural polymer produced by crustaceans in their shells, and 
as such is the second most abundant biopolymer behind cellulose.148 It is the deacylation of this 












Figure 29 Chitosan 
The free amine on the D-glucosamine fragments allows the chitosan to be easily functionalised as 
well as offering an attractive and reactive binding site for any chemical crosslinkers. Chitosan 
itself offers antimicrobial properties, however modifications to the structure can begin to introduce 
properties that make it suitable as a drug delivery vehicle.149 Modifications to make the polymer 
more hydrophilic include producing tetra-methyl chitosan, a permanently cationic polymer.150 This 
technique was utilised by Jintapattanakit et al. for the binding and release of insulin.151 
1.11.2 Synthetic Polymer Hydrogels 
Despite the environmental advantages of having a naturally derived polymer to create the 
hydrogel, the tailorability of the properties of synthetic polymers often outweighs the 
environmental factors. 
1.11.2.1 Poly(N-isoproylacrylamide) 
Poly(N-isoproylacrylamide) (PNIPAM) is commonly used in responsive hydrogels for biological 
applications owing to its temperature responsive nature. At low temperatures the amide group, 
figure 30, is solvated through hydrogen bonding with water, making the polymer soluble. As the 
temperature increases the amount of hydrogen bonding is lowered, increasing the interactions 
between the isopropyl groups. This ultimately expels water causing a phase transition and the 
polymer loses its solubility.152 Variations in the structure of the polymer, for example branching, 




Figure 30 poly(N-Isopropylacrylamide) 
PNIPAM has been utilised by Hathaway et al. in the release of bacteriophage K. Bacteriophage 
are viruses that are able to predate on bacteria and have received attention as a potential solution 
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to the problem of antibiotic resistance. PNIPAM was co-polymerised with allyl amine to produce 
a material with a trigger point of between 33 and 37 °C, an increase in temperature associated with 
infection.154 
1.11.2.2 Poly(vinyl alcohol) 
Polyvinyl alcohol (PVA) is a synthetic polymer of repeating diols. It is not directly synthesised via 
polymerisation of the vinyl alcohol monomer, but is created through the polymerisation and 
subsequent hydrolysis of poly(vinyl acetate).155 There exist numerous chemical and physical 
methods for the crosslinking of PVA. To improve the properties or PVA a number of co-polymers 
exist, often with saccharides, to improve its hydrophilic character.156  
1.11.2.3 Chemical Crosslinkers for PVA 
The reactivity of the hydroxyl groups on PVA is well documented, and as such a number of bi-
functionalised molecules have been used in the crosslinking of such polymers. A commonly used 
moiety in covalent crosslinking agent are aldehydes, for example glutaraldehyde. These reactions 















Figure 31 The use of di-aldehyde glutaraldehyde to form acetal bonds with the diols on PVA to crosslink the polymer 
into a hydrogel 
1.11.2.4 Physical Crosslinkers 
PVA has found use in a wide array of biomedical applications due to its non-toxic nature. Whilst 
chemical crosslinking offers an easy avenue to the generation of hydrogels they are often toxic, 
i.e. glutaraldehyde as a result physical crosslinking methods are often preferred for biomedical 
applications of PVA. 
Freeze thawing or cryo-crosslinking is a method of physically crosslinking PVA. In the freezing 
process, areas of crystallinity are formed within the hydrogel matrix. The number and size of these 
crystallites determine the mechanical properties of the produced gel, but an increase in the number 
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of freeze/thaw cycles will increase the mechanical strength of the gel.158 PVA containing hydrogels 
prepared in this manner have been utilised in a number of wound dressing and drug delivery 
systems.159, 160  
Using such chemistries and techniques as have been discussed throughout this introduction, this 
thesis will outline attempts that have been made to develop hydrogel systems for the detection of 
reactive species, and the methods by which these were developed into drug delivery systems. 
1.12 Cold Atmospheric Plasma (CAP) 
1.12.1 CAP; an Overview 
Plasma has a number of forms, the most clinically relevant being cold atmospheric plasma (CAP). 
Plasma is partially ionised gas containing both charged and non-charged particles including: ions, 
electrons, photons, atoms and molecules. Thermal plasma features a temperature equilibrium 
between the heavy particles (i.e. atoms and ions) and the lighter particles (i.e. electrons), whereas 
in CAP the lighter particles are at high temperatures, yet the heavy are at room temperature, 
yielding an overall average temperature of under 40 °C.161  CAP is generated by passing a high 
voltage across a flow of gas. This can be achieved with a variety of gases including helium and 
air, but oxygen, nitrogen air mixes and argon are the most commonly used in clinical settings.162 
There are different forms of plasma generation of which the most frequently used is the di-electric 
barrier discharge (DBD) system. A DBD system consists of two high voltage electrodes coated in 
a dielectric material between which gas passes and is ionised. A dielectric material that is an 
electronic insulator polarisable by the application of an electronic field, between which the gas 
will pass.163 One of these electrodes will possess a high voltage, whilst the other is the grounded 
electrode. Fridman et al. have developed a single, or ‘floating’ electrode. This essentially utilises 
a second, non-grounded, electrode. As it does not require grounding this electrode can be skin or 
cell lines, allowing for biological studies to be conducted more easily.164 
1.12.2 The Biological Effect of CAP 
CAP treatment has been shown to induce cell apoptosis, inhibit proliferation in cancer cells and 
cause bacterial cell death. There have been a number of recent studies seeking to understand these 
mechanisms.165 Its efficacy for the prevention of tumour growth was proved in-vivo by Tanaka et 
al., where direct plasma treatment of a subcutaneous xenograft tumour in mice was found to 
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significantly in reduce in size 24 hours after it was treated with plasma for two minutes.166 It is 
thought that the overall effect on living tissues is not down to a single factor but is the culmination 
of a number of elements. The increased concentrations of reactive oxygen and nitrogen species, 
the toxicity of which have already been discussed, make up a large part of this.167 DNA damage is 
one of the main causes of death to the cancer cells, and CAP has been found to be induce double 
stand breaks (DBS), as well as preventing phosphorylation of p53, an essential gene with many 
functions towards healthy cancer cell growth.168 For the inhibition of bacteria it has been shown 
that gram negative bacteria, in this study P. aeruginosa, show an increased membrane permeability 
following plasma treatment. This not only poses a threat to the cells on their own, but also increases 
their susceptibility to antibiotics. CAP has also been shown to have the ability to depolarise the 
bacteria membrane of S. aureus; this increases its permeability and changes the cell polarisation 
though movement of ions, inducing cell death.169 
The objective of this work is to use boronic acid chemistries in order to combine hydrogels with 
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 Boron Containing Polyacrylamide Hydrogels 
2.1 Introduction 
2.1.1 Boronic Acid and Boronic Ester Soft Materials 
Boronic acid containing hydrogels combine the previously discussed reactivity of boronic acids 
with a biocompatible, hydrophilic matrix, capable of being formed into a variety of 
macrostructures. These boronic acid macromolecules have been effective in sensors, nano-
materials, and in the delivery of insulin and other therapeutics.1 Whilst many polymeric systems 
for topical drug delivery tend to be plastic and rigid in their mechanical properties, the dynamic 
nature of the boronic ester bonds offers a route to the development of more ductile and responsive 
materials. In many cases these materials exhibit interesting properties, such as being self-healing 
(the ability to be cut, and be reformed without external influence).2, 3 Whilst for structural implants 
such as bone supports, rigidity is of the utmost importance,4 for medical devices such as wound 
dressings, less stiff materials can be advantageous.5 Boronic ester soft materials tend to offer much 
greater biocompatibility, as well as being able to act as a reservoir for drug release, an ability 
utilised heavily in the delivery of contraceptive drugs.6 
Of the number of forms of boronic esters possible, the most widely used in such materials is phenyl 
boronic acid (PBA). This is due to its availability, stability and well-documented reactivity. The 
incorporation of PBA moieties into polymeric systems can be achieved in numerous ways, figure 
1. Existing polymers containing pendant groups that offer reactivity, including polyesters and 
amides, can have PBA groups coupled to them using the wide range of available coupling 
chemistries available. Commonly used coupling methods include carbodiimide (CDI) and 
EDC/NHS couplings. Chen et al. used such chemistry to functionalise hyaluronic acid with either 
maltose or PBA, to produce a dynamic covalently crosslinked hydrogel of hyaluronic acid. 
Hyaluronic acid is ubiquitous within tissues and as such is highly biocompatible, offering a glucose 























Figure 1 Different ways of forming boronic acid functionalised polymers; (a) Formation of a PBA functionalised 
polymer by reacting pendant groups with a PBA containing compound, (b) PBA functionalised polymer synthesis 
using a PBA containing monomer, (c) crosslinking of a PBA containing polymer chain and a diol containing polymer 
chain. Adapted with permission from 8 Green ovals represent pendant reactive groups. Pink ovals represent phenyl 














2.1.2 Dye Displacement Assay Saccharide Detector 
Alternatively, a monomer can be synthesised containing PBA, which can then be polymerised 
forming polymeric chains featuring the boronic acid reactivity, which are then able to be 
crosslinked forming hydrogels. Utilising a similarly created hydrogel and the chromophore 
Alizarin Red S (ARS), Lampard et al. developed a hydrogel saccharide sensor.9 ARS is a deep red 
colour, appendix 7.2.1 and features a 1,2 diol in the form of a catechol, thus can form boronic 
esters. Upon binding, ARS exhibits a clear colour change from red to orange. Performing 
conventional UV-vis experiments on gels is difficult, owing to the light scattering nature of 
different gel morphologies. To navigate this issue, the gel was placed in solutions of different 
concentrations of glucose, fructose, mannose and galactose. The competitive binding of the sugars 
displaced the bound ARS, reverting its colour from orange back to red. The released ARS then 
dissolved in the surrounding solution, which was subsequently and UV-vis spectroscopy was 
performed on this solution at the absorbance max (513 nm) allowing the concentration of free ARS 
to be determined. From this, the concentration of saccharide bound could be back calculated. 
The different forms of boronic esters have different affinities for certain compounds. As such 
Lampard et al. produced not only the PBA containing hydrogel but also a benzoxaborole (BOB) 
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Figure 2 The overall synthetic route towards the BOB acrylamide monomer 
The gels were synthesised utilising radical initiated polymerisation (mechanism in appendix 2.1), 
yielding hydrogels containing water (60% w/w), acrylamide (38% w/w), methylene bisacrylamide 
(1% w/w) and the boronic acid containing monomer (1% w/w). The gels used as controls, the 
‘blank’ gels, contained 39 % w/w acrylamide. To maintain a constant gel size the activated 
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monomer solution was taken into a 3 mL syringe. Upon polymerisation and gel formation, the end 
of the syringe was cut off, allowing a cylinder to be formed with consistent volumes. These boron 



































Figure 3 Displacement of ARS from PBA containing hydrogel matric due to competitive binding of saccharide  
As the above figure shows, there is an equilibrium reached between saccharide and unbound ARS. 
To observe the difference in binding between the BOB and PBA gels, a cylinder of each gel was 
loaded with ARS. Upon placing these gels into a solution of saccharide, the increase in 
concentration of ARS was measured.   
The ARS concentration was measured via its absorbance and the results for each saccharide were 
compared in the table below, table 1. It is important to note here that for each of the monomeric 







Table 1  The amount of ARS released from each boronic ester functionalised polyacrylamide gel as abs g-1 at 513 nm-
1.Reporduced with permission from 9  
 FRUCTOSE GALACTOSE MANNOSE GLUCOSE 
BOB 0.94 0.53 0.59 0.53 
PBA 0.82 0.40 0.41 0.34 
BLANK 0.23 0.21 0.22 0.19 
 
2.1.3 Biofilm Inhibitors  
Small chemical biofilm inhibitors prevent the formation of a bacterial biofilm via the inhibition of 
intercellular signalling, or through the binding of crucial ions, i.e. Ca2+.10, 11 Ca2+ ions are crucial 
for biofilm formation of S. aureus at µM concentrations, yet the ions are inhibitory at mM 
concentrations. Lee et al. have found that the use of Alizarin and a number of other similarly 
structure compounds reduces the concentration at which Ca2+ is inhibitory to the formation of 
biofilms. This inhibition has been proved to not be electrostatic in nature by Shukla and Rao, and 
it is thought that the complexation of the alizarin related chemicals was the reason for the increased 
activity.12 There is also evidence for the anti-hemolytic activity of the Alizarin compounds.11 
Alpha toxin, a haemolytic protein, secreted by S. aureus is essential for its biofilm formation and 
the inhibition of this is another method by which the Alizarins are able to inhibit biofilm 
formation.13 
Whilst it is not clear the exact mechanism or mechanisms by which the Alizarin compounds are 
able to inhibit the formation of biofilms, it was assumed that ARS, whilst not tested in by Lee et 
al., would act in a similar manner, with the advantage of being more water-soluble owing to the 







2.2 Chapter Aims 
Following from work done previously, we theorised that we would be able to bind a diol-
containing compound to these gels, and then be able to release this compound on addition of H2O2. 
Where the binding and subsequent release of the ARS in response to the presence of sugars was in 
equilibrium, addition of H2O2 prevents the backwards reaction pathway. This is owing to the 
oxidation of the boron-carbon bond to a boron-oxygen bond, removing the binding site for the 
ARS’ catechol.  
While previously ARS was used as a colourimetric test compound to model the potential release 
of drug molecules, studies have shown it has the potential to act as a biofilm inhibitor. Using ARS 
the drug uptake and release can be measured using UV-vis, preventing the need for extensive 
microbiological experiments. As described in the previous work, PBA and BOB gels offer 
different binding affinities for different diols, which could allow for tailorable release 
concentrations.  
The ARS binding and release should occur in a similar fashion to that of the carbohydrate, with 
the oxidation of the boronic ester causing the release of the bound dye as opposed to displacement 
with the saccharide. The end result should be the same, with diffusion of the free (thus red) ARS 

































Figure 4 The binding of ARS to a PBA monomer within a polyacrylamide hydrogel, indicated by the red to orange 


































Figure 5 The binding of ARS to a BOB monomer within a polyacrylamide hydrogel, indicated by the red to orange 




There are a range of diol containing antimicrobial compounds, a large class of which are the 
aminoglycosides, for example streptomycin, figure 6. As these contain sugars, it is predicted that 
they will bind to both the PBA and BOB gels, but with a greater affinity to the PBA, as has been 
previously reported.9 Other small molecular antibiotics such as chloramphenicol, figure 6, also 











































2.3 Materials and Methods  
2.3.1 General Information  
All solvents and reagents were purchased from commercial suppliers and used without further 
purification unless otherwise specified. Thin-layer chromatography (TLC) was performed using 
commercial precoated silica gel plates containing a fluorescent indicator. Column chromatography 
was carried out using silica gel (0.040 - 0.063 mm). Proton and carbon NMR were recorded using 
a Bruker Advance 500. Chemical shifts are reported in ppm using TMS or solvent residual signals 
as internal reference standards. High-resolution mass spectrometry (HRMS) were performed on 
an Agilent 6545 LC/Q-TOF. UV-vis were performed on a BMG Labtech CLARIOstar using costar 
u bottom 96 well microplates. Data was collected via the BMG Labtech CLARIOstar data analysis 
software package MARS.  
Synthetic experimental information can be found in chapter 6.1. 
2.3.2 Blank Gel Synthesis  
Hydrogels were formed by the dissolution of acrylamide (3.9 g) and methylene bisacrylamide (0.1 
g) in distilled water (20 mL). Tetramethylethylenediamine (50 µL) and an aliquot of freshly 
prepared ammonium persulphate solution (10% w/v, 150 µL) were added. The solution was taken 
up into 1 mL syringes, which were then inverted and placed in a test tube rack. After the gel had 
set, as determined by a visual inspection (30 – 45 mins), the end of the syringe was removed with 
a pair of scissors and 0.1 mL pieces of gel were cut using a scalpel. 
2.3.3 PBA/BOB Containing Gel Synthesis  
Hydrogels were formed by the dissolution of acrylamide (3.8 g), PBA/BOB monomer (0.1 g) and 
methylene bisacrylamide (0.1 g) in distilled water (20 mL). Tetramethylethylenediamine (50 µL) 
and an aliquot of freshly prepared ammonium persulphate solution (10% w/v, 150 µL) were added. 
The solution was taken up into 1 mL syringes, which were then inverted and placed in a test tube 
rack. After the gel had set, as determined by a visual inspection (45 – 60 mins), the end of the 
syringe was cut off with a pair of scissors and 0.1 mL pieces of gel were cut using a scalpel. 
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2.3.4 Dye Uptake Experiments 
To measure the binding of the dye to the gel, a cylinder of gel with a volume of 0.1 mL was 
weighed and placed into the well of a 24 well microtitre plate. 1 mL of 2.5 x 10-4 M ARS solution 
in PBS was then added to the well. The initial absorbance of this solution was measured by taking 
a 100 µL aliquot in a 96 well microplate and measuring using its absorbance at 513 nm using a 
Spectrostar Omega plate reader from BMG Labtech. The aliquot was then returned to the well 
containing the gel in order to maintain its volume. Aliquots were then taken over time and the 
decrease in absorbance was plotted as a function of the mas of the individual gel used. 
2.3.5 Dye Washing Experiments  
To measure the release of non-covalently bound dye from the gel, a cylinder of ARS loaded gel 
with a volume of 0.1 mL was weighed and placed into the well of a 24 well microtitre plate. 1 mL 
PBS was then added to the well. The initial absorbance of this solution was measured by taking a 
100 µL aliquot in a 96 well microplate and measuring using its absorbance at 513 nm using a 
Spectrostar Omega plate reader from BMG Labtech. The aliquot was then returned to the well 
containing the loaded gel in order to maintain its volume. Aliquots were then taken over time and 
the increase in absorbance was plotted as a function of the mas of the individual gel used. 
2.3.6 Dye Release Experiments with H2O2 
To measure the release of dye upon exposure to H2O2, solutions of H2O2 were prepared in PBS, 
with concentrations ranging from 0 to 4 mM. ARS loaded gel cylinders with a volume of 0.1 mL 
were weighed and placed into the wells of a 24 well microtitre plate. 1 mL of either PBS of H2O2 
solution was added to the well and experiment aliquots were removed and their UV-vis was 
measured every 10 minutes for 60 minutes then hourly for 2 hours was repeated. Aliquots were 
returned to the experimental solution to maintain sink conditions. 
2.3.7 Dye Release Experiments with Plasma Activated Buffer 
In order to generate a ROS/RNS solution using cold plasma, PBS (1 mL) was treated with the cold 
plasma jet for set period of time (0 – 30 mins). The plasma conditions used were: 10 kV, 25 A, 0.6 
slp with a distance of 15 mm. Once the plasma activated solutions were generated, they were used 




2.3.8 Media, Buffers and Stock Solutions  
Medium or buffer Reagents 
Luria-Bertani (LB)  ThermoFisher Scientific U.K 
Luria-Bertani agar (LBA) ThermoFisher Scientific U.K 
Tryptic soya broth (TSB) ThermoFisher Scientific U.K 
Tryptic soya agar (TSA)  ThermoFisher Scientific U.K 
Phosphate buffered saline (PBS) Sigma Aldrich U.K 
*All media was sterilised using an autoclave prior to use 
2.3.9 Bacterial Strains and Overnight Cultures  
P. aeruginosa PAO1, S. aureus H560 and S. aureus MRSA252 were obtained from a strain 
collection belonging to the Biophysical Chemistry Research Group at the University of Bath. E. 
coli NCTC 10418 was obtained from Professor Maillard’s group at Cardiff University. All strains 
were stored in a 30% (v/v) glycerol solution at -80 °C. Overnight cultures of bacterial strains were 
routinely grown in 10 mL of LB medium for P. aeruginosa PAO1 and E. coli NCTC 10418, and 
TSB medium for S. aureus MRSA252 and H560 at 37 °C with shaking (225 rpm) for 24 hours.  
2.3.10 Bacterial MICs 
Antimicrobial susceptibility testing was carried out in a 96-well microtiter plate using a standard 
two-fold broth microdilution method as recommended by the Clinical Laboratory Standards 
Institute (CLSI). 100 µL of an antimicrobial agent of known concentration was serially diluted 
two-fold across the 96 well plate in 1% (w/v) D-(+)-glucose for TSB and 50% (w/v) D-(+)-glucose 
for LB. Re-suspended bacterial cultures were diluted in TSB/LB, and added in equal volume, so 
that each well contained approximated 5 x 105 Colony Forming Units per mL CFU/mL (range 
2 – 8 x 105 CFU/mL). The Minimum Inhibitory Concentration (MIC) was defined as the lowest 
concentration of antimicrobial agent required to inhibit the visible growth of bacterial strains after 
18 h incubation at 37 °C. 
2.3.11 Bacterial Biofilm Formation 
Bacterial biofilms were formed in 96 well microplates (Nunc, UK). Overnight bacterial cultures 
were sub-cultured into fresh medium, supplemented with 1% (w/v) D-(+)-glucose for TSB and 
50% (w/v) D-(+)-glucose for LB, to a starting bacterial concentration of 106 CFU/mL. An aliquot 
of 100 µL of subculture was added to selected wells, before an equal volume of known drug (or 
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drug combination) concentration was added at desired stage of growth. Plates were then incubated 
statically at 37 °C for 24 hours. Supplemented TSB or LB was used as a negative control. 
2.3.12 Crystal Violet Biofilm Staining  
After incubation, planktonic bacteria were removed from the microtiter plate, and the remaining 
biofilm was washed three times with PBS. Next, 250 µL of 0.1% (w/v) Crystal Violet (CV) was 
added to each well and left to incubate at room temperature for 15 min. After staining, the wells 
were rinsed three times in PBS and left to dry at room temperature for 3 – 4 hours. To quantify the 
biofilm biomass, 250 µL of 33% (v/v) acetic acid (AcOH) was added to each well to elute the CV 
stain, and left to incubate at room temperature for 15 min. Note – AcOH measured with pipette 
calibrated to water ergo uncertainty in measurement. Finally, 125 µL of eluted dye solution was 
transferred into a fresh 96 well microtiter plate and absorbance was measured at 570 nm 













2.4 Results and Discussion 
2.4.1 Synthesis of the Boronic Acid Containing Hydrogels 
The two boronic acid containing monomers were prepared according to the synthesis previously 















Figure 7 The binding of the PBA to an acrylamide monomer 
To create the hydrogel, acrylamide, methylene bisacrylamide and the chosen boronic ester 
containing monomer were dissolved in distilled water. TMEDA and ammonium persulphate 
solution were added into the flask using a syringe to initiate the polymerization, and the solution 
was taken up into 1 mL syringes. After 40 minutes the gelation was complete and the end of the 
syringe could be cut off, allowing cylinders with a measurable volume of 0.1 mL to be cut. The 
produced gels were very pale in colour, meaning they were able take on the colour of the dye, 
figure 8. 
 
Figure 8 Clear poly acrylamide gels doped with left PBA and right BOB monomers. Slight yellow tint due to TEMED 
impurities. 
2.4.2 Dye Loading and Washing Studies  
To bind the ARS to the boronic ester moieties within the hydrogel, the gels were placed in a 
solution of 2.5 x 10-4 M of ARS in PBS buffer for 5 hours. As the concentration of free ARS in the 
solution decreases, so does its absorbance in accordance to the beer lambert law.14 




 Aliquots were therefore taken and measured at different intervals to discover the minimum time 
required to soak the gels to allow them to obtain their maximum loading. The larger the gel, the 
more boronic acid binding sites would be available to bind the ARS. Therefore, to allow for 
potential differences in gel swelling and size, the absorbance was plotted as a function of the 
masses of the individual gels used, figures 9 and 10. 

































Figure 9 The decreasing absorbance at 513 nm of a solution of ARS (in PBS) as it binds to the PBA containing gel. 





































Figure 10 The decreasing absorbance at 513 nm of a solution of ARS (in PBS) as it binds to the BOB containing gel. 
The assay was conducted three times and results plotted as mean ± standard deviation 
It can be seen from the loading graphs, figures 9 and 10, that the final ARS concentration is greater 
in the solution containing PBA gel than in the solution containing the BOB gel. This is indicative 
of a higher binding affinity between the ARS and the PBA compared to the BOB boronic esters.  
 
Figure 11 ARS loaded left PBA containing and right BOB containing hydrogels pre-washing  
Following loading, it had to be ensured that all the non-specifically bound ARS was removed from 
within the gels. Gels with unbound ARS within the hydrogel matrix have a deep red colour, figure 
11. This shows that there is free ARS that requires removal. This simply involved washing the 
loaded pieces of gel in PBS (pH 7.4). To monitor the washing of un-bound ARS from the gels, 
aliquots of washings were removed periodically, and the concentration of ARS was measured. 
Once the absorbance stopped increasing, it was deemed that the washing process was complete 
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and the remaining ARS was covalently bound to the gel, figures 12 and 13. However, the 
surrounding solution would reach equilibrium with the internal gel matrix, ergo fresh PBS should 
have been used to gain a more true zero value. 


























Figure 12 Absorbance of ARS at 513 nm upon washing the ARS-containing PBA gel in PBS over time. Increased 

































Figure 13 Absorbance of ARS at 513 nm upon washing the ARS-containing BOB gel in PBS over time. Increased 
absorbance indicates release of non-bound ARS. The assay was conducted three times and results plotted as mean ± 
standard deviation 
As can be seen in figure 14 the unbound red free ARS has been removed, yielding gels that are the 
orange colour of ARS bound to boron. 
 
Figure 14 ARS loaded left PBA containing and right BOB containing hydrogels post washing 
Beyond 180 minutes there was a plateau in the absorbance, indicating the removal of all of the 
unbound ARS. To ensure complete removal each gel was washed for 5 hours. 
2.4.3 Triggering the Release of ARS With H2O2 
Following these washing steps the ARS loaded gels were exposed to differing concentrations of 
H2O2 in PBS. As any unbound dye had already been removed, the increase in absorbance was 
proportional to the amount of bonds oxidised by H2O2, which itself was proportional to the 
concentration of H2O2 used. Figures 15 and 16 shows the release of ARS from the hydrogel 
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matrixes containing PBA or BOB monomers, with increasing absorbance at 513 nm found upon 
increasing H2O2 concentration.  
 



































Figure 15 Absorbance at 513 nm of ARS released over time from PBA gels upon differing concentrations (0 – 4 mM) 
of H2O2 in PBS. The assay was conducted three times and results plotted as mean ± standard deviation 




































Figure 16 Absorbance at 513 nm of ARS released over time from BOB gels upon differing concentrations (0 – 4 mM) 
of H2O2 in PBS. The assay was conducted three times and results plotted as mean ± standard deviation 
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Exposure of ARS loaded hydrogels to concentrations of H2O2 ranging from 100 µM to 4 mM gave 
a dose dependent release of ARS from the hydrogel matrix for both the PBA and the BOB 
containing gels. Likely owing to the increased loading efficency of the ARS into the PBA gel, the 
maximum absorbance for ARS release upon addition of 4 mM H2O2 was much higher. The 
maximum release after 3 hours can be seen in figures 17 and 18. 
 
 
































Figure 17 Absorbance of released ARS from PBA gels in solution at 513 nm after 3 hours incubation with increasing 







































Figure 18 Absorbance of released ARS from BOB gels in solution at 513 nm after 3 hours incubation with increasing 
concentrations (0 – 4 mM) of H2O2 in PBS. The assay was conducted three times and results plotted as mean ± standard 
deviation 
As can been seen above in figures 17 and 18, after the 3 hours of release there was more than a 
two-fold increase in the release of the ARS when using the highest concentration of H2O2 (4 mM), 
regardless of the form of boronic ester used. However, in both the PBA and BOB gels there was 
still some non-specific release of the ARS. This could be due to the washing steps being 
incomplete, or the fact that the boronic ester-ARS bond is a dynamic covalant bond, hence an 
equiliburm with the surrounding solution was reached. 
The diameter of cyclinders of both gel were measured upon exposure to H2O2 to ensure that there 
was no degradation of the overall gel structure, but it was found to be stable under such conditions. 
Loaded gel cylinders of both the PBA and BOB gels were submerged in 5 mM H2O2 for 24 hours 












Figure 19  a) PBA containing gels loaded with ARS, b) BOB containing gels loaded with ARS, c) PBA containing 
gels loaded with ARS following 24 hour incubation with 5 mM H2O2, d) BOB containing gels loaded with ARS 
following 24 hour incubation with 5 mM H2O2 
2.4.4 Using Cold Plasma to Trigger ARS release 
While the proof-of-concept model of utilising H2O2 to trigger the release of a diol containing small 
molecule from the hydrogel matrix was achieved, the overall intended use was to trigger the release 
using Cold Atmospheric Plasma (CAP). Initial experiments were conducted using plasma treated 
PBS buffer. Briefly, 1 mL of PBS in a 24 well plate was treated with CAP for differing amounts 
of time to produce ROS/RNS solutions of differing concentrations. Whilst the produced ROS/RNS 
solution has yet to be fully quantified in terms of the concentrations of its indivdual components, 
it is known that H2O2 is the predominent species.15 As such, increasing the duration of treatment 
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Figure 20 Absorbance at 513 nm of released ARS in solution over time from a PBA hydrogel after incubation with  
solutions of ROS/RNS in PBS generated by plasma for different lengths of time (0 – 30 mins). The assay was 
conducted three times and results plotted as mean ± standard deviation 
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Figure 21 Absorbance at 513 nm of released ARS in solution over time from a BOB hydrogel after incubation with  
solutions of ROS/RNS in PBS generated by plasma for different lengths of time (0 – 30 mins). The assay was 
conducted three times and results plotted as mean ± standard deviation 
The longer the treatment of PBS with CAP, the greater the concentration of H2O2 (and other 
ROS/RNS) produced.16 This is exemplified in figures 20 and 21. The ARS release follows the 
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same dose dependent response on increased treatment time with CAP as it did with increasing 
concentrations of H2O2. There is little differentiation between the 10, 20 and 30 minute treatment 
times when investigating the release of the ARS form the BOB gel. This could indicate that the 
shorter lived species, i.e. peroxynitrite, within the plasma treated buffer offering a greater rate of 
reactivity with the BOB functionality than the longer lived species like hydrogen peroxide.  
The overarching aim of the project was to develop a system that would be able to release a 
molecule, or molecules, on contact with direct plasma treatment. This proved problematic, as it 
was found that the direct plasma onto the gel surface caused dehydration and as a result the gel 
burned. These initial experiments were conducted using small discs of gel. However, it was 
theorised that if larger pieces were used, the increased volume of hydrogel could act as a resevoir, 
allowing movement of water and decreasing the rate of burning. This was found not to be the case, 
and instead after only 5 minutes of direct application the centre of the gel would dry, causing the 
entire gel to deform, figure 22. 
 
Figure 22 The burnt hole within a sheet of PBA gel surrounded by a ring of dehydrated hydrogel caused by direct 
plasma treatment. The edges of the gel were taped down to avoid folding 
From this, numerous blank hydrogel gels were synthesised and exposed to CAP treatment, to 
screen for a gel that could withstand a greater degree of plasma contact. These gels include agarose, 
carboxymethyl cellulose (CMC) and PVA. Owing to the ease in which it can be cryocrosslinked 
(and bound to the polyacrylamide) PVA was chosen, and a bi-layered film of the two gels was 
produced. 
These gels provided a more robust layer for direct plasma treatment – the theory was that upon 
plasma treatment this could generate a resevoir of reactive species that could then diffuse through 
the hydrogel matrix, into the polyacrylamide layer. Upon reaching the acrylamide layer, the 
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ROS/RNS produced in the PVA layer would oxidise the boronic ester, releasing the ARS through 
the base of the gel. Unfortunately,  it was found that the reactive species reacted with the boronic 
acids closest to the reservoir, forming a concentration gradient in the wrong direction, hence the 
ARS diffused upwards, figure 23. Pre-soaking the PVA gels in ARS may have been a way to 
combat this. 




         
Figure 23 The dual layer PVA and poly acrylamide system which was able to withstand direct plasma treatment 
In terms of its application this diffusion is in the wrong direction (i.e. away from the wound) and 
thus the rest of the testing was performed using the loaded acylamide gels without any other gel 
layers. As such the biological testing was performed with only H2O2 solutions and solutions of 
plasma activated buffer, not direct plasma treatment. 
2.4.5 The Biological Activity of ARS 
During normal bacterial growth there are three key stages, lag, exponential and stationary phase. 
The growth of a bacterial population is exponential, owing to their reproduction via division. The 
initial lag phase is owing to bacterial using the nutrients within the broth to grow, preparing for 
division by synthesising crucial proteins. During the exponential phase the bacteria divide, the 
population doubling in size with each division. Following this growth the bacteria will reach 
stationary phase in which the number of cells platues and remains relatively consistent. Cells will 
still continue to replicate but others will die. At this stage their growth is limited by either lack of 
nutrients or the accumlation of toxic by products of growth. The length of each of these phases 
depends on the bacteria, figure 24. 
PVA  
ARS loaded PBA gel   
H2O2 produced by plasma   Diffusion of ARS from the 
acrylamide gel upwards into 
the PVA  




Figure 24 A bacterial growth curve showing the optical density change over 18 hours due to growth at the three key 
phases; lag exponential and stationary. This is generally measured at 37 °C. Reproduced with permission from17 
The antibacterial actvity of ARS was tested using MIC measurements against isolates of S. aureus 
H560 and MRSA 252, P. aeruginosa PA01 and E. coli NCTC 10418, but was found to be non-
inhibitory for all strains of bacteria tested, even at its maximum concentration in aqueous solution, 
appendix 7.2.2. An MIC is the measure of the minimum concentration of an antibiotic required to 
prevent the growth of bacteria. It has however been previously demonstrated by Lee et al that 
certain alizarins and other calcium chelators, have the ability to prevent the formation of biofilms 
in S. aureus.11 As ARS can also chelate to Ca2+ we assumed it to, would be able to inhibit biofilms. 
In order to measure biofilm formation, biofilms were grown and biomass was assessed by adding 
crystal violet stain. This dye bound to biological material, giving an indication of the amount of 
biofilm formed through absorpstion measurments.18 The ability of ARS to inhibit the formation of 










Figure 25 Absorbance at 570 nm of crystal violet, correlating to the amount of biological material present (and thus 
amount of biofilm formation), with the addition of ARS  (0 – 100 µM) at the lag phase. Data plotted as the mean, n 
= 3. Error bars indicate standard deviation 
As can be seen in figure 25 there is no decrease in the biofilm forming ability of the two gram 
negative strains, however there is a pronounced decrease in biomass measured for both S. auerus 
strains at 100 µM, less than half of the amount of ARS loaded in the gels. One of possibility as to 
why this would have a greater effect on the gram positive strains, is that the ARS can to the quorum 
sensing molecules that instigate biofilm formation, blocking the signals. As ARS is a known 
chelator of Ca2+, it is also possible that during this lag stage there are calcium dependant pathways 
for the formation of essential proteins for biofilm formation, and these unable to be created due to 
Ca2+ capture. Ca2+ is essential to the growth of extracellular DNA, which is a crucial component 
of the biofilm EPS, and it is during the lag phase that this synthesis occurs.19 As expected this 
S. aureus MRSA252 S. aureus H560 
P. aeruginosa PAO1 E. coli NCTC10418 
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inhibitory effect was not seen for the addition of ARS to any other stage of the bacterial growth, 
appendix 7.2.3 and 7.2.4. 
In order to ensure that the cause of the systems reduction in biofilm was the ARS and not due to 
the trigger, H2O2 was also assessed for biofilm inhibiton. Differing concentrations of H2O2 (0 – 
100 mM in PBS) were added to growing cultures of S. aureus H560, S. aureus MRSA252, E. coli 
NCTC 10418 and P. aeruginosa PAO1 at the lag phase, figure 26, the exponential phase, figure 
27, and at the stationary phase, figure 28. The different bacterial species grow in the same general 
pattern of stages, but with different timings at each stage. As such the growth curves of these 
bacteria were first obtained, appendix 7.2.5. 
2.4.6 Addition of H2O2 to Biofilms at Lag Phase 
 
Figure 26 Absorbance at 570 nm of crystal violet, correlating to the amount of biological material present (and thus 
amount of biofilm formation), with the addition of H2O2 (0 – 100 mM) at the lag phase. Data plotted as the mean, n 
= 3. Error bars indicate standard deviation 
S. aureus MRSA252 S. aureus H560 
P. aeruginosa PAO1 E. coli NCTC10418 
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As is to be expected from differening species, each bacteria reacted differently to the addition of 
the H2O2. During lag phase, the addition of H2O2 to the gram positive S. aureus strains at 
concentrations as low as 5 mM caused a large reduction in biomass. There was a comparitive 
increase in resistance to the effects of H2O2 seen in both gram negative strains, with the P. 
aeruginosa and E. coli strains requiring the addition of 100 mM and 10 mM of H2O2 respectively 
to see a significant decrease in biomass. That the H2O2 had a greater effect on the gram negative 
strains could be due to cell wall effects, or possibly due to a difference in the biofilm forming 
signalling molecules produced by the gram negative species having a greater reactivity with the 
H2O2. 
2.4.7 Addition of H2O2 to Biofilms at Exponential Phase 
 
Figure 27 Absorbance at 570 nm of crystal violet, correlating to the amount of biological material present (and thus 
amount of biofilm formation), with the addition of H2O2 (0 – 100 mM) at the exponential phase. Data plotted as the 
mean, n = 3. Error bars indicate standard deviation 
S. aureus MRSA252 S. aureus H560 
P. aeruginosa PAO1 E. coli NCTC 10418 
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There is a slightly increased resistance to the antibiofilm formation effects of H2O2 in both of the 
S. aureus  strains during the exponential phase when compared to the lag phase. The lag phase is 
the stage in which the bacteria are synthesising the enzymes and other factors that they require for 
division. It could be that the nutrients that are uptaken during this stage are broken down by the 
presence of the H2O2, and that once they have been synthesised the division can occur without 
interference. For the gram-negative bacteria the E. coli strain features no change in its biofilm 
forming ability, however there is a huge drop in the bioforming ability of P. aeruginosa. During 
this growth stage the concentration of the bacteria will become great enough that the bacteria will 
begin producing more autoinducers. That the P. aeruginosa is effected more strongly is likely due 
to the structure of one of its chief autoincudcers, autoinducer-2, a furanoysl sugar containing a 
borate diester.20 This would be oxidised by the presence of H2O2, preventing the signalling 




2.4.8 Addition of H2O2 to Biofilms at Stationary Phase 
 
Figure 28 Absorbance at 570 nm of crystal violet, correlating to the amount of biological material present (and thus 
amount of biofilm formation), with the addition of H2O2 (0 – 100 mM) at the stationary phase. Data plotted as the 
mean, n = 3. Error bars indicate standard deviation 
For stationary phase bacteria, no significant differences were observed for the addition of all 
concentrations of H2O2 compared to that of the controls. Though 100 mM is a large excess when 
considering triggered release, clinical topical use of hydrogen peroxide is 3%, which equates to 
980 mM. This is why there is bacterial survivabilty and biofilm formation at what appear to be 
high H2O2 concentrations. There is a large increase in tolerance to H2O2 for all of the bacteria at 
this phase. This is likely owing to the decrease in metabolic activity of the bacteria that they 
achieve in stationary phase. As well as their metabolic activity decreasing, the concentrations of 
bacteria has been high for a period of hours (depending on the bacteria). This therefore means that 
the interference of the H2O2 with intracellular signalling will have a lessened effect. 
E. coli NCTC 10418 P. aeruginosa PAO1 
S. aureus MRSA252 S. aureus H560 
P. aeruginosa PAO1 E. coli NCTC 10418 
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Following these experiments it was deduced that regardless of the bacterial species or strain used, 
or the stage of growth at which the H2O2 was addd, the addition of 2 mM of H2O2 would not inhibit 
the formation of biofilms on its own, and thus the ihibition of biofilm formation would be due to 
the addition of ARS.  
2.4.9 Addition of H2O2 and ARS to a Biofilm at the Lag Phase 
Next, the combination therapy of  2 mM H2O2 with two different concentrations of ARS (50 and 
100 µM) was tested at each stage of growth.  
 
Figure 29 Absorbance at 570 nm of crystal violet, correlating to the amount of biological material present (and thus 
amount of biofilm formation), with the addition of H2O2 (2 mM) and ARS (0 – 100 µM) at the lag phase. Data 
plotted as the mean, n = 3. Error bars indicate standard deviation.Statistical significance calculated using a one way 
anova 
The lag phase was the only phase at which the addition of ARS caused a statistically significant 
decrease in biomass for any of the bacteria, compared to using the 2 mM H2O2 on its own. This 
E. coli NCTC 10418 P. aeruginosa PAO1 
S. aureus MRSA252 S. aureus H560 
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indicates that the ARS is having an effect on the bacteria; either preventing the uptake of nutrients, 
or interfereing with the production of metabolites that are essential to the formation of biofilms. 
Its lack of effect on the rapidly dividing exponential phase is indicative that it is not interfering 
with any intercellular signalling pathways. Similarly to H2O2 having no effect on the biofilm 
forming ability of the bacteria at the stationary phase due to them already having formed the 
biofilm, it is unsurprising that the ARS follows this trend.  
As can be seen from figure 29 there was a significant decrease in the biofilm formation of both S. 
aureus MRSA252 and P. aeruginosa PAO1. Why this did not effect the other two bacteria is 
unknown, however it is possible that it is due to differences in the signalling molecules produced 
by each strain that triggers the biofilm formation between the species. Whilst this seems to not 
explain why the two S. aureus strains would be different, the mechanisms by which MRSA 252 
resists antibiotics may offer protection from the H2O2 in some manner, increasing its biofilm 
fitness. 
2.4.10 Testing the Gel System with Biofilm Inhibition  
Whilst the ARS had initially only been intended as a model system for a drug release, the above 
data shows it’s potential utility as a stand alone, triggered anti-biofilm agent release system. To 
prove this, the biofilm inhibition experiment was repeated using lag phase S. aureus MRSA252, 
but using gel excudate as opposed to a solution of ARS. A PBA gel loaded with 0.25 mM ARS 
was incubated with 2 mM of H2O2 for 3 hours, and the resultant this solution was used to assess 




Figure 30 The statistically significant decrease in absorbance at 570 nm (correlating to biofilm formation) by 
addition of excudate from an ARS loaded gel incubating in 2 mM H2O2 when compared to controls of H2O2 and a 
blank PBA gel in H2O2. Data plotted as the mean, n = 3. Error bars indicate standard deviation.Statistical 
significance calculated using a one way anova 
As can be seen above there is a large reduction in absorbance, correlating with reduced biofilm 
biomass, when the bacteria are exposed to the gel excudate triggered by 2 mM of H2O2 when 











Two different boronic ester containing acrylamide monomers have been synthesised, and 
subsequently polymerised into boronic ester functionalised polyacrylamide hydrogels. Both PBA 
and BOB gels have been shown to be able to bind to a diol containing dye (ARS), and then release 
it in response to the addition of hydrogen peroxide in a dose dependent manner. It was also shown 
that the release of ARS could be similarly triggered with the use of plasma treated buffer, the 
amount of the release again correlating to the duration of the plasma treatment. If this is to be 
translated into a working direct plasma treatable system, then a new gel layering system must be 
found. This offers immediate use as a solid state reaction based indicator of hydrogen peroxide 
concentration, but also as a model for a drug release system. Additionally, Alizarin Red S has been 

















2.6 Future Work 
Aminoglycosides are a large class of antibiotics, with varying solubilites and efficacies. One such 













Figure 31 The Aminoglycoside Kanamycin  
Kanamycin is an antibiotic that is prescribed for a number of infections, historically it was used to 
treat tuberculosis, however Mycobacterium tuberculosis strains are gaining resistance.21 The 
sugars that make up the aminoglycosides offer a number of 1,2 and 1,3 diols, which are attractive 
sites for the binding of boronic acids. Whilst the catechol featured in ARS offers a higher affinity 
of binding to the PBA moiety, simple sugars have already been shown to preferentially bind to 
benzoxaboroles. This could mean that the BOB containing gels could offer a triggered release 
system mirroring the ARS release from PBA, but with the release of an antibiotic. Kanamycin is 
a convenient drug to begin testing with owing to its high solubility in water. Much like ARS being 
used as model system to monitor release, it would be convenient to be able to do the same with 
this follow up work. A dye that could be used was developed by Maria Odyniac of the James group 
at the University of Bath. It is fluorescein derived and features a boronic acid functionality as well 













Figure 32 Fluorescein functionalised by glucose and BPin 
Originally designed as an and/or logic gate sensor for glucosidase enzymes and hydrogen peroxide, 
this probe will mimic the binding of the sugars of the aminoglycoside to the boronic acid 
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containing gels. The compound is colourless and non-fluorescent. On exposure to either the 
enzyme or H2O2 it exhibits a colour change and an increase in fluorescence, with increased 
fluorescence and colour intensity upon exposure to both external stimuli.  
Initial experiments using PBA (owing to material constraints) containing gels showed the ability 
of the dye to bind to the gels, with subsequent release and activation of fluorescence when exposed 
to H2O2 figure 33 This was performed following the methods used for ARS; however, a lower 
loading concentration (0.1 mM) of dye was used owing to its large fluorescence intensity.  
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Figure 33 A dose dependent increase of fluorescence due to addition of H2O2 (0.5 – 4 mM) to Glucose-Fluorescein-
BPin bound PBA gel 
Following this, to ensure that there would be binding of the kanamycin a simple dye displacement 
assay performed with ARS. Briefly, ARS loaded PBA gels were made and then subsequently 
exposed to differing concentrations of kanamycin.  This shown that the drug will bind to the PBA 
gel figure 34. Whilst the binding is only slightly increased compared with the blank, this is owing 
to the equilibrium nature of the binding. In a purely kanamycin loaded gel there will be no 
competition from the ARS; the ARS due to its catechol will likely bind to the PBA more strongly 


























 10   mM Kanamycin
 25   mM Kanamycin
 50   mM Kanamycin
 100 mM Kanamycin
 200 mM Kanamycin
 
Figure 34 Increasing absorbance at 525 nm due to the increasing concentration of ARS in solution due to displacement 
from the addition of different concentrations of kanamacyin (0 – 200 mM) 
As the concepts of the release of the drug from this system have been proved to work, the next 
step is to measure the difference in preference of binding of the kanamycin to either the PBA or 
the BOB gels, and to then look at testing the system with live bacteria to see if kill can be achieved. 
If sufficient concentrations of drug can be released on application of H2O2, then the dual release 
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 PBA Functionalised Drugs 
3.1 Introduction 
3.1.1 Prodrugs  
The term “prodrugs” refers to drugs that are inactivated or masked and become re-activated in-
situ.1 This can be either through a chemical or an enzymatic (biochemical) reaction, which for 
compounds with poor pharmacokinetic properties can increase their bio-availability.2 For drugs 
with inherently poor aqueous solubility this is of particular use; addition of polar groups such as 
phosphate esters can increase in water solubility, well exemplified by the antibiotic Clindamycin 
phosphate, figure 1. Clindamycin has poor solubility in water, but the highly charged phosphate 
group makes the molecule more hydrophilic, and is then removed in vivo. Approximately 20% of 














Figure 1 Clindamycin Phosphate 
The design of a prodrug should include a promoiety. This component of the prodrug prevents its 
activity, and is subsequently removed in vivo. Prodrugs of even common drugs such have aspirin 
have been synthesised in attempts to improve their pharmacokinetic profile.3 
Upon the co-administration of two or more drugs, and the subsequent drug-drug interactions, the 
drugs can inactivate eachother. They are acting as promoieties to each other. These are known as 
codrugs.4 An example of a co-drug is Ro 23-9424 produced by Jones et al., a combination of 
fleroxacin and desacetylcefotaxime, figure 2. It  displays greater efficacy than it’s individual 










Figure 2 Ro 23-9424, a codrug formed from Fleroxacin and Desacetylcefotaxime 
It is the through action of bacterial esterases and lipases that the drugs  reactivate, with hydrolysis 
of the ester between the two drug molecules. 
3.1.2 ROS Responsive Prodrugs 
Prodrugs and polymer-drug conjugates have been used extensively in cancer chemotherapies.6, 7 
Owing to the increased concentrations of ROS in tumours, ROS sensitive pro-drugs have been 
developed. This drive in creating prodrugs is due to the fact that several current cancer therapies 
are equally as damaging to healthy cells as they are to cancer cells, leading to a myriad of side 
effects and ill health associated with these treatments. ROS dependent prodrugs attempt to mask 
the toxicity of the active compound, only activating on exposure to the high oxidative stress within 
tumours. In simplistic terms cellular oxidative stress can be considered an increased ROS 
concentration. A number of these prodrug are boronic or boronate ester based.8 One such drug is 
a mustard gas derivative developed by Kuang et al. Mustard gas agents are able to crosslink strands 
of DNA causing cell death, but are not specific to cancer cells.9 With the addition of a phenyl 
boronate ester on the nitrogen of mechlorethamine, a large reduction in toxicity to mammalian cell 
lines was achieved; upon addition of H2O2, as per a tumour environment, the activity of the drug 






























Figure 3 The re-activation of a phenyl boronic ester masked mustard gas prodrug by hydrogen peroxide 
These drugs serve a two-fold effect; not only do they provide a method by which to only activate 
in proximity to tumour environments, they are also able to ‘mop-up’ some of the excess ROS 
which can cause oxidative stress, and thus reduce damage to healthy cells. 
3.1.3 Antibiotic Prodrugs 
With the increasing costs associated with the development of novel therapies, the ability to mask 
toxicity, or increase cell permeability of previously discarded drugs is a huge advantage, especially 
within antimicrobial therapy.10 Commonly used activating groups in the design of antibiotic pro-
drugs are ester groups. Bacteria specific esterase enzymes can be used as a target; a drug will have 
its polar ester group converted into a non-polar ester, increasing penetration through the bacterial 
membrane, before being activated by intracellular enzymes back into the active form of the drug.11 
An example of such a strategy is shown in figure 4. Clayton et al. used the addition of tertiary 
butyl esters to ampicillin, yielding the pro-drug pivampicillin. Now used in clinic, pivampicillin 























Figure 4 The esterase catalysed removal of a tertiary butyl ester to form ampicillin from pivampicillin 
This chapter aimed to develop a hydrogen peroxide activated prodrug, and utilise boronic acid/diol 
binding to develop a drug that could be inactivated while bound to a PVA gel, with activation via 
topical application of H2O2. Whilst such work has been done for the treatment of tumours, to the 
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best of the authors knowledge, this is the first example of either an antimicrobial drug being used 























This project aimed to develop synthetic methodologies in order to functionalise existing 
antimicrobial compounds with a boronic acid or a boronic ester, which will subsequently be bound 
to PVA via a cyclic boronic ester. This formed boronate ester could be bound either directly to the 
molecule to yield a phenol upon oxidation, or through a linker such as PBA. Upon exposure to 
H2O2, the boronic acid/ester ‘anchor’ gets oxidised, releasing and simultaneously activating the 
drug, figure 5.  It was hoped that these drugs would be released from the gel and restored to their 
active form in high enough concentrations to inhibit the growth of bacteria, with minimal non-





























3.3 Materials and Methods  
3.3.1 General Information 
All solvents and reagents were purchased from commercial suppliers and used without further 
purification unless otherwise noted. Analytical thin-layer chromatography (TLC) was performed 
using commercial precoated silica gel plates containing a fluorescent indicator. Column 
chromatography was carried out using silica gel (0.040 - 0.063 mm). Analytical thin-layer 
chromatography (TLC) was performed using commercial precoated silica gel plates. Proton and 
carbon NMR were recorded using a Bruker Advance 500. Chemical shifts are reported in ppm 
using TMS or solvent residual signals as internal reference standards. High-resolution mass 
spectrometry (HRMS) were performed on an Agilent 6545 LC/Q-TOF. UV-Vis and fluorescence 
measurements were performed on a BMG Labtech CLARIOstar using costar u bottom 96 well 
microplates or Greiner Bio-One microplates (96-well, PS, f-bottom (chimney well), black-walled) 
respectiely. Data was collected via the BMG Labtech Clariostar data analysis software package 
MARS. AzuFluor 483-Bpin™ was prepared by L C Murfin of the Lewis group in the University 
of Bath. 
Synthetic experimental information can be found in Chapter 6.2. 
3.3.2 Blank Gel Synthesis  
PVA (mw 13,000 – 23,000 kDa) was dissolved in DMSO to form a 10% w/v solution. Solutions 
of the crosslinker, 1,4 benzene bis-boronic acid, were prepared to achieve a final concentration of 
100 mM in DMSO. Aliquots of the PVA solution (0.5 mL) were combined with the crosslinker 
solution (0.5 mL), and spontaneous gelation occurred at room temperature. The resultant hydrogels 
were washed in PBS (3 mL overnight) and then stored in PBS until used. 
3.3.3 Drug/Dye Loaded Gel Synthesis 
Drug loaded gels were synthesised as outlined in Chapter 3 1.3.2 with one modification. Drug-
PBA conjugates were dissolved in the 10% w/v PVA solution (in DMSO) at the desired 
concentration before mixing with the crosslinker using a pipette tip.  
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3.3.4 Dye Release Studies 
Azufluor 483-Bpin™ loaded gels were synthesised as in 3.3.3. Gel pieces of mass 200 mg ± 10 
mg were cut with a scalpel, and incubated in either PBS, 0.5 mM H2O2 or 1 mM H2O2. The 
fluorescence of the resulting solutions was measured, Ex 350 – 20 nm, Em 450 – 550 nm.  
3.3.5 Gel Disc Diffusion Assay  
Gel discs (both with and without the addition of a pro-drug) with a diameter of 9 mm (±1 mm) 
were prepared as described in the above methods 3.3.3 and 3.3.4, lawns were prepared by 
spreading 500 µL of bacterial culture (grown in accordance with 2.3.9), using a sterile plastic 
spreader.  Drug-loaded gel discs was subsequently placed in the centre of the plates. Next, 100 µL 
of H2O2 (1 mM) or PBS (serving as a triggered-release control) were added to the surface of the 
gels before incubation at 37 °C for 18 hours. Further control experiments were conducted using 
blank gels exposed to either the test condition (H2O2) or control condition (PBS) to ensure the gel 
and H2O2 had no effect on bacterial growth. Each condition was repeated using three biological 
replicates. After incubation, the diameter of the zone of inhibition was then measured in 
millimetres and plotted as the mean ± SD. 
3.3.6 Modified Gel Disc Diffusion Assay  
Drug loaded gels were incubated with either a 2 mL solution of H2O2 (1 mM) or PBS for 3 hours. 
Subsequently, sterile paper discs were loaded with 100 µL of gel exudate and placed onto bacterial 
lawns as prepared in 3.3.5. The plates were then incubated at 37 °C for 18 hours, and measured as 








3.4 Results and Discussion 
3.4.1 Dye Release Studies with AzuFluor 483-Bpin™ 
The use of a dye as a model system for drug release can avoid the use of labour intensive 
microbiological experiments. To be representative of the drugs binding, the dye had to contain a 
single Bpin group which would enable it to be bound into a PVA hydrogel, and subsequently 
released with the addition of H2O2. The chosen dye was an azulene based sensor produced by the 






Figure 6 The azulene based fluorescent sensor, AzuFluor 483-Bpin™, produced by the Lewis group at the university 
of Bath 
Azulene compounds are bicyclic isomers of naphthalene featuring a 5 and a 7 membered ring as 
opposed to two six membered rings. Unfunctionalised, they are a dark blue colour, yet by adding 
functionality and changing electron density in certain positions, a number of different coloured 
compounds can be formed.14 These have found use in a number of sensing applications, as 
perturbation of the electronic system can lead to large chromic shifts in its absorbance spectrum. 
AzuFluor 438-Bpin™ shown above in figure 6 is oxidised to the corresponding phenol on exposure 












Non-Fluorescent Fluorescent  
Figure 7 The oxidation of the boronic ester on AzuFluor 438-Bpin™ to its corresponding phenol generating the highly 
fluorescent active species 
The fluorescent dye can bind to the diols within the PVA hydrogel through the formation of a 6-
membered cyclic boronic ester. On addition of H2O2 to these gels the boronic ester bond should 
oxidise, turning on fluorescence, figure 8. 
 
Figure 8 An increase in fluorescence at 485 nm due to the oxidation of the Azufluor 438-Bpin™ bound to PVA into 
it fluorescent form due to exposure to H2O2 Ex 350 – 20 nm, Em 450 – 550 nm 
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As can be seen from the above data, figure 8, there is a H2O2 concentration dependent fluorescence 
increase of the AzuFluor 438-Bpin™ doped PVA hydrogel. This indicates that there has been 
oxidative release of the dye and activation of the fluorophore; this shows the potential for the gel 
as a drug delivery system. 
3.4.2 Anchoring Drugs to Hydrogels 
A number antimicrobial compounds that can be found on the World Health Organisation’s 
(WHO’s) list of essential medicines contain phenols, including amoxicillin and chlortetracycline, 
figure 9.15 If boronic ester containing analogues of a phenol containing antibiotic were to be 






















Figure 9 Left Amoxicillin, Right chlortetracycline 
The selective transformations required to make the boronic acid containing analogues could be 
synthetically very challenging, owing to a number of potential groups that could be functionalised, 
for example the carboxylic acid on the amoxicillin or the numerous hydroxyl groups on the 
tetracyclines. Although precursors such as bromo-amoxicillin are commercially available, which 
would only require a single Miyuara borylation, they come at a vast expense (~ $5000 g-1).  
In order to navigate these synthetic hurdles, a PBA linker can be used. As shown in figure 10 upon 
oxidation to the phenol, the linker will undergo a 1,4 elimination, yielding the original drug 
product, boric acid and paraquinone methide. This is hugely advantageous as it increases the 
number of the therapeutic agents that can be used, as synthetically the only requirement is that the 














Figure 10 The initial oxidation of the boronic pinnacol ester to the phenolic anion, and the subsequent 1,4 elimination 
of paraquinone methide with the reformation of a drug. X = O or N 
The quinone methides are conjugated non-aromatic analogues to quinones, but with an oxygen 
atom replaced with a carbon atom. The para,1,4 quinone methide offers the greatest stability owing 
to the zwitterionic resonance form featuring an electron donating para O-,16 as shown in figure 11. 
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Figure 11 The resonance stabilised zwitterionic form of para quinone methide 
These simple quinone methides tend to be short lived, as they are highly reactive under a wide 
variety of conditions. They are very susceptible to nucleophilic attack as well as reduction, which 
is driven by the fact that on reduction, re-aromatisation can occur. The biological effects of these 
molecules have been studied in detail, due to their prevalence as intermediate metabolites in 
various biological pathways. Their presence has been linked to toxicity through a number of 
pathways, and are the central active core to a number of anti-cancer drugs. Testing on endothelia 
cell lines would thus need to proceed this linkers use as part of a topical system.17, 18 
The initial task was to produce a drug molecule bearing this H2O2 sensitive phenyl boronic acid 
linker. Phenol containing antibiotics were the first to be considered; a commonly prescribed 


























Figure 12 Amoxicillin and its proposed PBA derivative 
Initially an ether synthesis was attempted, however resulting NMR spectra showed a large number 
of peaks indicative of a compound degrading. Following literature searches, the alkylation at the 
phenolic hydroxyl group would have been problematic owing to the instability of the lactam ring 
to hydrolysis; as a result, industrial synthesis utilises enzymatic processes.19  
3.4.3 Synthesis of Triclosan-PBA 
As functionalising clinically relevant antibiotics were found to be synthetically challenging, 
attention was turned to finding a relevant active molecule that would be easy to functionalise as a 
proof of concept. 
Triclosan, figure 13, is an antimicrobial, used in antiseptics and in toiletries (i.e. toothpaste, soaps) 
owing to its activity towards S. aureus as well as a number of other bacterial species. This has led 
to concerns over it developing resistance, culminating in the banning of its use in the USA. 
However, as this was a proof of concept study, triclosan was deemed suitable for use, with the aim 







Figure 13 The antiseptic triclosan  
As can be seen in figure 13 triclosan features a phenolic hydroxyl group and no other overtly 




















61 %  
Figure 14 The reaction of the bromo-benzyl phenyl boronic acid linker (PBA-Br) with base and triclosan to yield 
triclosan ether bound to the benzyl linker with boronic acid functionality  
The reaction shown in figure 14 gave yields of over 80%, with no discernible loss in yield or in 
crude purity when the reaction as scaled up to over a gram. 
To ensure that the addition of H2O2 decomposes the compound as expected, and the active 
antimicrobial is released, two solutions of the compound (50 µM in MeOH) were made, to one of 
which 1 mM of H2O2 in PBS was added, and to the other PBS was added. After one hour HRMS 
was performed on both compounds, confirming the release of the active triclosan in the solution 
of H2O2, but not in that of the PBS. 
3.4.4  Crosslinking PVA Doped with Triclosan-PBA 
Once the drug-PBA conjugate had been synthesised, the next step was to develop a gel system in 
which to bind it. The affinity of boronic acids and esters to 1,2 and 1,3 diols has been discussed 
previously in detail (1.9.1). Owing to this affinity, an obvious choice of polymer to use in this 
study was PVA due to the abundance of repeating 1,3 diols, as well as its proven 
biocompatibility.21 
Previous work performed by the Sessler group utilised bis-boronic acid containing compounds for 
the crosslinking of PVA.22 Whilst the aim of this work was for the preparation of an -OH anion 
capture gel, the chemistry behind the crosslinking was convenient for the applications of sensing 
and drug delivery. Most of the prior work within our group regarding the use of PVA has involved 
physical crosslinking using freeze thaw cycles. This, whilst possible in DMSO/water mixes, 
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requires extremely low temperatures (< -50 °C) and yields less stable gels. The triclosan-PBA 
conjugate has little solubility in aqueous solutions and will not stay in solution for mixes including 
even with 95% DMSO. However, both 1,4 benzene bis-boronic acid and PVA are soluble in 
DMSO, allowing for efficient gelation without the need for water. Following this, the PBA-drug 
conjugate could be mixed with the PVA solution in DMSO at the required concentration, with 













Figure 15 A schematic representation of a triclosan-PBA doped 1,4 benzene bis-boronic acid crosslinked PVA 
hydrogel 
It was a considered that the large triclosan molecule between the polymer chains could interfere 
with the crosslinking, however despite this steric hindrance, a stable gel was able to be formed, as 
shown in figure 16. 
 
Figure 16 A 1,4 benzene bis boronic acid crosslinked PVA gel , doped with 1 mgml-1 of the triclosan conjugate 
Triclosan was loaded into the gel at concentrations up to 20 mg ml-1, far above the reported MIC 
values.23 This was to ensure that clear zones of inhibition could be seen in preliminary studies as 
it was unknown if the gel density would inhibit diffusion of the drug out of the gel once the boronic 
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acid had been oxidised. Additionally, at all concentrations of triclosan tested, the gels formed near 
instantaneously and with adequate mechanical strength.  
3.4.5 Disc Diffusion Assays with Triclosan-PBA 
The re-activation and subsequent release of the triclosan from the gel matrix was tested using a 
modified disc diffusion assay. While a standard disc diffusion assay involves the use of a sterile 
paper disc inoculated with an antimicrobial solution, in this modified version a gel disc of 9 mm 
(± 1 mm) was placed in the centre of an inoculated agar plate. To determine the triggered release, 
triclosan doped gels (1 mg mL-1) were either treated with H2O2 (100 µL, 1 mM), or PBS and left 
to incubate for 18 hours. The zones of inhibition produced by both conditions were compared with 
themselves, and to that of further controls (blank gels with and without treatment of 1 mM H2O2). 
These controls were to ensure that the zones of inhibition were due to the release of triclosan, and 
not due to the addition of H2O2 or the gels themselves. The experiment was performed using three 
separate bacterial species: P. aeruginosa PA01, S. aureus H560 and E. coli NCTC 10418. They 
were chosen as the efficacy of triclosan against these species was known, and are all relevant 
pathogens in wound care.24 



























Figure 17 Calculated zones of inhibition (mm) for: triclosan loaded gels with H2O2 (100 µL, 1 mM), triclosan loaded 
gels with PBS (100 µL), blank gels with H2O2 (100 µL, 1 mM; control 1), and blank gels with PBS (100 µL; control 
2) on a lawn of S. aureus H560. Data was plotted starting at 9 mm as this was the average diameter of the gel disc. 
Assays were performed three times, with results expressed as mean ± standard deviation. Statistical significance was 































Figure 18 Calculated zones of inhibition (mm) for: triclosan loaded gels with H2O2 (100 µL, 1 mM), triclosan loaded 
gels with PBS (100 µL), blank gels with H2O2 (100 µL, 1 mM; control 1), and blank gels with PBS (100 µL; control 
2) on a lawn of E. coli NCTC 10478. Data was plotted starting at 9 mm as this was the average diameter of the gel 
disc. Assays were performed three times, with results expressed as mean ± standard deviation  
As expected, for both S. aureus H560 and E. coli NCTC 10418, there was a large zone of inhibition 
for triclosan loaded gels incubated with H2O2, and no noticeable inhibition attributed to the blank 
gels (both with and without treatment). Hence it can be inferred that any inhibition was due to the 
release of triclosan from the gels.  
However, for S. aureus H560 it was noted that triclosan was also released when incubated with 
PBS, indicating the possibility of either passive release of triclosan, or the anchored triclosan 
retained some antimicrobial activity. The definitive way to test for such activity would be to do an 
MIC test of the conjugated triclosan. Unfortunately, the molecule itself is insoluble under aqueous 
conditions, solubility is only achieved in a DMSO/Water mix of over 20% DMSO, or 40% ethanol 
in an ethanol/water mix. This unfortunately prevents an MIC being undertaken as these solvent 
concentrations inhibit bacterial growth. Whilst it was tested, there was no inhibition of growth in 
any of the conditions with the bacteria P. aeruginosa PAO1. This is likely due to the widespread 
resistance to triclosan found in P. aeruginosa strains.25 
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3.4.6 Synthesis of Ciprofloxacin-PBA 
Once the triggered release of the triclosan had been confirmed using microbiology, the next step 
was to synthesise a new drug, one that was of more clinical relevance and had a greater spectrum 
of activity; namely one that could treat both gram-positive and gram-negative bacteria. Previous 
searches for drugs had been aimed towards finding a phenolic alcohol group. It was realised at this 
stage that this was a needlessly limiting option, and that the same chemistries could be one applied 
to carboxylic acids and amines. This resulted in a large new source of potential drug candidates. 
One of the most commonly prescribed antibiotics is the fluoroquinolone ciprofloxacin.26 This is 
largely due to its wide spectrum activity, making it any easy drug choice for infections of which 
the cause may not be specifically known. Ciprofloxacin offers either a secondary amine or a 
carboxylic acid that can be functionalised with the PBA linker. It was decided that the acid would 
be the target of choice, owing to the ease in which amines can be protected and de-protected at 


















Figure 19 Ciprofloxacin-PBA conjugate and its subsequent oxidation into the original drug ciprofloxacin 
The synthesis mimicked the conditions of a benzyl protection performed by Fardeau et al. in their 
work investigating the effects of binding catechol containing substituents to the amino group of 
ciprofloxacin.27 The reaction itself was simple and featured acceptable yields. Both the starting 
material and product were of very similar polarity, and weren’t highly soluble in common solvents 



























































88 %  
Figure 20 The overall synthesis of Ciprofloxacin-PBA 
That ciprofloxacin contains both an amine and an acid means that it required protection steps 
within the synthesis. There was also concern that its larger size had the potential to impede the 
crosslinking utilising the 1,4 dibenzene crosslinker, but as with the triclosan and the AzuFluo 483-
Bpin™ we were still able to form a solid gel. This offered evidence that this crosslinking method 
is tolerant to a range of molecules.   
As with triclosan, the ciprofloxacin containing gel was exposed to 1 mM H2O2 in PBS and the 
exudate was analysed by HRMS. This confirmed the presence of the reformed ciprofloxacin.  
Ciprofloxacin has an inherent fluorescence, and as a result concentration dependent fluorescence 
assays were performed to monitor release, figure 21. Ciprofloxacin’s excitation is 270 nm with an 
emission max of 445 nm in water.28 Owing to instrumental restrictions, the excitation wavelength 
used was 315 – 325 nm and an emission wavelength of 415-5 nm. Fluorescence could be observed 
at these wavelengths for a pure ciprofloxacin solution.  
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Figure 21 Dose dependent release of ciprofloxacin from a ciprofloxacin doped, 1,4 benzene bis-boronic acid 
crosslinked PVA hydrogel on exposure to different concentrations of H2O2 (0 -1 mM). Ex 315 – 325 nm, em 415-5 
nm. Assays were performed three times, with results expressed as mean ± standard deviation 
This preliminary data indicated that there was triggered release of ciprofloxacin, due to the rise in 
fluorescence intensity being 3-fold greater than that of the blank. However, the increase in 
fluorescence of the blank showed that a fluorescent compound was also being released by simple 
passive diffusion. Owing to the dynamic nature of the boronic ester diol bond, it is thought that 
some of ciprofloxacin was diffusing out, and that the drug-PBA conjugate also retained some of 
its fluorescence intensity.  
Once this evidence had been obtained, the same modified disc diffusion methodology used to 
evaluate the triclosan loaded gels was employed. The same three bacterial species were used in 
this assay, and the results obtained are shown in figures 22, 23 and 24. 
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Figure 22 Calculated zones of inhibition (mm) for: ciprofloxacin loaded gels with H2O2 (100 µL, 1 mM), ciprofloxacin 
loaded gels with PBS (100 µL), blank gels with H2O2 (100 µL, 1 mM; control 1), and blank gels with PBS (100 µL; 
control 2) on a lawn of S. aureus H560. Data was plotted starting at 9 mm as this was the average diameter of the gel 
disc. Assays were performed three times, with results expressed as mean ± standard deviation. Statistical significance 
was determined by an unpaired t-test with ** p < 0.01 






















Figure 23 Calculated zones of inhibition (mm) for: ciprofloxacin loaded gels with H2O2 (100 µL, 1 mM), ciprofloxacin 
loaded gels with PBS (100 µL), blank gels with H2O2 (100 µL, 1 mM; control 1), and blank gels with PBS (100 µL; 
control 2) on a lawn of E. coli NCTC 10478. Data was plotted starting at 9 mm as this was the average diameter of 
the gel disc. Assays were performed three times, with results expressed as mean ± standard deviation. Statistical 























Figure 24 Calculated zones of inhibition (mm) for: ciprofloxacin loaded gels with H2O2 (100 µL, 1 mM), ciprofloxacin 
loaded gels with PBS (100 µL), blank gels with H2O2 (100 µL, 1 mM; control 1), and blank gels with PBS (100 µL; 
control 2) on a lawn of P. aeruginosa PA01. Data was plotted starting at 9 mm as this was the average diameter of the 
gel disc. Assays were performed three times, with results expressed as mean ± standard deviation. Statistical 
significance was determined by an unpaired t-test with ** p < 0.05 
Whilst the controls in every case (a blank gel and a blank gel with added H2O2) showed no 
inhibition of growth, there was a large amount of non-triggered inhibition from the gels. This 
showed that not only was there leaching of the ciprofloxacin-PBA conjugate, but that this PBA 
bound drug was still active against bacteria. The dynamic nature of the bond between boron and 
diols was thought to be a potential reason for this leaching. A major component of bacterial agar 
is agarose, which could be binding the drug-PBA conjugate. It is also a possibility that there is 
endogenous production of ROS by the bacteria. Whilst this has not been studied specifically for 
the bacterial strains used, it is a known occurrence in a number of pathogenic bacteria.29 30 This 
would release and activate the bound drugs in the same manner as the addition of H2O2 and could 
explain the non-triggered kill that was seen. 
3.4.7 Modified Disc Diffusion Assay  
The assay was modified to prevent the potential interference of the agarose. The assay was 
modified by incubating the gels in a solution of either H2O2 (1 mL, 1 mM) or PBS for three hours, 
after which the exudate was added onto sterile discs, following more traditional disc diffusion 























Figure 25 Calculated zones of inhibition (mm) for: the exudate of ciprofloxacin loaded gels incubated with H2O2 (2 
mL, 1 mM), ciprofloxacin loaded gels incubated with PBS (2 mL), blank gels with H2O2 (2 mL, 1 mM; control 1), 
and blank gels with PBS (2 mL; control 2) on a lawn of S. aureus H560. All gels were incubated in their corresponding 
solution for 3 hours. Assays were performed three times, with results expressed as mean ± standard deviation. 
Statistical significance was determined by an unpaired t-test with ** p < 0.01 
 



















Figure 26 Calculated zones of inhibition (mm) for: the exudate of ciprofloxacin loaded gels incubated with H2O2 (2 
mL, 1 mM), ciprofloxacin loaded gels incubated with PBS (2 mL), blank gels with H2O2 (2 mL, 1 mM; control 1), 
and blank gels with PBS (2 mL; control 2) on a lawn of E. coli NCTC 10418. All gels were incubated in their 
corresponding solution for 3 hours. Assays were performed three times, with results expressed as mean ± standard 
























Figure 27 Calculated zones of inhibition (mm) for: the exudate of ciprofloxacin loaded gels incubated with H2O2 (2 
mL, 1 mM), ciprofloxacin loaded gels incubated with PBS (2 mL), blank gels with H2O2 (2 mL, 1 mM; control 1), 
and blank gels with PBS (2 mL; control 2) on a lawn of P. aeruginosa PA01. All gels were incubated in their 
corresponding solution for 3 hours. Assays were performed three times, with results expressed as mean ± standard 
deviation. Statistical significance was determined by an unpaired t-test with ** p < 0.05 
There was a statistically significant increase in the zones of inhibition caused by the ciprofloxacin-
loaded gels that were incubated in H2O2, compared to ciprofloxacin-loaded gels incubated with 
PBS. Owing to ciprofloxacin’s broad spectrum of activity it was able to inhibit the growth of both 
gram-negative and gram-positive bacteria. However, much like the triclosan gels, the non-specific 
release and kill is still present. As a result of the insolubility of the ciprofloxacin-PBA conjugate, 
it was impossible to dissolve in useable solvent mixes for microbiology, and thus we were unable 












Two compounds with antibiotic activity, triclosan and ciprofloxacin, were functionalised with a 
PBA group yielding antibiotics with the ability to bind to diols featured in a PVA. This drug bound 
PVA could then be crosslinked using 1,4 benzene bis-boronic acid, with the bound drugs not 
affecting the hydrogel formation. Following addition of these gels to H2O2 solutions HRMS 
confirmed that the native drugs had been released into the surrounding solutions. The biological 
effect of these hydrogels were tested against three bacterial species relevant to wound infection, S. 
aureus H560, P. aeruginosa PAO1 and E. coli NCTC 10418. It was found that there was a small 
amount of slow, passive release of the bound drug-PBA conjugates, likely due to the dynamic 
nature of the boronic ester bonds. These released compounds displayed a small amount of 
biological activity indicating either that the PBA bound drugs are active against the bacteria, or 
that the bacteria are producing enough endogenous RONS that they are causing oxidation of the 
PBA. However, the release of these molecules could be triggered by the addition of H2O2. Under 
these conditions, it was found that the drugs were released in high enough quantities to inhibit the 
growth of the bacteria towards which they were active significantly more than the passive release. 
It can be concluded that a H2O2 triggered release system has been has been successfully produced 
and its function tested, however, it requires further work to prevent passive diffusion in order for 











3.6 Future work 
Moving forward, one crucial aim is to develop analogues of the mentioned compounds which are 
more soluble in water. This will enable conclusions to be drawn about whether endogenous RONS 
produced by the bacteria themselves could be triggering the release of the active compounds, or if 
the PBA conjugated antimicrobials also feature antibiotic activity. In the case of ciprofloxacin, 
instead of using ciprofloxacin in its neutral form, the hydrochloride salt could be used. This ionic 
compound offers greater solubility in aqueous solutions. Another option for future use is to conduct 
the synthesis with the boronic acid analogue of the ester PBA linker compound used, exemplified 
by ciprofloxacin in figure 28. This boronic acid will increase the hydrophilicity of the molecules 












 Figure 28 Ciprofloxacin bound to a phenyl boronic acid linker 
As the PBA linker can be bound to several functional groups, and the crosslinking system is 
tolerant to a range of molecules, there is potential to use other antimicrobials. As seen with the 
lack of antimicrobial activity of triclosan against P. aeruginosa, often a single compound is unable 
to treat all infections. An advantage of this system is that there is a high number of binding sites 
for the boronic acid cross linker, making it possible to load drugs in a higher concentration, or use 
numerous antimicrobials at clinically relevant concentrations. This allows for the development of 
a combination therapy; preliminary HRMS data of a ciprofloxacin-PBA and triclosan-PBA both 
bound within a gel that was subsequently exposed to H2O2 supports this.  
Other sources of ROS as a trigger are also an area to be considered. Pyroelectric particles are 
particles that over a specific transition temperature undergo a phase change. This phase change 
causes spontaneous polarisation, able to generate enough potential difference to generate OH 
radicals, which can cause to development of other, longer lived ROS.31 In collaboration with other 
departments at the University of Bath, we are beginning to look at the incorporation of these 
particles into polymer matrices. The pyroelectric point of Strontium/Barium particles can be tuned, 
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and particles have been developed that produce low levels of ROS at 35 °C. As a normal wound 
is between 32 and 34 °C and an infected wound is often above 37 °C, they may be an avenue for 
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 Dynamic H2O2 sensitive hydrogels  
4.1 Introduction 
4.1.1 Hydrogen Peroxide Sensing 
Reactive oxygen species (ROS) and reactive nitrogen species (RNS) regulate a number of 
important biological processes, including cell apoptosis and a variety of signalling pathways.1, 2 
The cellular production of ROS/RNS is balanced by the production of antioxidants, which serve 
to ‘mop-up’ excessive ROS/RNS to prevent damage. The over-production of these reactive species 
is known as oxidative stress and is a well-documented disease state with links to chronic illness 
including diabetes, Alzheimer’s, and even the natural processes of aging.3 
There are two main types of reactive oxygen species, the radical compounds and the non-radicals. 
The radical compounds contain an unpaired electron in their valence shells, and include 
superoxide, nitric oxide, hydroxyl and peroxyl radicals. These radical species are shorter lived than 
the non-radicals owing to their greater reactivity. These non-radical compounds include hydrogen 
peroxide, peroxynitrite, singlet oxygen and hypochlorite, table 1. 
Table 1 Common ROS/RNS and their molecular formula 























4.1.2 Detecting ROS/RNS 
As well as being of biological importance, many industrial processes utilise the reactivity of 
ROS/RNS for applications such as disinfectants, but often these reactive species are an unwanted 
by-product. This is particularly the case in facilities utilising high temperature processes and those 
involved with metal production.4, 5 Hydrogen peroxide has found common use in decolourising 
hair and bleaching paper.6 As a result of both their biological relevance, and the need to ensure 
safe levels of these compounds for both health and environmental safety, the sensing of ROS/RNS 
is a field of research that has attracted much attention. A number of commercial detectors for 
potentially hazardous workplaces are available, with the ability to detect both gaseous and aqueous 
levels of H2O2 in industry, and a number of chemical sensors have been developed to detect them 
for medical purposes. 
Detection of biological ROS/RNS is achievable using fluorescent probes. Near infra-red/long 
wavelength probes are of particular interest due to their ability to visualise cells in vivo without 
damaging the host, whilst also maintaining good penetration through tissue and good visibility.7 
One such probe was developed by Sedgwick et al for the detection of peroxynitrite. The 
development of sensors for specific reactive oxygen species can be difficult owing to their often 
similar reactivity. The lifetime of peroxynitrite is low (in the millisecond range), however, as 
shown by Sikora et al its reaction with aromatic boronate compounds is around 106 times faster 
than that of hydrogen peroxide. It is this difference in the rates of reaction, which give such 
















Figure 1 Left TCFB1 Right TCFB2, two fluorescent peroxynitrite probes developed by Sedgwick et al.7 
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Detection of cellular H2O2 in vivo is particularly important for the monitoring of cellular messaging 
processes. Owing to the low rate reactivity of H2O2 compared to a number of the other reactive 
species, as well as the rapid degradation in cells (through enzymatic activity) it has been 
historically difficult to detect with a large degree of specificity.9 However, a number of small 
molecular fluorescent probes have now been developed for in vivo imaging, many with the ability 












Figure 2 Left MitoPY1, a H2O2 sensor which targets the mitochondria Right NucPE1 a H2O2 sensor that targets cellular 
nuclei 
Both of the probes in the above figure are able to detect H2O2 at biologically relevant 
concentrations. Being able to track the formation of H2O2 within regions of cells has allowed for 
the study of the contribution to disease that comes from the presence of these species in cells.10, 11 
This greater understanding of the sub-cellular processes and causes of disease allows for more 
targeted drug design. 
4.1.3 ROS/RNS and Their Uses 
Environmentally ROS/RNS are produced by UV radiation as well as high levels of man-made 
oxidants.12 Whilst these have an effect on those cells that they come into contact with, it is the 
biologically produced ROS/RNS that are more closely examined with chemical probes and will 
therefore be the focus of this section. 
Production of ROS within cells is by-product of anaerobic processes. Super oxide and hydrogen 
peroxide can be formed within the mitochondria; they are produced as part of respiratory chain 
complexes, in which a sufficient negative potential is generate to reduce molecular oxygen to 
superoxide.13 There are a number of other enzymatic processes that can occur at a cellular level to 




There are a number of biochemical methods that the ROS are used for signalling. Healthy 
signalling and oxidative stress will often be caused by the same molecules, but in different 
concentrations. One well-documented example of this is the reversible oxidation of thiols and 
thiolate anions on cysteine residues, catalysed by the redox potential of different ROS.15 In doing 
this cells can promote or prevent certain biosynthetic pathways, leading to a change in phenotypic 
expression. 
4.1.4 Hydrogels for Bio-imaging 
Supermolecular hydrogels for use as bio-imaging probes is an emerging area of research.16 These 
hydrogels have found utility in MRI imaging as well as the visualising of important polyanions 
polyamines and bacteria.17, 18 One area that to our knowledge is yet to be explored is the use of 
















4.2 Aims  
The aim of the work in this chapter is to utilise the binding between boronic esters and diols 
to develop a novel crosslinker for the synthesis of intelligent PVA hydrogels. The aim was 
to design a crosslinker that consists of a masked fluorophore featuring two boronic esters. 
Following the formation of the PVA hydrogels, the aim is to measure the reactivity and 
release of the crosslinking molecules ROS solutions and the activation of the fluorophores 
through UV-vis and fluorescence measurements, figure 3. 
The aim is to develop not only a stand-alone hydrogel H2O2 senor with potential for in vivo 
imaging, but a model system for the release of similarly functionalised and bound molecules 
for potential drug release in response to high ROS concentrations. 
Figure 3 The activation and release of boronic ester masked fluorophores from a boronate ester crosslinked 










4.3 Materials and Methods 
4.3.1 General Information 
All solvents and reagents were purchased from commercial suppliers and used without further 
purification unless otherwise noted. Analytical thin-layer chromatography (TLC) was performed 
using commercial pre-coated silica gel plates containing a fluorescent indicator. Column 
chromatography was carried out using silica gel (0.040 - 0.063 mm). Proton and carbon NMR 
were recorded using a Bruker Advance 500. Chemical shifts are reported in ppm using TMS or 
solvent residual signals as internal reference standards. High-resolution mass spectrometry 
(HRMS) were performed on an Agilent 6545 LC/Q-TOF. UV-vis and fluorescence measurements 
were performed on a BMG Labtech CLARIOstar using costar u bottom 96 well microplates or 
Greiner Bio-One microplates (96-well, PS, f-bottom (chimney well), black-walled) respectiely. 
Data was collected via the BMG Labtech Clariostar data analysis software package MARS. All 
UV-vis and fluorescence measurements were performed in triplicate and plotted as an average. 
4.3.2 Synthetic Experimental  
The synthetic experimental procedures and data can be found in chapter 6.3. 
4.3.3 Solution Based UV-vis Studies 
20 µM solutions of PF-1 or Pment were made in 1% DMSO PBS v/v. 100 µL of these solutions 
were combined with 100 µL of H2O2 (1 mM) in PBS giving final solution concentrations of 10 
µM of the probe solution and 500 µM H2O2. A control experiment was performed replacing the 
H2O2 with PBS. The UV-vis spectra of the two solutions was then measured after 1 hour of 
incubating at room temperature. 
4.3.4 Solution Based Fluorescence Studies  
20 µM solutions of PF-1 or Pment were made in 1% DMSO PBS v/v. 100 µL of these solutions 
were combined with 100 µL of H2O2 (1 mM) in PBS giving final solution concentrations of  
10 µM of the probe solution and 500 µM H2O2. A control experiment was performed replacing the 
H2O2 with PBS. The fluorescence was measured every 10 minutes for one hour at room 
temperature, Ex = 472 – 16 nm, Em = 500 – 600 nm for PF-1, Ex = 570 – 16 nm, 
 Em = 600 – 700 nm for Pment. 
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4.3.5 Hydrogel Synthesis  
PVA (mw 13,000 – 23,000 kDa) was dissolved in DMSO to form a 10% w/v solution. Solutions 
of PF-1 and Pment were prepared to achieve a final concentration of 100 mM in DMSO. Aliquots 
of the PVA solution (0.5 mL) were combined with either PF-1 or Pment solutions (0.5 mL), and 
while stirring were heated to induce gelation within 30 s. The resultant hydrogels were left 
overnight at 60 °C in an oven, before being washed twice with petroleum ether (5 mL) and PBS 
(5 mL, 10 mM, pH 7.4). The hydrogels were stored in PBS until required. 
4.3.6 Gel Based UV-vis Studies 
After the gels had been formed they were cut with a scalpel into pieces with a mass of 200 mg ± 
10 mg. These gel pieces were submerged in 2 mL of 1 mM H2O2 in PBS. Aliquots of 200 µL of 
the resulting solution were removed and a UV-vis spectrum measured at 30 minute intervals for 
90 minutes at room temperature. 
4.3.7  Gel Based Fluorescence Studies  
After the gels had been formed they were cut with a scalpel into pieces with a mass of 200 mg ± 
10 mg. These gel pieces were submerged in 2 mL of H2O2 in PBS, at a concentration of either 0, 
125, 500, 750 or 1000 µM. Aliquots of 200 µL were removed from the solution and transferred to 
a black walled micro-plate and the fluorescence was measured. After the measurement the aliquot 
was returned to the experimental solution. Ex = 472 – 16 nm, Em = 500 – 600 nm for Gment, 
Ex = 570 – 16 nm, Em = 600 – 700 nm for Pment. 
4.3.8 Gel Dissolution Study 
Gment and Pment hydrogels were prepared with a mass of 1000 mg ± 50 mg. These pieces of gel 
were placed in H2O2 (10 mL, 100 mM) and shaken in an incubator at 37 °C for 1.5 hours. A control 
of PBS was used as a comparison. 
4.3.9 Gel Stability Study in Air 
Gment and Pment hydrogels were prepared with a mass of 500 mg ± 50 mg. They were exposed 
to air at room temperature and photographed at 24 hour intervals for 48 hours, then 48 hour 
intervals for 10 days.  
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4.3.10 Gel Stability in Aqueous Solution  
Gment and Pment hydrogels were prepared with a mass of 500 mg ± 50 mg. The gels were 
submerged in PBS (5 mL) at room temperature. 200 µL aliquots of this solution were transferred 
to a clear micro-plate and the UV-vis spectrum was measured at 24 hour intervals for the first 48 



















4.4 Results and discussion 
4.4.1 Existing Boronate Ester Fluorophores  
Boronic acid masked fluorophores have already been widely utilized in ROS sensing, and as a 
result there are a number of well documented compounds that could have been utilised as 
crosslinkers. The main criteria was that there had to be more than one boronate ester on the 
molecule, to act as a crosslinker. Chang et al. at the University of Berkley developed three 
compounds: PR-1, PF-1 and PX1, that feature the bis-boronic acid moiety required, and are 




















Figure 4 Chang et al.’s boronate based fluorescent sensors based on resorufin (PR-1), fluorescein (PF-1) and 
xanthone (PX-1) 
4.4.2 Synthesis of PF-1 






























Figure 5 The synthetic route for the production of PF-1 
PF-1 will be oxidised as in scheme figure 5 to form the fluorophore which is also strongly coloured. 
UV-vis and fluorescence measurements were performed to ensure the PF-1 reacted as according 
to literature, despite already having confirmation through NMR and HRMS that the compound 
had been synthesised; this was to give further confirmation that the synthesised probe would act 
as reported. 
4.4.3 PF-1 Testing in Solution  











Figure 6 The oxidative activation of PF-1 to the green florescent fluorescein, fluorescent over pH 5-9 (encompassing 
most biological systems). 
4.4.3.1 PF-1 Testing in Solution UV-vis 
The initial test to ensure that the synthesised compound acted as expected was to obtain its  
UV-vis spectrum. Figure 7 shows the increase in absorbance of a solution of PF-1 after 1 hour 

























 PF1 with H2O2
 
Figure 7 The increase in absorbance of 10 µM PF-1 on addition of H2O2 500 µM after 1 hour, indicating the 
activation of the compound by oxidation of the boronate esters after 60 minutes at 25 °C in 1% DMSO 99% PBS 
buffer 
4.4.3.2 PF-1 Testing in Solution Fluorescence  
Confirmation of successful synthesis was further investigated through the use of more sensitive 
fluorescence measurements, to gain an understanding of the timescale at which the gel may 







































Figure 8 Fluorescence spectra of 10 µmol PF-1 in PBS, on addition of 0.5 mM H2O2 in PBS. Measurements were 
taken over the course of 1 h at room temperature in 1% DMSO 99% PBS buffer Ex = 472 – 16 nm, Em = 500 – 600 
nm 
Both the degree of fluorescence increase and the change in absorbance values indicated that the 
PF-1 would be suitable for use as a fluorescent and colourimetric ROS sensitive crosslinker, both 
with regards to its activity, its rate of activation and its sensitivity. It is known from making the 
blank PVA gels in chapter 3 that the bis-boronic acid crosslinker concentration required to form 
stable hydrogels is 1000 times higher than that used in this experiment. The timescale of activation 
is suitable for its intended use, as a clear activation, with a 5-fold increase in fluorescence, can be 
observed within 10 minutes. 
4.4.4 PF-1 Crosslinked Hydrogel Development 
As with the gels produced in chapter 3 solutions of 10% PVA in DMSO and 100 mM PF-1 in 
DMSO were made. However, whereas the 1,4 benzene bis-boronic acid solution gelled 
immediately upon mixing with the PVA, it was found that this mixing caused the formation of a 
viscous liquid. Upon heating with a heat gun for around 30 seconds this viscous liquid would begin 
to gel, however, upon standing overnight at room temperature a large portion of the gel would 
revert back to this liquid form. It is thought that the increased temperature is to aid in the removal 
of the free displaced pinacol through evaporation, preventing re-binding to the diols. The would 
reduce the binding sites available for the crosslinker in the PVA. The fact that overnight the gel 
would revert back to liquid was thought to be due to this displacement of crosslinker with free 
144 
 
pinacol, that as itself displaced when the crosslinker bound to the diols. As such, the two solutions 
were combined and the vial placed in a 70 °C oven for 12 hours, figure 9. This gel will be known 
from here onwards as greenment (Gment). 
 
 
Figure 9 Crosslinking PVA with PF-1 to form a stable Gment hydrogel  
To remove the DMSO and any unbound pinacol, the gels were washed with PBS buffer and 
petroleum ether before being rewashed and stored in PBS buffer to prevent dehydration.  
4.4.5 Gment Gels in H2O2 Solutions  
The gels are intended to react with H2O2 in two separate manners; not only will the fluorophore be 


















Figure 10 The degredation of GMent gel into the green fluorescent fluorescein and a solution of PVA 
This dehydration back into solution would be accompanied by the release of water trapped within 
the hydrogel matrix, which would serve to aid in the rehydration of a wound. When considering 
this material as an in vivo imaging system, its degradation into only PVA and fluorescein, both 
non-toxic compounds, is crucial.20 
4.4.5.1 Gment Gels in H2O2 Solutions – UV-vis 
To test the reactivity of the washed Gment gels, pieces of gel were cut into 200 mg ± 10 mg and 





















were removed every 30 minutes. The UV-VIS spectrum of each aliquot was recorded and the 
aliquot replaced. This took place every 30 minutes for 90 minutes, figure 11. 















 60 mins 
 90 mins
 
Figure 11 The increasing absorbance of solution of Gment as the gel is degraded by H2O2 back into fluorescein over 
time in PBS 
As can be seen in figure 11 there is an increase in the absorbance of the solution containing the gel 
over time, due to the release of the activated chromophore. This colour change can be seen visually 
in figure 12. Within the first time period of 30 minutes there is a large increase in the colour, 
showings its potential utility in point of care diagnostics. The broadness of the peak and the 
presence of a second peak in this spectrum is tentatively assigned to the monoboronate species. It 
is assumed that this would be lost at higher concentrations of H2O2. 
  
Before addition of H2O2 After addition of H2O2 
  
Figure 12 Left photo showing the Gment gel in PBS, Right photo showing the Gment gel in 1 mM of H2O2 in PBS 
after 90 mins 
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As can be seen in these photos there is a clear increase in colour, but the gel is still solid, and has 
not noticeably degraded from exposure to the low concentration of H2O2. 
4.4.5.2 Gment in H2O2 Solutions – Fluorescence  
To test the sensitivity of the Gment gels to H2O2 the gels were placed in solutions of varying 
concentrations of H2O2, from 0 – 1 mM. The fluorescence of the resulting solutions was measured 
after 1 hour, figure 13. 































Figure 13 The dose dependent increase of fluorescence from the addition of Gment gels to solutions of increasing 
H2O2 concentration in PBS. Readings taken after 1 hour 25 °C. Ex = 472 – 16 nm, Em = 500 – 600 nm 
As can be seen above the sensitivity of the Gment hydrogel is similar to that of the free PF-1, with 
a clear increase in fluorescence after one hour. This is to be expected from a reaction-based 
indicator.  
This data gave us confidence that the use of a boronate ester masked fluorescent and colour 
changing dye as a crosslinker could yield a H2O2 sensitive PVA hydrogel. As such, we aimed to 
expand the work beyond that of Chang et al. and develop a new molecule, which shall be hence 











Figure 14 The Phenothiazene derived H2O2 sensitive compound, Pment 
Purplement, figure 14, has not been previously published in literature for the purpose of sensing. 
The only online reference to the structure is within a patent, in which it is used as a reagent for the 
synthesis of dyes.21 Whilst it has been assigned a CAS number it is not available from commercial 
sources, but was synthesised according to figure 15. 

























Figure 15 The synthetic route for Pment 
 
4.4.7 Purplement Testing in Solution  
Upon exposure of Pment to H2O2, it should oxidise to the purple fluorescent compound thionol, 













Figure 16 The oxidation of the boronate esters by H2O2, converting Pment into the purple fluorescent compound 
thionol 
 
4.4.7.1 Purplement Testing in Solution – UV-vis 


















 Pment in H2O2
 Pment in PBS
 
Figure 17 The increase in absorbance of 10 µM Pment on addition of H2O2 500 µM after 1 h indicating the 
activation of the compound by oxidation of the boronate esters in 1% DMSO 99% PBS buffer 
In an analogous experiment to that performed with PF-1, a solution of Pment was exposed to a 500 
µM H2O2 solution, resulting in a colour change with an absorbance increase at 595 nm, 
characteristic of the absorption of thionol. 
4.4.7.2 Purplement Testing in Solution – Fluorescence  
As done with the PF-1 solution, the increase in fluorescence of a solution of Pment upon reaction 
with a solution of H2O2 was measured over the course of an hour, figure 18. 
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Figure 18 Fluorescence spectra of 10 µmol PF-1 in PBS; 0.1 mM, on addition of 500 µM H2O2 in PBS. Measurements 
were taken over the course of 1 h at 25 °C. in 1% DMSO 99% PBS buffer Ex = 570 – 16 nm,  
Em = 600 – 700 nm 
Pment shows the same general increase in fluorescence over time, with a nearly 20000-fold 
increase in fluorescence after only 10 minutes. This indicates that much like PF-1 it would offer a 
rapid enough response to be considered for use in a diagnostic or drug delivery system. 
4.4.8 Purplement Crosslinked PVA Hydrogel Development 
As the Pment molecule features the same reactivity as the PF-1 when crosslinking, we used the 
same conditions as were found to be successful in making the Gment gels. A 100 mM solution of 
Pment in DMSO was mixed in a 1:1 ratio with 10% w/v PVA in DMSO, in a vial, and the vial was 
placed in a 70 °C oven overnight. As expected this yielded hydrogels similar in properties to the 



















Figure 19 Crrosslinking a PVA solution into a stable hydrogel using Pment as the crosslinker 
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4.4.9 Pment Gels in H2O2 Solutions 
As with the Gment gels we wanted to ensure that the activity of the Pment compound would not 
be hindered in its activity by the binding of the PVA. Just as fluorescein is produced by the 
oxidation of the Gment gel by H2O2 thionol should be produced by the Pment gels, thus there 
should therefore be a colour change to purple and a large increase in fluorescence of the 

















Figure 20 The degredation of the Pment gel into purple fluorescent thionol due to exposure to H2O2 
4.4.9.1 Pment Gels in H2O2 Solutions – UV-vis 
To test the gels, the same procedures were followed as with the Gment gels, and the UV-vis 
spectrum was measured of a H2O2 solution with a piece of gel, figure 21. 




















Figure 21 The increasing absorbance of solution of Pment as the gel is degraded by 1 mM H2O2 into thionol over 90 
minutes in PBS 
Once again this change in the colour is obvious by visual inspection, figure 22, and the time scale-





Before the additon of H2O2 After the addition of H2O2 
Figure 22 Left photo showing the Pment gel in PBS, Right photo showing the Pment gel in 1 mM of H2O2 in PBS after 
90 mins 
 
4.4.9.2 PMent Gels in H2O2 Solutions – Fluorescence  
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Figure 23 The dose dependent increase of fluorescence from the addition of Pment gels to solutions of increasing 
H2O2 concentration in PBS. Readings taken after 1 hour 25 °C in PBS Ex = 570 – 16 nm, Em = 600 – 700 nm 
As in solution the Pment gels offered a similar reactivity to that of the Gment, giving an increase 
in fluorescence with increasing concentrations of H2O2, figure 23. When directly comparing the 
relative fluorescence increase of the two gels, it can be seen that the Pment does require a greater 
concentration of peroxide for the same increase of intensity. However, an 8 fold increase in 
intensity can be seen at with only 125 µM H2O2, which for the use as a topical drug delivery vehicle 
is well below clinically approved concentrations of H2O2 for wound care. 
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4.4.10 Gel Stability  
Once the activity of the gels had been confirmed, the stability of the gels in both aqueous 
environments and to the air was investigated. Gels were synthesised of both Gment and Pment and 
the gels were placed either in 10 mL of PBS buffer or exposed to air. The gels were initially 
photographed, and then photographed every 24 hours for 48 hours and then every 48 hours for 
another 8 days. As can be seen in figure 24 the gels exposed to air dehydrated but remained stable.  















Figure 24 Photographs of gels of Gment and Pment exposed to air for 10 days 
To demonstrated their stability in aqueous solution an aliquot of the solution they had been placed 
in was taken every time a photo of the gels in air was taken, and the UV-VIS spectrum was 
measured. There was no discernable increase in the absorbance spectra of either fluorescein or 
thionol in either spectra appendix 7.4.1. For application in either wound care or sensing it is 
important that the structural integrity of the gel is maintained over periods of time, to maintain 
both the shelf life of a potential product and retain activity.  
4.4.11 Gel Dissolution  
As previously discussed the H2O2 triggered oxidation of the crosslinker should cause the eventual 
collapse of the hydrogel. At the concentrations and timescales used for the fluorescence and UV-
vis studies this was not observed. To ensure that the gels would dissolve as assumed, both Gment 
and Pment gels were exposed to 100 mM H2O2 and placed in a shaking incubator at 37 °C for 1.5 










Figure 25 The decomposition of clear Gment and Pment gels into highly coloured solutions of fluorescein and thionol 
respectively 
Whilst it is less clear in the photo of the Pment due to the opacity of the coloured solution, these 
conditions proved sufficient to fully dissolve the PVA, compared to the solid, insoluble PVA gels 
in PBS. In wound care, particularly in the treatment of burn wounds, maintaining a moist wound 
environment is crucial to wound healing.22 The collapse of the gel is associated with the release of 







Gment in PBS Solution of fluorescein and PVA due to decomposition 
of Gment gel by H2O2 
  
Pment in PBS Solution of thionol and PVA due to decomposition of 




4.5 Conclusions  
A literature reported H2O2 responsive green fluorescent and colourimetric dye, PF-1, has been 
successfully synthesised and repurposed as a ROS activated crosslinker for the preparation of PVA 
hydrogels. A novel, analogous dye has been designed and synthesised, offering similar reactivity 
in solution at different excitation and emission wavelengths, giving a deep purple coloured 
response to H2O2. This was also able to crosslink PVA forming stable hydrogels. 
This novel smart material has been proved to give a fluorescent and colourimetric response to 
H2O2 concentrations of as low as 125 µM in aqueous solution. This material can also collapse, 
redissolving into solution in response to excess amounts of H2O2, with the crosslinker oxidizing 
into its fluorescein (Gment) or thionol (Pment). This hydrogel offers a potential as a smart wound 
dressing material due to being formed of materials and compounds already proven biocompatible, 
and its ability to release molecules in response to a stimulus. Should different crosslinking densities 
be investigated, it is likely that these soft materials also potentially have application in the field of 














4.6 Future Work  
With the utility of the binding method shown, the use of a number of different fluorophores could 
be used in order to gain different colours, for example PR-1 and PX-1 produced by Chang et al.23 
Having different coloured probes can aid in biological imaging, when more than one substrate is 
being investigated, as there is the opportunity to increase the contrast.24 Red and green probes find 
great utility due to their contrast, for example in the LIVE/DEAD® stain.25  
The PVA hydrogels that have been synthesised are rigid and therefore not injectable. Whilst these 
properties are desirable hydrogels that will be applied topically, this restricts their use. The delivery 
of drugs through injectable PVA hydrogels has been achieved, and as such investigating new 
polymers or simply adjusting the molecular weight of the PVA used and the crosslinking density 
could lead to new applications of these gels for imaging.26 There are a number of injectable 
polymers utilising boronate esters that have been formed including derivatised hyaluronic acid and 
PEG, both of which are known for their low toxicity.27, 28 This is also relevant for the use of these 
materials in bio-imaging.  
The concept of using boronate ester masked active molecules as responsive crosslinker has been 
proved; the dyes work well as a model system in this respect. More interesting would be to start to 
develop masked forms of active pharmaceuticals that can be released in response to H2O2. These 
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 Development of Prodrug Crosslinkers 
5.1 Introduction 
5.1.1 Polymeric Drug Delivery Systems 
Polymeric drug release systems can take many forms, both on the macro and nano-scales, often 
depending on the drugs’ target site. Those systems designed to cross the blood brain barrier or 
deliver cargo to specific cells will often be nano-particles. Whereas, hydrogels prepared for topical 
use will be macro-sized polymers.1, 2 Polymer systems are utilized for a range of purposes 
including targeted drug delivery, improvement of the drugs half-life and as drugs themselves.3 
This work will focus on systems that are targeted, and more specifically those that are stimuli 
responsive.  
Owing to the toxicity of numerous anti-cancer chemotherapeutics, there has been great interest 
into the development of polymer systems that only release drugs within tumour environments, 
minimising the exposure of healthy cells to the drug. This behaviours is similar to that of a pro-
drug, just on a much larger scale.4 The stimuli that many of these polymeric release systems 
respond to is the increased levels of ROS that are present within cancer cells.5 An example of such 
a system reported by Shim et al. utilized the ROS sensitive thioketal bond as a trigger. They 
synthesised a cationic poly(amino thioketal) polymer, onto which were grafted cancer targeting 
proteins; these could deliver genes directly to cancer cells, only breaking down to release the 
genetic material on ROS triggered degradation of the thioketal.6  
5.1.2 Ciprofloxacin   
Ciprofloxacin figure 1 is a second-generation fluoroquinolone antibiotic. It is one of the most 
highly prescribed antibiotics, with over 7 million prescriptions being filled in the USA in 2016.7 
This is owing to its broad spectrum of activity, particularly its ability to treat P. aeruginosa, which 
very few antibiotics can.8 It is known to treat nearly all common causes of burn wound infection, 
as it also offers activity against a number of S. aureus strains as well as E. faecallis. The three 












Figure 1 Ciprofloxacin 
5.1.3 Ciprofloxacin Mechanism of Action 
The mechanism by which ciprofloxacin and other quinolones kill bacteria has been studied in 
detail. In brief, they inhibit DNA gyrase, an enzyme belonging to type II topoisomerases which 
induce supercoiling within the bacterial chromosome. This is essential to bacterial survival as the 
bacterial chromosome is thought to be around 1300 µm in length, and must be super coiled in order 
to fit spatially within a bacterial cell that is only 1 µm2. 10 The inhibition of DNA gyrase by 
ciprofloxacin increases the size of the chromosome to the point that the cell can no longer replicate. 
At concentrations that are higher than those required to inhibit DNA gyrase, ciprofloxacin has also 
been seen to inhibit the action of topoisomerase I in E. coli, which is thought to be a potential 
explanation for its broader spectrum of activity when compared with other fluoroquinolones.11 
Studies utilising a different fluoroquinolone, norfloxacin, have shown that the fluoroquinolones 
antibiotics do not bind directly to the enzymes initially, but instead bind to the DNA before forming 
the complex with the DNA gyrase prior to the super-coiling.11  
5.1.4 Structure Activity Relationship of Ciprofloxacin  
The structures of ciprofloxacin and the other quinolones have varied greatly since the initial drug, 
nalidixic acid, was first discovered. The different constituent parts of the drug each convey 
different reactivity, with respect to different binding modes, as can be seen in figure 2. 
As can be seen below in figure 2 the acid at position 3 is essential for the binding of the drug 
molecule to the DNA gyrase as well as for transport into the bacteria. This would thus make a 
convenient modification site when considering the creation of a ciprofloxacin pro-drug, as this 
should inactivate the drug.12 The alkylation of position 7 with differing amines can direct the 
spectrum of activity towards different bacterial species. Previously synthesised analogues of 
ciprofloxacin have used this position to bind groups such as catechols in order to improve cellular 




Figure 2 The different domains of the fluoroquinolones and differing the groups at various sites effects the activity 
and efficacy of the antibiotics versus different bacteria. Reproduced with permission from 12 
5.1.5 Resistance to Ciprofloxacin  
As with most modern antibiotics, a number of bacterial strains and species are developing 
resistance to ciprofloxacin. Aboshanab et al. investigated the prevalence of ciprofloxacin 
resistance in a study using 169 gram-negative isolates taken from cancer patients suffering from 
infection.14 Using the broth micro-dilution method, it was found that 89.3% of these isolates 
showed increased levels of ciprofloxacin resistance. Following the investigation of selected 
isolates using polymerase chain reaction (PCR) and DNA sequencing, the cause was found to be 
a combination of factors. These include: the upregulation of the CCCP efflux pump, which 
removes the antibiotics from the cell, a mutation in the gyrA gene, which determines the structure 
of the DNA gyrase enzymes, as well as an increase in the production of a mutant aminoglycoside 




5.1.6 Infection and Cancer 
Over 15% of malignancies across the globe have been shown to have an infectious cause, including 
viruses, bacteria, fungi and trematodes (parasitic flat worms).18 Cancer development through 
infection is most commonly attributed to viral infections,  being responsible for the formation of a 
variety of different cancers including: T-cell leukemia and lymphoma attributed to HTLV-1, 
Merkel cell carcinoma attributed to MCV and Kaposi sarcoma that is attributed to HIV.19 Owing 
to viruses being such prevalent infectious causes of cancer formation, bacterial causes have been 
widely overlooked, despite being associated with a number of malignancies. Examples of this 
include Helicobacter pylori, a bacteria with the proven ability to induce the growth of non-cardia 
gastric carcinoma in humans.20, 21 Salmonella trachomatis is also another bacterial initiator of 
cancer growth, aiding the development of carcinoma in the cervix and ovaries. The exact cause-
and-effect relationship between skin cancer and S. aureus infections remains unknown, but there 
is greatly increased incidence of squamous cell carcinoma of the skin (a type of tumour) and these 
bacterial skin infections.22 
5.1.7 5-Flourouracil 
5-fluorouracil, figure 3, is an anticancer chemotherapeutic used to treat a number of cancers 
including breast, colon, and importantly, skin cancers.23 The fluoropyrimidine molecule is uptaken 
in cells in the same manner as uracil, an RNA base, and acts as both an antimetabolite drug as well 








Figure 3 5-Fluorouracil 
There is clearly a clinical need that is yet to be addressed for the co-treatment of both of these 
disease states. Whilst it is unknown on the direction of the cause-and-effect relationship between 
S. aureus infections and skin cancers, controlled topical release of two separate drugs from a 




5.2 Aims and Objectives  
The aim of this chapter is to combine the two concepts introduced in chapters 3 and 4. Utilising 
the concept of prodrugs, antibiotic molecules masked with two boronic acids will be synthesised.  
These will act as crosslinkers to create PVA hydrogels and will activate in response to H2O2 due 
to oxidation of the boronic acid groups. The initial application of this is to develop a topical anti-
bacterial hydrogel for the purpose of wound dressings. Beyond this we wish to use other active 
compounds to show the utility of this method for a number of different drug classes and treatments, 




















Figure 4 A schematic representation of a PVA hydrogel crosslinked with boronic acid functionalised drugs that on 











5.3 Materials and methods  
5.3.1 General Information 
All solvents and reagents were purchased from commercial suppliers and used without further 
purification unless otherwise noted. Analytical thin-layer chromatography (TLC) was performed 
using commercial pre-coated silica gel plates containing a fluorescent indicator. Column 
chromatography was carried out using silica gel (0.040 - 0.063 mm). Analytical thin-layer 
chromatography (TLC) was performed using commercial pre-coated silica gel plates. Proton and 
carbon NMR were recorded using a Bruker Advance 500. Chemical shifts are reported in ppm 
using TMS or solvent residual signals as internal reference standards. High-resolution mass 
spectrometry (HRMS) experiments were performed on an Agilent 6545 LC/Q-TOF. UV-vis 
measurements were performed using either a BMG Labtech Clariostar in Co-star 96 well plates of 
variable pathlength, or a Shimadzu UV-1800 UV spectrometer at room temperature in a quartz 
cuvette, path length 10 mm.  Fluorescence measurements were performed on a BMG Labtech 
CLARIOstar using Greiner Bio-One microplates (96-well, PS, f-bottom (chimney well), black-
walled). Data was collected via the BMG Labtech Clariostar data analysis software package 
MARS.  
Synthetic experimental information can be found in chapter 6. 
5.3.2 Gel Synthesis 
PVA hydrogels were prepared as in chapter 4 A 100 mM solution of ciprofloxacin 
bisphenylboronic acid (CBPBA) or 5-fluorouracil bisphenylboronic acid (5-FBPBA) in DMSO 
was mixed with a 10% w/v solution of PVA in DMSO. These were then placed in a 70 °C oven 
overnight, before washing with PBS, petroleum ether and PBS again. The gels were stored in PBS 
until needed. 
5.3.3  UV-vis Measurements in Solution 
UV-vis spectra of the conversion from CBPBA to ciprofloxacin were obtained by addition of H2O2 
(0.5 mL, 100 µM) in PBS to a solution of CBPBA (0.5 mL, 100 µM) in PBS (1% v/v DMSO). 
The solution was allowed to react for 30 minutes and was measured against a blank of PBS (1% 
v/v DMSO) with a control of CBPBA solution (50 µM) in PBS (1% v/v DMSO). 
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5.3.4 UV-vis Measurements Using CBPBA Hydrogels  
CBPBA hydrogels (200 mg ± 10 mg) were incubated in varying concentrations of H2O2 in PBS (0 
– 50 mM, 1 mL) for 60 minutes at 25 °C. This solution was transferred to a quartz cuvette with a 
path length of 10 mm.  
Alternatively, for the measurements against time the solutions were measured at intervals of 5 
minutes, and then returned to the vial containing the CBPBA hydrogel. 
5.3.5 Fluorescence Measurements in Solution 
Fluorescence spectra of the conversion from CBPBA to ciprofloxacin were obtained by addition 
of H2O2 (0.5 mL, 100 µM) in PBS to a solution of CBPBA (0.5 mL, 100 µM) in PBS (1% v/v 
DMSO). The solution was allowed to react for 30 minutes and an aliquot of 100 µL was transferred 
to a micro-plate. This was measured against a control of CBPBA solution (50 µM) in PBS (1% 
v/v DMSO). Excitation 317 – 14 nm, Emission 330 nm - 600 nm. 
5.3.6 Initial Fluorescence Measurements Using CBPBA Hydrogels  
CBPBA hydrogels (200 mg ± 10 mg) were incubated in varying concentrations of H2O2 in PBS (0 
– 980 mM, 1 mL) for 60 minutes at 25 °C. At 10 minute intervals 100 µL of each solution was 
removed and transferred to a microplate, the fluorescence intensity was measured, and the aliquot 
was returned to the original solution to maintain sink conditions. Excitation  
327 – 14 nm, Emission 415 – 20 nm. 
5.3.7 Ciprofloxacin Standard Curve  
Solutions of ciprofloxacin in PBS (1% v/v DMSO) at concentrations ranging from 1 – 40 µM were 
measured by UV-Vis at their absorbance max (275 nm). This data was then plotted as a straight 
line (R2 = 0.9998) and the Beer Lambert law re-arranged to yield the extinction coefficient of 
ciprofloxacin (49443 M-1 cm-1). 
5.3.8 MIC Determination  
Antimicrobial susceptibility testing was carried out in a 96-well microtiter plate using a standard 
two-fold broth microdilution method as recommended by the Clinical Laboratory Standards 
Institute (CLSI).24  Briefly, 100 µL of an antimicrobial agent of known concentration was serially 
diluted two-fold across the 96 well plate in calcium adjusted Mueller Hinton Broth (CAMHB). 
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Re-suspended bacterial cultures were diluted in CAMHB, and added in equal volume, so that each 
well contained approximated 5 x 105 CFU/mL (range 2 – 8 x 105 CFU/mL). The Minimum 
Inhibitory Concentration (MIC) was defined as the lowest concentration of antimicrobial agent 
required to inhibit the visible growth of bacterial strains after 18 h incubation at 37 °C. 
5.3.9 Pseudo-MIC CBPBA Release Studies 
The pseudo-MIC experiment follows the same procedure as a standard MIC determination 
(outlined above), however the starting solution is not an antimicrobial of known concentration. 
Instead it is a solution of gel exudate, generated by the incubation of CBPBA hydrogel (1 g) in 
H2O2 (3 mL, 50 mM in PBS) for 3 hours. Instead of being able to plot the concentration of the 
drug against the optical density of the bacteria, the data must be plotted as a function of the number 















5.4 Results and Discussion 
5.4.1 Modification of Ciprofloxacin  
In chapter 4 it was shown that masking the hydroxyl groups on fluorescein and thionol with boronic 
acids was able to quench the fluorescence of the fluorophores, and that these boronic acids could 
crosslink PVA solutions into hydrogels. A number of studies have investigated the structure 
activity relationships of the antibiotic ciprofloxacin, and all have agreed that the presence of the 
acid group and two carbonyls (red, figure 5) in fluoroquinolones are essential for activity, as well 
as bacterial transport.12, 25 Substituents in the other commonly modified position (blue, figure 5) 
are less essential, and the adjustment of the moiety bound can affect the activity of the drug both 









Figure 5 Ciprofloxacin and potential boronic acid linker binding sites 
As the intention was to inactivate the drug to form a pro-drug crosslinker, the aim was to use the 
acid as the anchoring point, as according to literature it would prevent the activity of the drug 
should there be any crosslinker left unbound within the PVA matrix. Theoretically, the drugs 
binding to the PVA should prevent any uptake into cells, but as previously discussed, the nature 
of the boronic acid/diol binding is dynamic, ergo there is the potential for the diffusion of the pro-
drug crosslinker out of the system. 
As we no longer wished to target a single reactive part of the molecule as in chapter 3, the synthetic 
procedure became simpler as the need for protection chemistry had been removed. Now a simple 
one-pot synthesis could be performed, producing a crude product that could be recrystallized as 




























48 %  
Figure 6 The one pot synthesis towards Ciprofloxacin bis-phenylboronic acid (CBPBA) 
The first experiment performed was to ensure that the compound would be able to crosslink PVA 
in the manner of PF-1 and Purplement. As outlined previously, a 100 mM solution of the 
crosslinker was stirred with a 10% w/v PVA solution and heated at 70 °C overnight. This produced 
hydrogels that were stable and pale green in colour, figure 7. 
 
Figure 7 PVA hydrogel crosslinked with CBPBA 
5.4.2 Solution Testing CBPBA  
The oxidative degradation of CBPBA to native ciprofloxacin using H2O2 was confirmed by 
















 CBPBA + H2O2
 
Figure 8 The shift in UV-vis spectra of CBPBA (50 µM) as it is oxidized into ciprofloxacin after 30 minutes after the 
addition of H2O2 (50 µM) in 10% DMSO 90% PBS buffer at 25 °C 
The double peak at around 330 nm is characteristic of ciprofloxacin in free solution, as is the 
absorbance max at 278 nm (in 10% v/v DMSO), indicating the release of the free, active drug. 
Ciprofloxacin has inherent fluorescence. However, it was unknown whether binding the phenyl 
bpin linkers would affect the fluorescence, hence the fluorescence before and after the addition of 







































 CBPBA + H2O2
 
Figure 9 The fluorescence increase of CBPBA (50 µM) as it is oxidized into ciprofloxacin after 30 minutes following 
the addition of H2O2 (50 µM) in 10% DMSO 90% PBS buffer at 25 °C Ex 327  Split width: 14 nm 
There is a clear increase of fluorescence on addition of H2O2, however, the emission maxima 
wavelength remains stationary. This indicates that the fluorescence of ciprofloxacin is owing to 
the bicyclic core and the quinolone, and that the binding of non-conjugated moieties to this (in this 
example through the acid and the amine), only serves to partially quench this fluorescence. 
5.4.3 Initial Ciprofloxacin Release From CBPBA Hydrogel  
Before starting detailed release studies, preliminary testing was performed to determine the 
concentration range of H2O2 which would elicit a response via release of the active compound 
from the hydrogel. To do this, hydrogels (each measuring 200 ± 10 mg) were incubated in solutions 
of differing concentrations of H2O2, and the fluorescence of the solutions were measured. 
Additionally, topical use of H2O2 as a wound disinfectant uses 3% w/v H2O2 solution, which 
equates to 980 mM.27 This was tested alongside lower concentrations, figure 10. 
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Figure 10 The increase in fluorescence intensity of CBPBA gel (200 ± 10 mg) exudate on exposure to increasing 
concentrations of H2O2 (0 – 980 mM) after 60 mins at 25 °C. Ex 327 – 14 nm, Em 415 – 20 nm. Error bars indicate 
standard deviation (n = 3) 
Over time the fluorescence intensity was found to increase, higher concentrations of H2O2were 
found to achieve the fluorescence maximum at a quicker rate. However, this trend was not 
followed by the 980 mM solution. This reaches a maximum fluorescence intensity after only 20 
minutes, before falling and plateauing at around 60% of its maximum fluorescence. The reason for 
this is made apparent when the solutions are inspected visually, figure 11, with the solution to the 
far left being clearly more turbid. 
 
Figure 11 Five pieces of CBPBA gel incubated in H2O2 of concentrations (left to right) of 0, 10, 20 50 and 980 mM 
in PBS after 60 minutes 
The solubility of unbound ciprofloxacin in aqueous solutions is very low.28 Due to the high drug 
content of the gels, exposure to 980 mM H2O2 cause the solution to quickly become saturated with 
172 
 
ciprofloxacin. As the gels continue to break down the ciprofloxacin molecules begin to aggregate 
and become solid – it is suspected that this is quenching the fluorescence of the molecules. It may 
not be a complex chemical quenching however, and it may simply be that the turbidity of the 
solution is preventing the transmittance of the emitted light.  
5.4.4 UV-vis CBPBA Gel Release Studies  
Fluorescence was used to confirm that the rate of ciprofloxacin release was dependent on H2O2 
concentration, UV-vis spectra was then used to investigate this phenomenon in a quantitative 
manner, figure 12. 





















Figure 12 UV-vis spectra of gel exudate from CBPBA gels (200 mg ± 10 mg) incubated in H2O2 of varying 
concentrations (0 – 50 mM) in PBS at 25 °C after 60 minutes. Measurement at 50 mM above instrument maximum. 
As can be seen in figure 12, an increase in the absorbance of due to the presence of ciprofloxacin 
can be seen at concentrations of H2O2 as low as 1 mM. The concentration of ciprofloxacin begins 
to reach the maximum that can be detected by the spectrometer when using 50 mM of H2O2, and 
begins to reach its maximum after one hour on exposure to at 25 mM, figure 13. 
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Figure 13 The increase in absorbance at 275 mM of CBPBA gel (200 mg ± 10 mg) exudate after incubation with H2O2 
solutions (0 – 50 mM) in PBS at 25 °C for 60 minutes. Error bars indicate standard deviation, (n = 3) 
Whilst a response could be gained at lower concentrations, the experiments proceeded with 50 mM 
of H2O2, to ensure maximum release of the ciprofloxacin from the gels. This is still a H2O2 
concentration nearly 20 fold lower than that approved for topical use in healthcare.29  
5.4.5 Converting Absorbance to Concentration  
To gain an understanding of the rate at which the CBPBA gels would decompose with H2O2, the 
UV-vis spectra were measured every five minutes for gels that had been incubated with and 
without 50 mM of H2O2 (in PBS). From figure 13 it was found that after an hour of exposure the 
solution becomes saturated to the point that further increases of ciprofloxacin concentration could 
not be detected. As such, the experiment was given a maximum time limit of 45 minutes, Appendix 
7.5.1. 
Whilst the absorbance values can show that the drug is being released and in concentrations 
relative to other absorbance experiments, exact concentrations are important for determining if 
enough drug is being released above the MIC. A standard curve, figure 14, of ciprofloxacin was 
produced in order to convert the data from absorbance units to concentration. 
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Concentration of ciprofloxacin (µM) 
 
Figure 14 A standard curve of ciprofloxacin in PBS (with 1% DMSO). R2 = 0.9998, Error bars indicate standard 
deviation (n = 3) 
By rearranging the Beer-Lambert law, this standard curve gives an extinction coefficient for 
ciprofloxacin of 49443 M-1 cm-1, agreeing with the literature values. Using this extinction 
coefficient appendix 7.5.1 can be replotted as a concentration, figure 15. 































Figure 15 The increasing concentration of ciprofloxacin from CBPBA gel (200 mg ± 10 mg) on exposure to H2O2 (50 
mM) in PBS at 25 °C over time (45 minutes). Error bars indicate standard deviation (n = 3) 
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As can be seen in figure 15 there is a near linear increase in concentration until 25 minutes, at 
which time the value begins to plateau. In contrast, the PBS control shows an initial release, 
assumed to be due to unbound crosslinker being removed, and then no further increase in 
ciprofloxacin concentration. 
When considering MIC values in microbiology, concentrations are most often reported in  
mgmL-1; after only 25 minutes of exposure to 50 mM of H2O2, 200 mg of CBPBA gel is able to 
produce a ciprofloxacin concentration of 0.014 mgmL-1. Despite this being the maximum 
concentration that could be detected by UV-vis, it was not the maximum concentration that would 
likely be released, owing to the loading concentration of 100 mM. As per methodology 5.3.9 gels 
with a volume of 1 mL were submerged in 3 mL of solution, giving a potential final volume of 8.2 
mgmL-1. The practical value is likely to be lower than this owing to washing steps and incomplete 
reaction of the H2O2 with all of the crosslinker molecules. 
5.4.6 Biological Testing – MICs of Ciprofloxacin and H2O2 
Once it had been established that the gel system would release a therapeutic amount of 
ciprofloxacin it needed to be tested on an in-vivo bacteria model. The MIC’s of ciprofloxacin were 
determined against the bacteria that were going to be tested, which were: gram-positive  






























































































































Figure 16 Minimum Inhibitory Concentration (MIC) of Ciprofloxacin for S. aureus H560 (top left) E. coli NCTC 
10418 (top right) and P. aeruginosa PAO1 (bottom). Optical density was measured at 600 nm after 18 h incubation 
at 37 °C. Error bars indicate standard deviation (n = 3) 
As can be seen in the MIC data, the amount of ciprofloxacin measurable would inhibit the growth 
of E. coli but not the other two bacteria. The calculated MICs were 0.20 – 0.39 µgmL-1 for S. 
aureus H560, 0.0039 – 0.0078 µgmL-1 for E. coli NCTC 10418 and 0.78 – 1.56 µgmL-1  for P. 
aeruginosa PAO1. To ensure that there was enough drug released to inhibit the bacterial growth 
when performing the CBPBA gel experiments, the gels were allowed to incubate in the H2O2 
solutions for 3 hours. 
As when measuring the efficacy of ARS as a biofilm inhibitor in chapter 2, the effect of the trigger 
H2O2 had to be considered. The MICs of H2O2 versus the same bacteria were measured, figure 17. 
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Figure 17 MIC of H2O2 for S. aureus H560 (top left) E. coli NCTC 10418 (top right) and P. aeruginosa PAO1 
(bottom). Optical density was measured at 600 nm after 18 h incubation at 37 °C. Error bars indicate standard deviation 
(n = 3) 
As can be seen from figure 17 the concentration of H2O2 required to inhibit the growth of all three 
species of bacteria is far lower than the 50 mM solution that we are using to trigger the release of 
ciprofloxacin from CBPBA. The calculated MICs were 0.20 – 0.39 mM for S. aureus H560, 0.0039 
– 0.0078 mM for E. coli NCTC 10418 and 0.78 – 1.56 mM for P. aeruginosa PAO1. As a result 
of these values being lower than the H2O2 concentrations being used for the release conditions, 
both H2O2 and the gels in PBS were required as controls. The experiment was designed as a pseudo 
MIC. It was clear from the bacterial testing above that the large concentration of H2O2 would kill 
the bacteria, masking any effect the released ciprofloxacin may have had. To overcome this a 
control solution of 50 mM H2O2, a control of the CBPBA gel in PBS, as well as the test solution 
of the CBPBA gel in H2O2 were treated as a solution of antimicrobial. These were then diluted 
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across a microtitre plate, with a two-fold dilution in each well. This allowed a comparison to be 
made between the H2O2 on its own and the solution of H2O2 with ciprofloxacin. Each piece of gel 
was left in the solution for 3 hours to ensure maximum ciprofloxacin release. 
5.4.7 Pseudo MICs to Measure Ciprofloxacin Release from CBPBA Gels 
The optical density at 600 nm was used as a measure of bacterial growth and was plotted against 
two fold dilutions. This number, whilst arbitrary as the initial concentration was not known, 
allowed comparison between our release condition and our control experiments, yielding values 
shown in table 1 for the number of dilutions required to allow the bacteria grow. Full data can be 
seen in appendix 5.2.  
Table 1 A comparison of the number of two fold dilutions required until the inhibition of growth of bacteria was no 
longer observed. An increase in the number of diltuions required is indicative of a solution with increased ability to 
inhibit bacterial growth 
Bacterial Species 
Experimental condition 
Number of 2-fold dilutions until growth 
H2O2 50 mM CBPBA + PBS CBPBA + 50 mM H2O2 
S. aureus H560 8 7 13 
E. coli NCTC 10418 7 7 15 
P. aeruginosa PAO1 7 3 9 
 
This ‘pseudo-MIC’ data indicates high levels of killing from both of the controls, across 
all three bacteria. This was expected for H2O2, as the MICs had been calculated to be lower than 
50 mM. What was surprising, however, was that the CBPBA in PBS induced a large inhibition of 
growth. Owing to the previously discussed structure activity relationships of ciprofloxacin, it was 
assumed that CBPBA would be inactive against all strains. However, despite the change in 
structure at the acid group there is a clear and obvious bactericidal effect on all the strains tested. 
This could potentially be due to the large excess of CBBPA that is present within the gel.  However, 
despite this non-specific killing, there is a clear decrease in bacterial growth, thus triggered release, 
from gel exudate exposed to H2O2. The black line, indicating the solution under release conditions, 
clearly shows that bacterial growth was presented after 8, 2-fold dilutions (a total dilution of 512-
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Figure 21 Optical density of S. aureus H560 upon exposure to 512-fold diluted: 50 mM H2O2, exudate from CBPBA 
hydrogels in PBS and exudate CBPBA hydrogels in 50 mM H2O2. CBPBA hydrogels were incubated for 3 h at 25 °C 
before subsequent use. Optical density was measured at 600 nm after 18 h incubation at 37 °C. Error bars indicate 
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Figure 22 Optical density of E. coli NCTC 10418 upon exposure to 512-fold diluted: 50 mM H2O2, exudate from 
CBPBA hydrogels in PBS and exudate CBPBA hydrogels in 50 mM H2O2. CBPBA hydrogels were incubated for 3 h 
at 25 °C before subsequent use. Optical density was measured at 600 nm after 18 h incubation at 37 °C. Error bars 
indicate standard deviation (n = 3). Statistical significance was determined using a one way anova when compared to 
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Figure 23 Optical density of P. aeruginosa PAO1 upon exposure to 512-fold diluted: 50 mM H2O2, exudate from 
CBPBA hydrogels in PBS and exudate CBPBA hydrogels in 50 mM H2O2. CBPBA hydrogels were incubated for 3 h 
at 25 °C before subsequent use. Optical density was measured at 600 nm after 18 h incubation at 37 °C. Error bars 
indicate standard deviation (n = 3). Statistical significance was determined using a one way anova compared to 
bacteria only control  
5.4.8 CBPBA Biological Activity  
This proved that the methodology of synthesising bis-PBA compounds was able to make active 
crosslinkers that could be reactivated, with release of the drug from the PVA matrix following the 
addition of H2O2. It was assumed that there would be a measure of non-specific release of the 
crosslinker over the period of incubation (3 hours) owing to the dynamic nature of the bonds, 
however it was not expected to produce such a great inhibition of bacterial growth. The obvious 
experiment to check this would be to perform the MIC of this compound against the three bacteria 
used. This normally would require making up a solution of 1 mgmL-1 in PBS and then perform 
serial dilutions, testing each dilution to determine if it prevented bacterial growth. For antibiotics 
with low solubility, co-solvents of DMSO or EtOH can be used up to 10% v/v, however beyond 
this there can be significant effects on the bacterial growth, invalidating results.30, 31 To prevent 
this solvent interference the initial solution could only be made at an initial concentration of 50 
µgmL-1 (0.64 mM) meaning when incubated with the  bacteria the first measurable 




Table 2 MIC value of CBPBA 
 Minimum Inhibitory Concentration / µgmL-1 
S. aureus H560 > 25.00 
E. coli NCTC 10418 12.50 – 25.00 
P. aeruginosa PAO1 > 25.00 
 
After 1 hour the gel exudate from 200 mg of CBPBA gel had given a solution concentration of 
over 10 mM when measured by UV-vis. It is assumed that due to the increased mass of CBPBA 
gel used (1 g), as well as the increased time of incubation (3 hours), that the concentration would 
be above that of the MIC, hence the non-specific kill. It is unknown if the CBPBA itself is active, 
or if endogenous ROS species produced by the bacteria are activating it and producing 
ciprofloxacin in-situ. 
5.4.9 Expansion of the Methodology 
Once a working hydrogel system had been designed for the release of an antibiotic, we aimed to 
prove the more universal utility of this approach for other classes of drug, for other disease states. 
5-Fluorouracil is an anti-cancer chemotherapeutic, used in the treatment of a number of conditions, 
including skin cancers.32 A topical anti-cancer drug that can treat carcinomas was chosen due to 
the potential for dual release of the drug with ciprofloxacin, which would be a potential avenue for 
treatment for the S. aureus infections commonly associated with Squamous cell carcinoma 
patients.22 
Similarly to the development of CBPBA, the synthesis of 5-fluorouracil bis-phenyl boronic acid 
(5-FBPBA) could be performed in a single step with commonly used reagents and moderate 



























Figure 24 The one pot synthesis for the crosslinking molecule 5-FBPBA 
A 100 mM solution of 5-FBPBA in DSMSO was mixed with a 10 % w/v PVA in DMSO solution  
in the same manner that the previous gels were synthesised, forming a solid hydrogel with PVA 
that had a faint orange colour, figure 25. These were then washed in the same manner, resulting in 
gels with similar characteristics. 
 
 
Figure 25 5-FBPBA crosslinked PVA hydrogel  
It was shown by HRMS that the native 5-fluorouracil was released from the PVA hydrogel upon 
exposure to the H2O2. Due to not having the facilities within our group to conduct cancer cell line 
testing, this and further study will be conducted by our collaborators at the University of Austin. 
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5.4.10 Gel Stability  
As in the previous chapter using masked fluorophores, the hydrogels were tested for their stability 
in both air and aqueous solvent. Figure 26 shows the stability of the gels exposed to air over the 
course of ten day 
 
 















Figure 26 The stability of the CBPBA and 5-FBPBA crosslinked PVA hydrogels on exposure to air over the course 
of 10 days  
As can be seen above, the gels began to dehydrate over time, however they remain solid and 
gelatinous. This could be problematic in the future, as a fully hydrated gel is essential for the 
application of wound dressings, as the shelf life of such products are of utmost importance to their 





















We have developed a novel system for the release of drugs in response to H2O2 using PVA 
hydrogels, which have been crosslinked using PBA functionalised drugs. Through simple 
synthetic modifications, any drug with two carboxylic acids, amines or hydroxyl groups can be 
functionalised to form a similar crosslinker. It has been shown that ciprofloxacin can be released 
at concentration that are inhibitory to bacterial growth, to a greater extent than that of control 
conditions. The CBPBA however, has shown to be effective against bacteria, and thus further 
study is needed to determine its mode of action, and if this activity is due to the oxidation of the 
drug by endogenous H2O2 produced by bacteria, or if it is simply active in its full form.  
The scope for the expansion of this methodology has been shown with the use of the anticancer 
drug 5-fluorouracil. Identical chemistry was employed to synthesise a derivative of this compound 
with phenyl-boronic ester, allowing it to act as a crosslinker. This was shown to also form stable 
PVA hydrogels and release the native anti-cancer drug. This offers the potential for the triggered 
release of these to drugs in the treatment of skin cancer associated infections.   
 As a drug delivery mechanism this methodology also shows great promise for use in the triggered 













5.6 Future Work 
5.6.1 Increasing Scope 
Following the development of a release system able to individually release ciprofloxacin and 5-
fluorouracil, it would be an advantage to release the two simultaneously. Theoretically, as long as 
the total crosslinker concentration used was the same, the composition of that solution could be 
formed of any number of functionalised drugs. This could be of particular advantage when 
considering wound infection, in particular mixed species biofilms. A number of biofilm disruptors 
exist which could help the clearance of a biofilm, whilst the bacteria within could be treated with 
multiple antibiotics at once in order to maximize the possibility of treatment. As his been discussed 
throughout this thesis there are a number bacteria that are resistant to antibiotics, and so a cocktail 
of bio-film disruptors and antibiotics could be released that would clear hard to treat infections. 
As such, a library of drug molecules come cross-linkers could be developed which would allow 
for the treatment of persistent infections with antibiotics of various classes. Potential candidates 
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Figure 27 Potential additional therapeutics that could be co-delivered to treat wound infection using the bis-PBA acid 
PVA technique 
Other gels and gel formulations could allow for new applications of the system. As previously 
discussed, cancer cells have a much higher levels of H2O2 than normal cells. A system such as this 
could potentially allow for an injectable hydrogel anti-cancer drug delivery system into tumours. 
The masked drugs would only activate in the presence of ROS, and the gel would degrade into 
harmless products as the drug is released, making the process highly  
bio-compatible, and increasing the pharmacokinetic profile of the drugs. Much like antibiotics, 
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anticancer drugs often feature a number of functionalities that would be suitable for the synthesis 
of the bis-PBA crosslinkers.  
5.6.2 Theranostic Development  
The purpose of the work within this thesis was for the development of a hydrogel system that could 
be used in a wound dressing and would able to detect and treat bacterial infection. A dressing that 
could do this without being removed, thus exposing the wound to the air, would help prevent 
reinfection.  
A system that can both diagnose and treat a disease state is known as a theranostic system. Whilst 
in this instance we are tailoring our work toward infection, theranostics have been used extensively 
in the treatment of cancer.33  These often involve the use of H2O2 triggered systems that are mainly 
used for imaging purposes due to an increase in fluorescence, although they can be tailored to 
release a drug. 
Of the two PVA systems outlined in chapter 3 and chapters 4 and 5, the most suitable system to 
produce a theranostic system would be that in chapter 3, binding compounds with just a single 
PBA or boronic acid moiety. This expands the scope of potential molecules greatly, however 
would require a separate crosslinking method compared to the bis-PBA functionalised compounds 
of this chapter. This can be overcome by methods as discussed in chapter 3. Whilst this would give 
rise to the therapeutic aspect of a theranostic, it still does not contain a diagnostic method. There 
are numerous ways in which this could be incorporated, two of which will be outlined. 
5.6.2.1 Incorporation of Bacterial Toxin Sensitive Vesicles 
As previously discussed, bacteria secrete a number of different virulence factors, including toxins. 
One of these toxins, delta toxin produced by S. aureus amongst other pathogens, is used by the 
bacteria to disrupt phospholipid membranes aiding in its colonization of the host. This has been 
utilized by Thet et al. to create detection systems for bacteria, based around the use of phospholipid 
vesicles. The breakdown of the phospholipid vesicles, thus the presence of bacteria, can be 
detected through the release of a self-quenching fluorescent dye (i.e. fluorescein) or through 
electrochemical methods.34, 35 
These vesicles form the basis of the ‘Smart Wound’ technology developed, and can be suspended 
in a variety of hydrogels including CMC, agarose and PVA.9 
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If a PVA hydrogel were to be created in which a boronic acid or PBA functionalised drug were 
bound, and fluorescein filled vesicles were suspended in the hydrogel, there would be a 
colorimetric and fluorescent response to the presence of an infection. This obvious change in the 
wound dressing would act as an alert to a medical professional that an infection had occurred, and 
they could then apply H2O2 or CAP to the dressing to release the bound drug, clearing the infection. 



















Figure 28 A schematic representation of a PVA wound dressing loaded with carboxyfluorescein filled vesicles, and 
with boronic acid bound ciprofloxacin in the gel matrix. On infection, the bacteria release toxins, breaking down the 
vesicles. This then releases carboxyfluorescein giving a colour change. This indicates an infection to the clinician, 
who would then apply topical H2O2 to release the bound antibiotic, clearing the infection  





 Infection clearance  
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The use of the boronic acid/diol functionalisation could allow multiple therapeutic agents to be 
bound within the matrix. There is also the potential for modification of the phospholipid vesicles 
to give a more rapid response versus certain species and strains of bacteria, which is ongoing work 
within the Jenkins group. 
5.6.2.2 Use of Pyroelectric Particles to Create an Automatic Wound Infection Warning and 
Drug Release 
Pyroelectric particles are a subset of piezoelectric particles. In piezoelectric or pyroelectric 
particles or materials, mechanical or thermal energy is converted into chemical energy.36 The 
formation of a dipole due to mechanical stress results in a collection of surface charges at each 
pole. Upon depolarization this electrochemical gradient can cause redox reactions with water, 
producing ROS such as ·OH and ·O2.37 This has led to interest in their use as a green methods of 
waste water treatment. Some more recent materials can produce H2O2, giving them the potential 
for incorporation into the previously discussed ROS sensitive triggered release systems.38 
Sr0.3Ba0.7TiO3 particles, produced by the Bowen group in the mechanical engineering department 
at the University of Bath, have been shown to both disinfect bacterial solutions as well as degrade 
organic dyes in solution. The temperature at which these particles depolarise is 35 °C, though this 
can be tuned by varying the ratios of Sr to Ba. The amount of organic dye decomposition, 
correlating to the amount of ROS, is dependent on the number of heating/cooling cycles. Similarly, 
with the inhibition of bacterial growth, more effective bacterial clearance is achieved with more 
cycles. In order to get sufficient production of ROS to achieve the inhibition of bacterial growth 
the particles need to be heated and cooled cycled 6 times. Whilst inherently there is ROS produced, 
it is clear that in a clinical scenario this would be an inefficient way of treating bacteria. 
A healthy and normally healing wound has a temperature of around 32 - 33 °C, whilst an infected 
wound has a surface temperature of 37 - 38 °C.39, 40 The temperature associated with the generation 
of ROS by the SrBaTiO3 particles lies between these ranges, offering the possibility of an infection 
initiated trigger for a theranostic system. As the amount of ROS generated by a single cycle is 
insufficient for the killing of bacteria, this ‘killing signal’ requires amplification. A way of doing 
this would be to suspend the particles within a PVA matrix, to which is bound a boronic acid doped 
dye and a boronic acid doped drug. In order to ensure the biocompatibility of this system, cryo-
crosslinking would be the optimum crosslinking methodology, preventing the need for any toxic 
crosslinking chemicals. This requires both the drug and the dye to be soluble in a solution of 
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aqueous PVA. Aqueous solubility of the original boronic pinacol ester compounds used can be 
improved by the conversion of the boronic ester to the boronic triflate, which in aqueous solution 
will convert to the boronic acid. Once bound to the PVA through this boronic acid, previously 
aqueous insoluble compounds can be dissolved, as proved with the AuFluor 483-Bpin™. 
The different drug delivery and sensing systems developed, offer potential route to the 
development of novel medical materials. Their combination with other emerging medical 
technologies such as CAP and the ‘smart wound’ vesicles gives them potential for being developed 
further and being incorporated into theranostic systems. The full extent of the potential 
applications of these boronic acid soft materials is only just being realised, and it is my hope that 
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 Synthetic Experimental  
6.1 Chapter 2 








A solution of NEt3 (0.49 g, 4.88 mmol) and methacryloyl chloride (0.51 g, 4.88 mmol) in DCM 
(4.0 mL) was added dropwise to a solution of 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)aniline (1.00 g, 4.56 mmol) in DCM (60 mL) at 0 °C. The reaction mixture was stirred for 2 h 
and was allowed to warm to rt, which was then stirred for a further 30 min. It was ensured that the 
temperature did not rise above 30 °C in order to minimise the occurrence of side polymerisation 
products. The solution was then washed with H2O (3 x 40 mL) and dried over MgSO4. The organic 
solvent was removed under reduced pressure and the title compound yielded as an off white solid 
(1.25 g, 95 %). Mp 138 – 142 °C. 1H NMR (δ; 300 MHz; DMSO-d6) 7.98 (1H, dq, CH), 7.68 (1H, 
d, CH), 7.56 (1H, d, CH), 7.36 (1H, t, CH), 5.79 (1H, s, CHH), 5.44 (1H, s, CHH), 2.05 (3H, s, 
CH3), 1.35 (12H, s, 4 x CH3). 13C NMR (δ; 75 MHz; DMSO-d6) 166.54, 140.90, 137.32, 130.73, 
128.74, 125.89, 123.23, 119.15, 84.14, 24.98, 18.85. FTIR (thin film) ν (cm-1),; 1622, 1662, 2977, 



















Methacryloyl chloride (1.32 mL, 13.42 mmol) was added dropwise to a solution of 6-
Aminobenzoxaborale (1.00 g, 6.71 mmol) and NaHCO3 (2.26 g, 26.84 mmol) in H2O:THF (1:1, 
40 mL) at 0 °C. The reaction was stirred for 2 h at 0 °C, then overnight at room temperature. The 
organic solvent was removed under reduced pressure and solid product obtained via extraction 
with EtOAc for 2 h. The organic layer was continuously washed with H2O, sat. NaHCO3 solution 
and brine. The organic layer was dried over MgSO4 and the solvent removed under reduced 
pressure, yielding a pale brown solid (1.19 g, 82 %). Mp 167 - 170 ℃. 1H NMR (300 MHz, DMSO-
d6): δ 9.81 (1H, NH, s), 9.19 (1H, s, OH), 8.07 (1H, d, CH, J = 1.6 Hz), 7.68 (1H, dd, CH , J1 = 
8.2, J2 = 1.9 Hz), 7.35 (1H, d, CH, J = 8.2 Hz), 5.82 (1H, CH, s), 5.51 (1H, s, CH), 4.95 (2H, s, 
CH2), 1.97 (3H, s, CH3); 13C NMR (75 MHz, DMSO-d6): δ 167.10, 149.34, 140.77, 138.12, 
123.85, 122.60, 121.68, 120.20, 70.05, 18.46; FTIR ν (cm-1): 3276, 3086, 2973, 1655, 1214, 979.  




























Ciprofloxacin (1.00 mmol, 331 mg) and Di-tert-butyldicarbonate (1.20 mmol 260 mg) were stirred 
in 5 mL of Dioxane. Triethylamine (1.20 mmol, 167 μL) was added. The reaction was stirred at 
room temperature for 4 hrs. The solvent was evaporated in-vacuo and the resulting powder was 
dissolved in Acetonitrile (8 mL). After stirring for 5 minutes 2-(4-bromomethyl-phenyl)-4,4,5,5-
tetramethyl [1,3,2]dioxaborolane (1.20 mmol, 356 mg) and K2CO3 (1.20 mmol, 165 mg) were 
added. Following heating the mixture at reflux (90 °C) overnight. After cooling the solution down, 
solids were separated with a sintered glass funnel. The precipitate was washed with water (ca. 50 
mL) followed by cyclohexane (20 mL) and dried under reduced pressure. The pale yellow powder 
was mixed with THF (5 mL) and 4N hydrochloric acid (0.5 mL). The reaction was stirred at rt for 
24 hrs. Then the mixture was basified with an aqueous solution of NaHCO3 and the solvent was 
removed in-vacuo.  This was followed by a soxhlet extraction in diethylether. The resulting powder 
was dissolved in THF (2 mL) and TFA (1 mL) was added. After stirring at room temperature for 
24h the solvent was removed in-vacuo yielding the title compound as an orange oil (47%). Mp 
112 – 115 ℃. 01H NMR (500 MHz, CD3OD): δ 8.7 (1H, s CH), 7.98-7.90 (1H, CH, m), 7.78-7.70 
(4H, m, CH), 4H), 7.57-7.32 (2H, m CH), 5.41 (2H, s, CH2), 5.34 (1H, s, CH), 3.73-3.70 (2H, m, 
CH2), 3.62-3.45 (4H, m, CH2, 4H), 1.86 (1H, quin, CH2, J = 1.8 Hz), 1.40-1.11 (17H, cycloprop, 














Triclosan (480 mg, 1.64 mmol) and potassium carbonate (909 mg, 6.57 mmol) were stirred at  
55 °C in 3 mL anhydrous dimethylformamide for 2 hours. 2-(4-bromomethyl-phenyl)-4,4,5,5-
tetramethyl [1,3,2]dioxaborolane (586 mg, 1.97 mmol) was added and stirred for 22 hours at 55 
°C. The reaction mixture was dissolved in ethyl acetate (50 mL), washed with brine (3 x 50 mL) 
and dried with MgSO4. Solvent was removed in-vacuo, yielding a white crystalline solid (501 mg, 
60%) that was purified via silica chromatography: EtOAc:petroleum ether (5:95) Mp 130-131 
°C.1H NMR (500 MHz, CDCl3): δH = 7.75 (2H, d, CH), 7.42 (1H, d, CH), 7.21 (2H CH, d), 7.08 
(1H, dd, CH), 7.00 (1H, d, CH), 6.93 (1H, dd, CH), 6.96 (1H, d, CH), 6.65 (1H, d, CH), 5.07 (2H, 
s, CH2), (12H, s, CH3). 13C NMR (157.5 MHz, DMSO-d6): δC = 24.9, 70.2, 83.8, 115.5, 118.4, 
121.7, 123.1, 123.9, 125.9, 126.1 126.6, 127.2, 128.7, 130.1, 134.8, 139.9, 142.7, 150.6, 152.6. 















3-Bromophenol (3.66 g, 20.0 mmol) and pthalic anhydride (1.43 g, 10.0 mmol) were dissolved in 
methanesulfonic acid (10 mL). The reaction was stirred under reflux at 140 °C for 16 hours. The 
reaction was quenched with ice. Reaction mixture was extracted with EtOAc (3 x 30 mL) then 
washed with water and sat NaCl solution. Combined organic extracts were dried with MgSO4 and 
the solvent was removed in vacuo. Crude product was purified by trituration in pet. ether yielding 
a dark grey solid (2.87 mmol, 6.3 mmol, 63%). Mp 289-290 °C. 1H NMR (δ 500 MHz, CDCl3); 
8.04 (1H, d, CH J= 1.0 Hz); 7.66 (2H, m, CH); 7.49 (2H, d, J=1.9 Hz, CH), 7.19 (2H, dd, 1J = 8.5 
Hz, CH 2J=1.9 Hz); 7.12 (1H, d, CH, 1J = 7.5 Hz, CH); 6.70 (2H, d, CH J=7.5 Hz,). 13C NMR (δ 
125 MHz, CDCl3); 168.87, 152.71, 151.05, 135.53, 130.12, 129.15, 127.37, 125.71, 125.34, 
124.12, 123.58, 120.31, 117.85. FTIR (thin film) ν max (cm-1); 1760.91. HRMS (ES) m/z 

























Dibromofluorescein (666 mg, 1.4 mmol), potassium acetate (1.30 g, 13.2 mmol), 
bis(pinacolato)diboron (1.33 g, 5.2 mmol) and Pd(dppf)Cl2 (330 mg, 0.45 mmol) were dissolved 
in anhydrous degassed DMF (5 mL) under N2 in a dried 100 mL round bottomed flask. The reaction 
stirred at 80 °C for 12 hours. The product was extracted thrice with EtOAc and the combined 
organic extracts were washed three times with brine. The organic fractions were combined and 
drired with MgSO4. The crude product was isolated as a sticky brown solid. Compound was 
purified by column chromatography (10:90 EtOAc:Pet ether – 20:80 EtOAc:Pet Ether) yielding a 
pale pink solid (435 mg, 0.79 mmol, 58%). Pink colour was reduced when washed with Pet ether. 
Mp 239-241 °C. 1H NMR (δ 500 MHz, CDCl3); 8.03 (1H, m, CH); 7.73 (2H, s); 7.60 (2H, Q, CH, 
J=3.5 Hz); 7.43 (2H, dd, CH 1J = 10 Hz, 2J = 1.0. Hz); 7.06 (1H, m, CH); 6.86 (2H, d, CH, J = 8.0 
Hz); 1.35 (24H, s, (CH3)8). 13C NMR (δ 125 MHz, CDCl3); 169.60, 154.00, 150.47, 135.08, 
129.70, 129.30, 126.89, 125.44, 125.16, 123.56, 123.50, 121.29, 84.16, 24.71. FTIR (thin film) ν 

















Phenothiazine (5.0 g, 25 mmol) was dissolved in AcOH (200 mL). Br2 (3.3 mL, 128 mmol) was 
dissolved in AcOH (200ml), this Br2 solution was added to the phenothiazine solution dropwise 
over 1 h. The reaction was then stirred overnight at room temperature. The reaction was then 
cooled to 0 °C and Na2SO3 (6.50 g, 51.5 mmol) was added. After stirring for one more hour KOH 
(4.5 g, 80.2 mmol) in H2O (1 L) was added. The formed dark purple precipitate was isolated and 
recrystallized to yield the title compound as a green solid (6.60 g, 18.5 mmol, 74%). M.p. 191 – 
193 °C; 1H NMR (500 MHz, DMSO-d6) δ 8.85 (1H, s, CH), 7.20 - 7.09 (4H m, CH), 6.58 (2H, 
d, CH J = 8.3 Hz); 13C NMR (125 MHz, DMSO-d6) δ 141.3, 130.7, 128.5, 118.6, 116.4, 113.1; 
I.R (thinfilm) ν max (cm-1): 3310.68; HRMS (ES) m/z calculated for C12H7Br2NS, [M+H]+ 
























3-7-dibromo-10H-phenothiazine (1.00 g, 2.1 mmol), potassium acetate (1.95 g, 14.7 mmol), 
bis(pinacolato)diboron (2.00 g, 7.8 mmol) and Pd(dppf)Cl2 (500 mg, 0.68 mmol) were dissolved 
in anhydrous degassed DMF (8 mL) under N2 in a dried 100 mL round bottomed flask. The reaction 
stirred at 80 °C for 12 hours. The product was extracted thrice with EtOAc and the combined 
organic extracts were washed three times with brine. The organic fractions were combined and 
dried with MgSO4. The crude product was isolated as a gummy brown solid. Compound was 
purified by recyrystalisation in DCM and MeOH yielding a yellow solid (407 mg, 0.90 mmol, 
43%). Mp > 300 °C. 1H NMR (500 MHz, d6-DMSO) δ 8.94 (1H, s, NH), 7.23 (2H, dd, CH J = 1.3 
Hz), 7.04 2H ,s, CH), 6.61 (2H, d, CH J = 10 Hz), 1.23 (24H, s, (CH3)8); 13C NMR (125 MHz, d6-
DMSO) δ 145.3, 135.6, 133.8, 118.0, 115.3, 84.7, 25.6; HRMS (FTMS-NSI): m/z calculated for 
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Ciprofloxacin (1.00 g, 2.73 mmol) was stirred with K2CO3 (1.54 g, 10.7 mmol) in MeCN (15 mL) 
at 100 °C for 90 minutes. 4-Bromomethylphenyl boronic acid pinnacol ester (3.41 g, 10.7 mmol) 
was added, and the reaction was stirred for 36 hours at 100 °C. The reaction mixture was extracted 
with EtOAc and washed twice with brine. The resulting pale green precipitate was filtered. The 
crude product was recrystallized in EtOAc yielding a white solid. (48 %). MP 267 – 270 °C. 1H 
NMR (δ; 500 MHz: CDCl3) 8.50 (1H, CH, s), 8.04 (1H, d, CH, 1J = 13.2 Hz) 7.80 (4H, m, CH) 
7.49 (2H, d, CH, 1J = 8.1), 7.38 (2H, d, CH, 1J = 7.5) 7.24 (1H, d, CH, 1J = 7.0), 5.38 (2H, s, 
CH2O) 3.62 (2H, s, CH2N) 3.38 (1H, m, CH(CH2)2) 3.28 (4H, br, N(CH2)2) 2.67 (4H, br, N(CH2)2) 
1.35 (12H, s, (CH3)4) 1.33 (12H, s, (CH3)4) 1.26 (2H, m, (CH2)2), 1.08 (2H, m, (CH2)2). 13C NMR 
(δ; 125 MHz: CDCl3) 173.05, 165.39, 154.42, 152.45, 148.18, 139.57, 137.97, 134.96, 134.85, 
128.59, 127.09, 113.46, 113.28, 110.10, 104.73, 83.79, 83.75, 66.22, 52.79, 49.95, 34.46, 14.19, 

















5-fluorouracil (1.00 g, 7.63 mmol) was stirred with K2CO3 (3 g, 21.7 mmol) in MeCN (15 mL) 
at 100 °C for 90 minutes. 4-Bromomethylphenyl boronic acid pinnacol ester (5.92 g, 20 mmol) 
was added, and the reaction was stirred for 36 hours at 80 °C. The reaction mixture was extracted 
with EtOAc and washed twice with brine. The resulting pale orange precipitate was filtered. 
The crude product was recrystallized in EtOAc yielding a white solid (87%). Mp 216 -220 °C. 
1H NMR (δ; 500 MHz: CDCl3) 7.83 (2H, d, CH, 1J = 8.1 Hz) 7.77 (2H, d, CH,1J = 8.1 Hz) 7.4 
(2H, d, CH, 1J = 8.1), 7.26 (2H, d, CH, 1J = 21.0), 7.13 (1H, d, CH, 1J = 5.2), 5.18 (2H, s, CH2N) 
4.90 (2H, s, CH2N) 1.35 (12H, s, (CH3)4) 1.34 (12H, s, (CH3)4). 13C NMR (δ; 125 MHz: CDCl3) 
157.16, 156.99, 141.09, 139.22, 139.03, 137.39, 135.60, 134.93, 128.30, 127.43, 125.97, 
125.69, 84.02, 83.68, 52.26, 45.22, 24.85, 24.83. I.R (thinfilm) ν max (cm-1): 2978.05, 1717.01, 
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7.2 Chapter 2  












































Appendix 2 – The Deep red colour of ARS solution 
  
Appendix 3 - Determination of the Minimum Inhibitory Concentration (MIC) of Alizarin Red 
S (ARS) for (A) Staphylococcus aureus MRSA252, (B) Staphylococcus aureus H560, (C) 
Pseudomonas aeruginosa PAO1 and (D) Escherichia coli NCTC 10418. The MIC was above 









Appendix 3 – The effect of adding ARS at exponential phase on biofilm formation for (A) 









Appendix 4 – The effect of adding ARS at stationary phase on biofilm formation for (A) S. 
aureus MRSA252, (B) S. aureus H560, (C) P. aeruginosa PAO1 and (D) Escherichia coli 












Appendix 5 – Bacteral growth curves for (A) S. aureus MRSA252, (B) S. aureus H560, (C) 



















7.3 Chapter 4  
Appendix 1 Gment gel stability in PBS as measured by UV-vis 

























Appendix 2 – Pment gel stability in PBS as measured by UV-vis 
 


























7.4 Chapter 5  
Appendix 1 Increasing absorbance at 275 nm as ciprofloxacin is released from PVA due to 
exposure to H2O2 




































Appendix 2 Full data for CBPBA release  













5 0  m M  H 2 O 2
C B P B A  in  P B S
C B P B A  in  5 0  m M  H 2 O 2
 
Optical density of S. aureus H560 upon exposure to 2-fold serially diluted: 50 mM H2O2, exudate from CBPBA 
hydrogels in PBS and exudate from CBPBA hydrogels in 50 mM H2O2. CBPBA hydrogels were incubated for 3 h 
at 25 °C in PBS/H2O2 before subsequent use. Optical density was measured at 600 nm after 18 h incubation at 37 




















5 0  m M  H 2 O 2
C B P B A  in  P B S
C B P B A  in  5 0  m M  H 2 O 2
 
Optical density of E. coli NCTC 10418 upon exposure to 2-fold serially diluted: 50 mM H2O2, exudate from 
CBPBA hydrogels in PBS and exudate from CBPBA hydrogels in 50 mM H2O2. CBPBA hydrogels were incubated 
for 3 h at 25 °C in PBS/H2O2 before subsequent use. Optical density was measured at 600 nm after 18 h incubation 
at 37 °C. Error bars indicate standard deviation (n = 3) 














5 0  m M  H 2 O 2
C B P B A  in  P B S
C B P B A  in  5 0  m M  H 2 O 2
 
Optical density of P. aeruginosa PAO1 upon exposure to 2-fold serially diluted: 50 mM H2O2, exudate from 
CBPBA hydrogels in PBS and exudate from CBPBA hydrogels in 50 mM H2O2. CBPBA hydrogels were incubated 
for 3 h at 25 °C in PBS/H2O2 before subsequent use. Optical density was measured at 600 nm after 18 h incubation 
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Reaction-based Indicatior Displacement Assay (RIA) for the Development of a Triggered 
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